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Abstract
The objectives of th is  th es is  a re  to describe, analyse  and  ev a lu a te  th e  
principal HIV surveillance schemes co-ordinated a t th e  Scottish C entre  
for Infection and Environmental Health (SCIEH) between 1984 and 1994.
C h a p te r  one b e g in s  w ith  a b r ie f  rev iew  of su rv e illa n c e , in c lu d in g  
ex am p les  of su rv e illan c e  schem es an d  th e i r  b e n e fits , fo llow ed by a 
detailed statem ent of the aims of th is thesis. The chapter continues w ith 
a re v ie w  of th e  f i r s t  r e p o r t s  o f A ID S , th e  d isc o v e ry  o f HIV, th e  
transm ission  of HIV, the  im m une response to HIV, and the  developm ent 
of a te s t for HIV antibodies. A b rief in troduction  to th e  p rincipal HIV 
su rv e illan c e  schem es is given, w ith  a d e sc rip tio n  of th e  ro le  of each  
schem e in  th e  context of th e  overall HIV su rve illance  p rogram m e for 
S co tland . T h is is follow ed by an  o u tlin e  of th e  fram ew o rk  u sed , in  
chapter eight, to evaluate each surveillance scheme. Finally, the  chapter 
concludes with a methods section.
C hapters two to six all follow a sim ilar pattern , each concentrating on one 
p a r t ic u la r  HIV su rv e illan c e  schem e. T hese  a re  th e  AID S R e g is te r  
(chapter two), HIV Register (chapter three), Denom inator Study (chapter 
four), UAT surveillance (chapter five) and th e  CD4 Study (chapter six). 
Each chapter contains a detailed description of the  surveillance scheme 
and an analysis of the data  collected.
C h ap te r seven exam ines com puter linkage of th ese  HIV su rve illance  
schem es, both  w ith  one ano ther and w ith d a ta  from o ther surveillance 
schemes. I t describes linkages th a t have already tak en  place, analyses 
results from them, and highlights areas for future work.
C hapter eight begins w ith an evaluation of key a ttr ib u te s  of each of the  
HIV surveillance schemes described in chapters two to six. It continues 
with a dem onstration of the importance of the linked HIV/AIDS Register, 
to g e th e r  w ith  th e  CD4 and GUM S tud ies , in id en tify in g  w here  new  
in fection  m ay be occurring, and  in e s tim a tin g  th e  p reva lence  of HIV 
infection. It also addresses a variety of issues regarding the performance, 
value and future role of the principal HIV surveillance schemes in Scotland.
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Summary
Introduction
In  Ju n e  1981, a re p o rt w as p u b lish ed  abou t five p rev io u s ly -h ea lth y  
hom osexual m en who had  pneum ocvstis carin ii pneum onia (PCP) and 
unexplained profound im m une deficiency [1]. T hroughout th e  next few 
months, it became apparent th a t there were m any people presenting w ith 
a variety  of infections and tum ours associated w ith unexplained im m une 
deficiency [2,3] and  th e  te rm  ‘acquired  im m une deficiency syndrom e’ 
(AIDS) was introduced to encompass them  [4].
In  1982, a re trov irus {later nam ed the  hum an  im m unodeficiency 
virus (HIV)} was discovered to be the causal agent of AIDS [5], although 
it was not un til 1985 th a t a tes t for detecting antibodies to HIV, in serum  
samples, became readily available.
The AIDS Register
Since 1984, clinicians in Scotland have voluntarily reported AIDS cases to 
the  Scottish  C entre  for Infection and E nvironm ental H ealth  (SCIEH), 
w here  a reg is te r  of such cases is m ain ta in ed . A nalysis of th is  AIDS 
R eg is te r show s th a t  by 30 th  Ju n e  1994, 518 cases of AIDS h ad  been  
reported, of whom 366 (71 per cent) were known to have died [6]. Since 
1989, the  num ber of newly-reported AIDS diagnoses (ranging from 70 - 
100 per year) has exceeded the  num ber of deaths from AIDS, leading to 
a n  a n n u a l  in c re a se  in  th e  n u m b er of peop le  liv in g  w ith  AID S [7]. 
Predictions show th a t  th is  tren d  is expected to continue, so th a t  by th e  
y ear 1999 th ere  will be approxim ately 270 people w ith  AIDS liv ing in  
Scotland [8].
M edian survival, from AIDS diagnosis to death, is 17 m onths, w ith 
37 per cent of AIDS cases surviving for two years from diagnosis, and 22 
per cent surviving for th ree  years. Analysis of survival following AIDS 
d iagnosis  show s th a t  age and  clin ical p re se n ta tio n  a t  d iag n o sis  a re  
im portan t prognostic factors, with younger people surviving longer th an  
older people.
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The HIV Register
Since HIV testing began in Scotland in 1985, staff at NHS laboratories have 
reported all persons testing HIV antibody positive (HIV positive) to SCIEH 
w here a reg is te r  of these  repo rts  is m ain ta ined . A nalysis of th is  HIV 
Register shows th a t by 30th June  1994, 2,129 HIV positive persons had 
been reported [6].
The number of HIV positive tests rose from 250 in 1984 to 325 in 1986 
before falling to 248 in 1987. Of the 966 HIV-positive test results, from blood 
specimens taken before 1987, 66 per cent were attributable to injecting drug 
use, 20 per cent to homosexual/bisexual risk, 7 per cent to haem ophiliacs 
receiving infected blood products, and 3 per cent to heterosexual risk. Since 
1988, the num ber of HIV positive tests among IDUs has fallen, while the 
num ber a ttribu tab le  to heterosexual transm ission has risen. Of the 915 
HIV-positive test results reported since 1988, 38 per cent are a ttribu ted  to 
homosexual/bisexual risk, 28 per cent attributed to injecting drug use, and 
27 per cent attributed to heterosexual risk.
The Denominator Study
In  1988, the  HIV reporting  scheme was extended to include repo rts  on 
everyone having an HIV antibody test, regardless of the tes t resu lt. This 
extended scheme, the Denominator Study, allows HIV positive results to be 
interpreted in conjunction with the denominator of all HIV tests. This study 
shows th a t  the  num ber of persons hav ing  an HIV te s t  has r isen  from 
approximately 9,000 in 1989 to 13,000 in 1992.
Most HIV test requests are made through the general practitioner 
se tting  (33 per cent), although most HIV positive resu lts are found in the 
hospital setting. High rates of testing are found (for males and females) in 
the  20-24 year age group, and in Lothian H ealth  Board. H igh ra te s  of 
testing HIV positive are found among men aged 30-44 years, and in Tayside 
and Lothian Health Boards.
Logistic regression analysis of the 46,673 HIV test resu lts reported 
between 1989 and 1992, shows th a t risk category, health  board, reason for 
testing, source of test request, age, and presence of clinical symptoms, are 
all associated with the probability of testing  HIV positive. In particu lar, 
men in the homosexual/bisexual category were found to be seven times more 
likely to test HIV positive than those with no known risk factors for HIV.
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Unlinked Anonymous Testing
B oth th e  HIV R egister and  the  D enom inator S tudy  a re  based  on te s t  
resu lts of people who voluntarily seek HIV testing, and therefore cannot 
be used  to provide estim ates  of prevalence of HIV in  o th er popu lation  
g ro u p s . In  1989, th e  UK G o v e rn m e n t a n n o u n c e d  t h a t  u n l in k e d  
anonymous testing  (UAT) for HIV antibodies in residual blood specimens 
could begin [9].
In  UAT, th e  re s id u a l blood from  a n o th e r te s t  (such as syph ilis  
se ro lo g y ) is  i r r e v e r s ib ly  u n l in k e d  from  a n y  p a t ie n t - id e n t i f i a b le  
in fo rm ation  before being  te s te d  for H IV  Hence, th e  HIV te s t  re s u lt  
cannot be linked to a particu lar patient, bu t can be linked to inform ation 
such as gender and age group.
In  Scotland, the  cu rren t netw ork of UAT schemes w as introduced 
betw een 1990 and 1992, covering d ifferent populations. These include 
people th o u g h t to be a t h igh  r isk  of acqu iring  HIV infection , such  as 
genito-urinary medicine (GUM) clinic attenders, and those thought to be 
a t lower risk , such as a n te n a ta l clinic a tten d e rs . T hese su rve illance  
schem es provide estim ates of the  prevalence of HIV in th e ir  population 
groups, and trends in prevalence with time. Estim ated prevalence of HIV 
among those participating in the  GUM Study is 9 per 1000 in Edinburgh, 
and  5 per 1000 in  Glasgow, com pared w ith  a p revalence am ong those 
p a rtic ip a tin g  in  th e  A n te n a ta l S tudy  of less th a n  2 p e r 1000 in  bo th  
Dundee and Edinburgh.
WHO Staging System: the CD4 Study
Several staging system s for HIV exist, each dividing the spectrum  of HIV 
infection into d istinc t categories [10-12]. In  1991, an  HIV surveillance 
scheme was introduced in Scotland, based on a WHO staging system  [13]. 
All HIV positive adults who receive immunological m onitoring, a t one of 
five Scottish  laboratories, partic ipa te  in th e  surveillance schem e. The 
pa tien t’s clinical and immunological s ta tu s are recorded every tim e he or 
she is m onitored, and  th ese  re su lts  sen t by th e  labo ra to ry  to SCIEH. 
From  these  records, a profile of the  HIV infected population in Scotland 
(under monitoring) can be produced. Results show th a t 942 persons were 
m onitored in 1993, 18 per cent of whom had  la te  stage infection, and 40 
per cent had  CD4 counts of less than  200.
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Computer Linkage of HIV Surveillance Schemes
A lthough each of th e  HIV surveillance schem es a lready  m en tioned  is 
im portant in its own right, the value of these schemes (with the exception 
of UAT) will be increased by being linked to other schemes. This linkage 
is simplified by the centralisation and standardisation of da ta  a t SCIEH.
Linkages have been m ade betw een th e  AIDS and  HIV reg is te rs , 
enabling progression from HIV to AIDS to be studied. Linkage betw een 
the  HIV Register and the CD4 Study enables CD4 counts, pe rta in in g  to 
th e  tim e of HIV diagnosis, to be ascertained . Successful linkages have 
also been performed between the HIV Register and all deaths in Scotland 
(1980 - 1991), and between the HIV Register and hospital discharge da ta  
[14,15].
Evaluation of HIV Surveillance at SCIEH (1984 -1994)
In  th e  la s t  c h ap te r, each  of th e  in d iv id u a l su rv e illa n c e  sch em es is 
evaluated for a ttribu tes of simplicity, flexibility, acceptability, sensitivity, 
r e p re s e n ta t iv e n e s s  an d  tim e lin e s s . T he focus th e n  c h a n g e s  from  
in d iv id u a l su rv e illan c e  schem es to b ro a d e r is su e s  c o n ce rn in g  HIV 
su rve illance  in Scotland. Key in form ation  req u ired  by public  h e a lth  
officials, c lin ic ians and  o th er p ro fessionals, involves id e n tify in g  th e  
occurrence of new infection, and  assessing  th e  resources req u ire d  for 
those who are already infected [8,16-18]. By providing th is  inform ation, 
th e  im portance of th e  AIDS/HIV Register, toge ther w ith  th e  CD4 and  
GUM Studies, is demonstrated.
To conclude, the  focus re tu rn s  to th e  individual HIV surveillance 
schemes, where a variety  of issues surrounding their perform ance, value 
and  fu tu re  role are  addressed . These issues include d iscussion  of th e  
relevance of AIDS surveillance, the  fu ture of the  Denom inator and  CD4 
Studies, and the coverage of the UAT surveillance programme.
Chapter 1
Introduction
1.1 Background
1.1.1 Introduction to surveillance
The concept of surveillance  is know n to d a te  from  a t le a s t th e  fou rth  
c e n tu ry  BC, w hen  H ip p o c ra te s  follow ed th e  p ra c tic e  of observ in g , 
recording, and  analysing  d a ta  re la te d  to h ea lth , before decid ing  on a 
particu lar course of treatm ent. However, it was not un til th e  pioneering 
work of Gottfried Wilhelm von Leibnitz, John G aunt and W illiam Petty  in 
the  17th century, and W illiam Farr, John  Snow and Edwin Chadwick in  
the  19th century, th a t surveillance as we know it today began to develop 
[19].
S u rve illance  in  th e  19th century, and  th e  f irs t  h a lf  of th e  20 th  
cen tu ry , w as p r im a rily  concerned  w ith  in fec tio u s  d ise a se s  such  as 
cholera, sm allpox, and  the  plague, u sua lly  re su ltin g  in  th e  iso lation  of 
infected individuals and the  protection of those who had  been in  contact 
w ith  them . In  th is  second h a lf  of th e  20th  century, p a rticu la rly  in  th e  
developed world, su rve illance  h as  w idened to include non-in fec tious 
diseases, chronic diseases, congenital defects, drug reactions, accidents, 
and a wide variety of environmental and occupational hazards.
1.1.2 Examples of surveillance schemes
(1) M ortality surveillance
The ro u tin e  collection, analysis, and  d issem ination  of in fo rm ation  on 
d ea th s , p a rtic u la rly  cause of d ea th , h a s  p layed  an  im p o rta n t ro le  in  
public health  surveillance since it was established in the 19th century. In 
particu la r, it  has enabled d a ta  to be collected on the  an n u a l num ber of 
death s due to specified causes, th u s  allowing yearly  com parisons to be 
m ade, changes to be no ticed  and  possib le  rea so n s  in v es tig a te d . For 
example, an  increase in the  num ber of deaths from asthm a in  the  1960s 
was found to coincide with an increase in the  use of pressurised aerosols. 
The subsequen t lim ita tio n s im posed on th e  use  of th ese  aerosols w as 
followed by a drop in the number of asthm a-related deaths [20].
2
(2) C ongenital m alform ations and b irth  defects
The surveillance of congenital m alform ation and b irth  defects has been 
dem onstrated to be of particular importance in identifying possible causes 
of congenital m alform ation. This was h ighlighted  in  th e  1940s w hen a 
link  was discovered betw een in fan ts exhibiting specific eye defects and 
the  infection of their m others with rubella during pregnancy [21]. It was 
again highlighted in 1962, when a link  was identified betw een m others 
ta k in g  th e  s e d a tiv e  d ru g  th a lid o m id e  d u r in g  p re g n a n c y  a n d  th e  
subsequent b irth  of infants with gross limb defects [22].
(3) C ardiovascular d isease  surveillance
C a rd io v a sc u la r  d ise a se  is  a le a d in g  cau se  of d e a th  a n d  d is a b il i ty  
th ro u g h o u t th e  world. Accordingly, th e  WHO card io v ascu la r u n it  in 
Geneva in itia ted  a surveillance scheme for coronary h e a r t d isease and  
cerebrovascular disease. This scheme, known as the  MONICA project, is 
ru n  in 27 countries covering more th an  12 million people [23]. One of the 
prim ary aim s of MONICA is to tes t hypotheses re la ting  coronary-risk to 
f a c to rs  su c h  as c h o le s te ro l, d ia s to lic  b lood  p r e s s u r e  a n d  to b acco  
consumption.
(4) C ancer Surveillance
Cancer surveillance schem es were introduced in  th e  UK betw een 1958 
and  1962. They collect d a ta  on m orbidity and  m ortality , w hich enable 
tre n d s  in  incidence to be no ticed  and  in v es tig a te d . D a ta  from  such  
schemes have helped to justify  the introduction of screening program m es 
for early diagnosis of cancer (such as cervical cancer and b rea st cancer). 
The da ta  have also been used to calculate survival ra tes following cancer 
diagnosis, and have played an im portan t role in  evaluating  th e  success 
both of these screening programmes and new methods of treatm ent.
D a ta  from  can cer su rv e illa n c e  schem es h av e  b e en  u se d  v e ry  
successfully to suggest possible aetiological hypotheses. For example, the 
num ber of cases of bladder cancer among workers in the  rubber industry  
suggested a possible link to an antioxidant used in  the  rubber industry  
[24].
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(5) C om m unicable d iseases
Most microbiology laboratories in the United Kingdom voluntarily report 
any occurrence of specific infections (such as salm onella, chlam ydia and 
hep atitis) to na tional surveillance cen tres in  Glasgow and  London. In  
addition to these laboratory reports, health  professionals report notifiable 
d iseases (such as chicken pox, rubella  and  tuberculosis) to these  sam e 
centres. This information is collated and published weekly, together w ith 
d a ta  from  th e  p rev ious w eek an d  th e  p rev ious year, for com parison  
purposes. This enables changes in incidence of infection to be identified 
and action to be taken . For exam ple, in  la te  1993 and  early  1994, an  
increase in  the  num ber of m easles infections among school-age children 
w as noticed, prom pting  a vacciniation program m e to be im plem ented. 
S u b seq u en t su rv e illan ce  d a ta  show ed th a t  th e  incidence  of m easles  
dropped and a possible epidemic had  been averted. M edical advances, 
such as the  eradication of smallpox, together w ith the  emergence of new 
in fe c tio n s , su c h  a s  HIV, le a d  to  c h a n g in g  r e q u i r e m e n ts  fo r th e  
surveillance of communicable diseases.
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1.2 The aims of this thesis
The discovery of AIDS and its causative agent HIV, in  th e  early  1980’s, 
w ere th e  ca ta ly s ts  for th e  in troduction  of a series of HIV su rve illance  
schemes. However, in the haste  to establish these surveillance schemes, 
th e  ta s k  of com prehensive  d e ta ile d  d o cu m en ta tio n  w as le f t la rg e ly  
undone. This lack of documentation occurred because priority was rightly 
given in itially  to da ta  collection. Thus, there  were early  publications on 
the num ber of AIDS cases reported and the num ber of people testing  HIV 
positive , w hile  p u b lica tio n s on th e  su rv e illan ce  m ethodology lagged  
behind . T his p a tte rn  w as rep ea ted  w ith  th e  in troduc tion  of th e  UAT 
schem es and  the  CD4 m onitoring schem es, w ith th e  need to estab lish  
these schemes, and produce results, taking priority over documentation.
One of th e  a im s of th is  th e s is  is to  fill th is  gap by p ro d u cin g  a 
reference document containing a historical record of the  developm ent of 
H IV  s u rv e illa n c e  a t  S C IE H , from  1985-1995 , in c lu d in g  d e ta i le d  
descriptions of the individual schemes together w ith the ir aims, the  type 
of da ta  collected, and how the schemes are managed. It is envisaged th a t 
th is  docum ent will be of practical help to people cu rren tly  w orking on 
th ese  HIV surveillance  schem es, those who will w ork on th em  in  th e  
fu ture, and  those who requ ire  to reference p a rticu la r m ilestones in  the  
development of HIV surveillance in Scotland.
A fu r th e r  aim  of th e  th e s is  is to in crease  u n d e rs ta n d in g  of th e  
s p r e a d  o f H IV  in  S c o tla n d , by  a n a ly s in g  d a ta  p ro d u c e d  by  th e  
surveillance schemes.
For the HIV and AIDS Registers, th is involves looking a t trends in 
rep o rted  HIV infection  and  AIDS, w ith  tim e, by fac to rs such  as age, 
gender, geographical region and risk  category. F u rther analysis involves 
in stig a tin g  a follow-up of all reported  AIDS cases before carry ing  out a 
m ultivariate survival analysis from AIDS diagnosis to death.
For the  Denominator Study, analysis includes looking a t trends in 
HIV te s tin g , w ith  tim e, by factors such as age and  gender, as well as 
calculation of testing  ra te s  in specific age bands. F u rth e r work includes 
estim ating the effect of risk  category, geographical region, reason for test, 
source of request, gender, age, presence of clinical symptoms, and year of 
test, on the  probability of testing HIV positive.
For both the  UAT and the CD4 schemes, analysis involves looking 
a t t re n d s  in  HIV te s tin g , w ith  tim e, by fac to rs  such  as age, gender,
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g eo g rap h ica l reg ion  and  r isk  category. In  a d d itio n , th e  CD4 s tu d y  
includes analysis of the relationships between region, risk  factor for HIV, 
and severity of HIV infection.
In  addition to analysing each surveillance scheme separately, it is 
aimed to dem onstrate the advantages to be gained by linking the  d a ta  in 
th e  HIV and AIDS R egisters w ith  d a ta  from the  CD4 Study. W ith th is  
link established, various analyses are carried out, including estim ation of 
the  proportion of reported HIV positive persons who progressed to AIDS, 
and the CD4 values of people newly reported HIV positive.
The final aim  of th is  th es is  is to ev a lu a te  th e  HIV su rve illance  
schem es curren tly  co-ordinated a t SCIEH. This includes looking a t the  
u tilisation  of the  da ta  gathered, in particu lar w hat do these schemes tell 
u s about the  spread of HIV in the  general population, the  spread  of HIV 
in high-risk categories, and about the m agnitude of resources required for 
the  care of HIV positive patien ts. This evaluation also involves looking 
a t th e  b iases  in h e re n t in  each schem e and  a ssessing  each schem e for 
a t t r ib u te s  such  as s im p lic ity , f lex ib ility , a c c e p ta b ility , s e n s it iv ity , 
representativeness and tim eliness. Finally, each scheme is exam ined for 
its contribution to the overall surveillance of HIV in Scotland.
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1.3 First reports of AIDS
In  Ju n e  1981, th e  M orbid ity  and  M orta lity  W eekly R eport (MMWR) 
published by the Centers for Disease Control (CDC) in A tlan ta, Georgia, 
c a rr ie d  a re p o r t  of five p rev io u s ly -h e a lth y  hom osexual m en  in  Los 
Angeles, California, who had pneumocvstis carinii pneum onia (PCP) and 
unexplained  profound im m une deficiency [1]. W ith in  th e  nex t m onth, 
tw enty-six  cases of a ra re  m alignan t tum our called K aposi’s sarcom a 
(K S), a n d  a n  a d d it io n a l  te n  c a se s  of PCP, w e re  r e p o r te d  am o n g  
hom osexual m en [2]. Soon it became apparen t th a t there  w as a rap id ly  
in c r e a s in g  e p id e m ic  of in fe c tio n s  a n d  tu m o u rs  a s s o c ia te d  w ith  
unexplained immune deficiency [3].
W hen the  im m une system  is im paired, persons affected become 
susceptible to a wide range of infections and tum ours. The infections are 
often called ‘opportunistic infections’ because they  take  the  opportunity  
p rov ided  by th e  deficiency in  th e  p e rso n ’s im m une sy s tem  to  cause  
d iseases th a t  w ould not norm ally  occur. In  1982, th e  te rm  ‘acqu ired  
im m une deficiency syndrom e’ (AIDS) was introduced, to encom pass the  
ran g e  of in fec tions and  tu m o u rs th a t  w ere be ing  seen  in  people w ith  
u n e x p la in e d  im m une deficiency. In  S ep tem b er 1982, s ta f f  a t  CDC 
published  th e  firs t AIDS-case definition [4]. In  each of th e  years 1985, 
1987 and  1993, th e  defin ition  of AIDS w as expanded to  encom pass a 
g re a te r  v a rie ty  of oppo rtun is tic  in fections and  clin ical p re se n ta tio n s  
[25-27].
1.3.1 AIDS cases world-wide
Betw een Ju n e  1981 and December 1994, 1,025,073 cases of AIDS were 
r e p o r te d  to  th e  W orld  H e a l th  O rg a n iz a t io n  (W HO) in  G e n e v a , 
Sw itzerland [28]. I t  is well known th a t  th is  is an  u n d erestim a te  of the  
t r u e  fig u re  b ecau se  of u n d e r-d ia g n o s is , u n d e r-  r e p o r t in g  a n d  la te  
reporting. WHO estim ated the true  figure (at 31st December, 1994) to be 
over 4.5 million [28].
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1.4 The discovery of HIV
The num ber of reported AIDS cases increased throughout 1982, and  the 
sam e op p o rtu n is tic  infections assoc ia ted  w ith  u n ex p la in ed  profound 
im m une deficiency in hom osexual m en w ere reported  in  in jecting  d rug  
users (IDUs) and haemophiliacs [4]. A virus was deemed the  m ost likely 
c au se  of AID S, b ecau se  of th e  re sem b lan c e  to  th e  ep idem io logy  of 
H e p a titis  B. H ep a titis  B w as know n to have a v ira l cause, and  to be 
spread by sexual intercourse and through blood contact.
In  1983, a r e tro v iru s  w as th o u g h t to  be a s so c ia te d  w ith  th e  
development of AIDS. This retrovirus was isolated by a team  led by Dr L. 
M o n ta g n ie r  a t  th e  I n s t i tu t  P a s te u r  in  P a r is ,  F ra n c e , a n d  n a m e d  
‘ly m p h a d en o p a th y  a sso c ia ted  v iru s ’ (LAV) [5]. By 1986, w hen  th e  
retrovirus was renam ed the ‘hum an immunodeficiency v irus’ (HIV), most 
epidemiologists agreed th a t HIV was the causal agent of AIDS. Although 
a few epidemiologists have rem ained unconvinced th a t HIV causes AIDS, 
th is  view has become increasingly un tenab le  th rough  tim e as evidence 
has increased th a t HIV does indeed cause AIDS [29,30].
1.4.1 Viruses and retroviruses
A v iru s is an  infectious agen t th a t  invades cells of o th er o rgan ism s in  
order to replicate. A single v irus partic le  (called a virion) consists of a 
core of deoxyribonucleic acid (DNA) surrounded by a protein shell and an 
ou ter layer of p ro te in  called th e  v ira l envelope. I t  a tta c h e s  i ts e lf  to a 
suitable cell of another organism, often called the  host cell, th en  invades 
i t .  V iru se s  can  only  a tta c h  th e m se lv e s  to  ce lls  t h a t  h a v e  s u i ta b le  
receptors on their surfaces. The viral DNA uses the  raw  m ateria ls of the  
host cell to make large num bers of new copies of itself. These new virions 
th e n  leave  th e  h o st cell and  inv ade  o th e r cells, th u s  c o n tin u in g  th e  
replication process. The host cell may be destroyed in th is process.
A r e t r o v i r u s  ( lik e  a v iru s )  c o n s is ts  o f a co re  of n u c le ic  ac id  
su rrounded  by a pro tein  shell and a v iral envelope bu t, in  a re trov irus, 
th e  nucleic acid is ribonucleic acid (RNA). On en te rin g  a host cell, th e  
RNA is  c o n v e rte d  to DNA b efo re  r e p l ic a t in g  a n d  b e in g  re le a s e d . 
Throughout th is thesis, HIV is referred-to sim ply as a v irus ra th e r  th an  
more specifically as a retrovirus.
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1.4.2 Immune response
W hen people w ith  h ea lth y  im m une system s a re  a ttac k ed  by foreign 
organisms such as viruses, bacteria or fungi, the immune system reacts in 
a specific way. This immune response involves a range of different blood 
cells, including two specific types of white blood cells called B-lymphocytes 
and T-lymphocytes.
The first step in the immune response is to recognise the  invading 
o rg a n ism . A p a r t ic u la r  ty p e  of T -lym phocy te , c a lle d  th e  T -h e lp e r 
lymphocyte, plays a crucial role in th is recognition process, th en  "helps" 
o th e r  lym phocy tes to m oun t an  a p p ro p ria te  im m une re sp o n se . An 
im p o r ta n t  fu n c t io n  of th e  T -h e lp e r  ly m p h o c y te  is  to  s t im u la te  
B-lymphocytes and T-killer lymphocytes to multiply. B-lymphocytes then  
produce antibodies which may attach  them selves to the  antigen  (foreign 
protein) on the  surface of the invading organism. This, in  tu rn , s ta r ts  a 
process which enables the T-killer lymphocytes, and other white cells such 
as phagocytes, to destroy  th e  re su ltin g  c lu s te rs  of cells. Some of th e  
B-cells and T-killer cells rem ain in the body as memory cells, so th a t if the 
organism should invade again, the immune response will be more rapid.
1.4.3 Immune response to HIV infection
HIV attaches itse lf to CD4 molecules which are found on th e  surface of 
T-helper cells, monocytes and macrophages. Thus, each of these types of 
cells m ay become infected w ith  HIV. W hen HIV a ttac h es  i ts e lf  to th e  
T-helper cells, they are unable to function correctly, and a crucial p a rt of 
the  im m une system  is weakened. The person’s im m une response is then  
in a d e q u a te ly  eq u ip p ed  to w ith s ta n d  su b s e q u e n t a t ta c k s  by o th e r  
invading organism s, m aking the  person susceptible to a whole range of 
opportunistic infections and tumours.
1.4.4 Transmission of HIV
There are three known routes of transm ission of HIV :-
(1) Sexual intercourse
(2) Blood to blood transm ission
(3) Mother to child transm ission
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Injecting drug users may become infected by blood to blood transm ission, 
through injecting with needles previously used by an HIV-infected person.
1.4.5 Progression of HIV infection
B etw een th ree  to twelve weeks after infection w ith  HIV, alm ost 50 per 
cent of people will experience a flu-like illness, possibly accompanied by 
fever, le thargy , ly m p hadenopa thy  or a ra sh , called  a se roconversion  
illness [31]. However, these symptoms occur so frequently in the  general 
popu la tion  th a t  HIV is un like ly  to be su spec ted  as th e  cause  of such  
symptoms. Infection is usually, bu t not necessarily, followed by a period 
w hen the  p a tien t is well. This tim e period w hen clinical sym ptom s are  
absent (commonly called the asymptomatic period) is very variable. After 
the  asym ptom atic period, opportunistic infections, which m ay be of long 
or short duration, will usually develop .
The m edian  tim e from infection  to th e  developm ent of AIDS is 
estim ated  to be betw een 1 0 -1 1  years [32,33]. A lthough progression to 
AIDS is the  norm  for HIV infected individuals, a num ber of persons who 
have been infected w ith HIV for m any years, w ithout developing AIDS, 
are beginning to be identified. There is much debate as to w hether these 
peop le  h av e  developed  im m u n ity  to HIV, or a re  s im p ly  v e ry  slow  
progressors [34-36].
HIV progression  can be m easu red  im m unologically  as w ell as 
clinically. The best known, and most widely used, of these immunological 
m easurem ents is the absolute num ber of T-helper cells (also known as T4 
cells or CD4 cells) per cubic m illim etre of blood. This count (often called 
th e  CD4 c o u n t)  is  k n o w n  to  d e c lin e  in  H IV -in fe c te d  p e o p le  by  
approximately 40-80 counts per year, on average [13], although individual 
counts m ay fluctuate widely.
1.4.6 HIV antibody test
In  1985, a te s t  for de tec ting  an tibod ies to HIV, in  sam ples of se rum , 
becam e rou tinely  available. D etectable antibodies to HIV will u sua lly  
develop betw een th ree  to twelve weeks a fte r infection; th is  process is 
c a lle d  se ro co n v e rs io n  [31]. T he p e rio d  from  H IV  in fe c tio n  to  th e  
development of detectable antibodies is often referred  to as the  ‘window 
period’.
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An indiv idual is said  to be ‘HIV positive’, or have a ‘positive te s t 
resu lt’, if the  HIV tes t detects antibodies to HIV If the  HIV tes t does not 
detect HIV antibodies, the person is said to be ‘HIV negative’. If a person 
is HIV positive then, w ith the exception of babies, they  are  regarded  as 
be ing  in fec ted  w ith  H IV  A person  who is HIV negative  m ay s till  be 
infected w ith HIV if they are in the  ‘window period’. Babies born to HIV 
positive m others, carry  m aterna l antibodies which m ay be detected  by 
HIV testing. Approximately 84 per cent of these in fan ts la te r  lose these  
m aternal antibodies, and are found not to be infected w ith HIV [37].
1.4.7 HIV infection world-wide
WHO estim ated  (at 31st December 1994) th a t approxim ately 18 million 
ad u lts  and  1.5 m illion children have been infected w ith  HIV since th e  
epidemic began [28]. The worldwide distribution of these estim ated cases 
is given in Figure 1.01.
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1.5 Surveillance of HIV infection in Scotland
As the AIDS epidemic unfolded, staff at the  Scottish Centre for Infection 
an d  E n v iro n m e n ta l H e a lth  (SCIEH ) re sp o n d ed  to th e  ch a lle n g e  of 
prov id ing  ap p ro p ria te  su rveillance  schem es. T hese schem es evolved 
naturally , as a te s t for antibodies to HIV became available, and  as other 
immunological param eters became m easurable. A nother im portan t step 
in  th e  su rv e illa n c e  of HIV a ro se  w hen  th e  UK G o v e rn m e n t gave  
perm ission for the  in troduction of un linked  anonym ous te s tin g  (UAT). 
These developments have led to a network of surveillance schemes which 
are mentioned briefly in th is chapter and, in detail, in la ter chapters.
T he C om m unicab le  D iseases  (S co tlan d ) U n it (CD (S)U ) w as 
established in 1969, to undertake surveillance of communicable diseases 
in  Scotland . In  1993, i t  w as am a lg am ated  w ith  th e  E n v iro n m en ta l 
H ealth  (Scotland) U nit (EH(S)U) to become the Communicable Diseases 
and Environm ental H ealth (Scotland) U nit (CDEH(S)U). In  1994, it was 
renam ed  th e  Scottish C entre for Infection and E nv ironm en ta l H ealth  
(SCIEH). T hroughou t th is  thes is , irrespective  of th e  tim e period , th e  
surveillance centre is referred to as the Scottish C entre for Infection and 
Environm ental H ealth (SCIEH).
Throughout th is  thesis, I have consistently  analysed  all th e  d a ta  
available to me, from each individual surveillance scheme, a t th e  tim e of 
th e  a n a ly s is . T h is  h a s  c re a te d  d if fe re n t cu t-o ff  d a te s  in  d if fe re n t  
analyses, depending upon the date at which the analysis was performed. 
These d ifferent cut-off da tes are  th e  penalty  paid  for m aking  th e  m ost 
effective use of all the available data.
F ig u re  1.02 show s th e  in tro d u c tio n  of th e  H IV  s u rv e i lla n c e  
schemes, co-ordinated a t SCIEH, against the  background of cum ulative 
HIV-positive test results reported to SCIEH.
1.5.1 The AIDS Register
Since 1982, all clinicians w orking in Scotland have been encouraged to 
report any AIDS cases in the ir care, in s tric t m edical confidence, to the  
d irec to r of th e  AIDS/HIV surveillance program m e a t SCIEH . To d a te  
(31st December 1994) 604 cases of AIDS have been reported to the  centre 
[38].
All AIDS cases are reported to SCIEH on a specially designed AIDS
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report form. This form is used to record the  opportunistic  infections, or 
clinical presentations, a t the tim e of AIDS diagnosis. The report form is 
also used to record possible routes of transm ission for acquiring HIV, date 
of b irth , gender, in itia ls  and h ea lth  board of residence. M odification of 
th e  form h as been necessary  every tim e th e  AIDS defin ition  h as  been 
widened. The la test version of the form, introduced in 1994, is described 
in  detail in chapter two.
1.5.2 The HIV Register
In  1985, a reg is te r  w as in itia te d  a t SCIEH to record  all persons who 
te s te d  H IV positive  as a re s u lt  o f ‘v o lu n ta ry -n am ed ’ HIV  te s t in g  in  
Scotland. The term  ‘voluntary-nam ed’ m eans th a t the  person has agreed 
to  be te s te d  and  is know n, by nam e or clinic id en tifie r, to  th e  doctor 
re q u e s tin g  th e  te s t  and  to  th e  HIV te s tin g  labo ra to ry . T he p e rso n ’s 
surnam e is encoded a t the  laboratory, and the code forwarded to SCIEH. 
H ence, th e  p e rso n ’s su rn a m e  is no t know n to s ta f f  a t  SC IE H . I t  is 
im portan t, however, th a t  individuals who are  te s ted  a t m ore th a n  one 
laboratory are able to be detected. These individuals m ay be recognised 
by their encoded surnam e, date of birth, gender, and initials.
To date (31st December 1994) reports of 2,209 HIV positive persons 
a re  on th is  re g is te r  [38]. T h is re g is te r  is com m only ca lled  th e  ‘HIV 
Register’ and is examined more fully in chapter three.
1.5.3 The Denominator Study
I t  w as soon rea lised  th a t  th e  HIV R egister w as difficu lt to in te rp re t, 
because very little  was known about the characteristics of the  population 
who were coming forward for voluntary-nam ed HIV tests. Accordingly a t 
SCIEH, in 1989, a scheme was initiated to collect laboratory reports of all 
persons undergoing voluntary-nam ed HIV tests  in Scottish laboratories, 
re g a rd le s s  of th e  te s t  r e s u l t  [39]. T h is w as offic ia lly  know n as th e  
‘Scottish  N ational Collaborative HIV Seroprevalence S tudy’, b u t soon 
became colloquially known as the  ‘Denom inator S tudy’. This nam e was 
appropriate, since the  study enabled the num erator of HIV positive tes ts  
to be in te rp re ted  in  conjunction w ith the  denom inator of all HIV tes ts . 
This study is examined in detail in chapter four.
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1.5.4 Reporting of mortality from HIV infection
C lin ic ia n s , w ho r e p o r t  A ID S c a se s  to  S C IE H , h a v e  a lw a y s  b e e n  
encouraged to notify SCIEH of the death of any of their patients. In 1994, 
clinicians caring for AIDS pa tien ts were contacted to ascerta in  if any of 
th e ir  p a tie n ts  had  died and  th e ir  deaths not repo rted  to SCIEH. The 
outcom e of th is  exercise show ed th a t  th e  rep o rtin g  system  for AIDS 
deaths was working well (see section 2.6.1).
I t  is less  easy  to m on ito r m o rta li ty  in  th e  p o p u la tio n  of HIV- 
infected persons who have not developed AIDS. Accordingly, in  1989, an 
arrangem ent was made with the Registrar General for Scotland (RGS) to 
collect, and forward to SCIEH, information on HIV-related deaths.
This reporting system is examined more fully in  chapter three.
1.5.5 Unlinked anonymous testing for HIV
In  N ovem ber 1989, th e  UK G overnm ent announced  th a t  U n lin k ed  
Anonymous Testing (UAT) of serum  for HIV would begin, in certain areas 
of the UK, on a pilot basis [40]. The principles of UAT are :-
(1) To use only residual specimens from blood (or urine) originally 
collected for some other test.
(2) To ensu re  anonym ity, by irreversib ly  u n lin k in g  th e  re s id u a l 
specim en from any inform ation  w hich would enable  it to  be 
linked to the  individual from whom it came, b u t not from basic 
epidemiological data.
For exam ple, the  residual specim en would be un linked  
from  th e  nam e, ad d re ss  or exact d a te  of b ir th , b u t  re m a in  
linked to inform ation on the  gender, hea lth  board of residence 
and age group of the patient.
The m ain  advantage of UAT is th a t  it d ispenses w ith  th e  need to seek 
p e rm iss io n  from , and  provide counselling  for, everyone to  be te s te d , 
thereby m inimising participation bias and counselling resources.
By d isplaying m ultilingual leaflets and  posters a t clinics tak in g  
p a rt in UAT schemes, people are informed th a t their blood, or urine, m ay 
be tested  anonymously for HIV, unless they choose not to participate. In 
p rac tice , th e  com pliance ra te  is over 98% in  m ost of th e  s tu d ie s  (see 
chapter five).
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The m ain d isadvantage of UAT is th a t  any specim en found to be 
HIV positive cannot be traced back to the person from whom it was taken, 
therefore th a t individual cannot be notified and  helped. Betw een 1990 
an d  1992, a nu m b er of UAT s tu d ie s  w ere in s tig a te d , fu nded  by th e  
Medical Research Council (MRC). Details of these studies are provided in 
chapter five.
1.5.6 The CD4 Study
In  Ju ly  1990, the World H ealth Organization (WHO) published a staging 
system  for people who were infected w ith HIV [13]. This WHO stag ing  
system  classifies people according to th e ir CD4 count and th e ir  clinical 
sym ptom s. In  November 1991, a surveillance schem e w as introduced, 
applying the WHO staging system to all HIV-infected persons undergoing 
ly m phocy te  m o n ito rin g  a t  th re e  H IV  im m uno logy  la b o ra to r ie s  in  
S c o tla n d . T h is  s u rv e i l la n c e  sc h em e  is  c a l le d  th e  ‘CD 4 S tu d y ’. 
Inform ation from the CD4 Study has enabled epidemiologists to discover 
m ore about th e  h e a lth  of the  HIV-infected popu lation  in  Scotland. In  
particu lar, it provides new and useful inform ation on the  large num bers 
of HIV-infected persons who have not progressed to AIDS. This study is 
described and analysed in chapter six.
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1.6 Public health importance of HIV infection
The public h ea lth  im portance of an infection m ay be assessed  by th ree  
m ain criteria
(1) Number of cases
(2) Severity of cases
(3) Prevent ability
W ith an estim ated 4.5 million persons having developed AIDS since 1981, 
and  alm ost 20 m illion persons having become infected w ith HIV w orld­
wide, the  num ber of cases of AIDS and HIV is obviously large enough to 
cause great concern.
T here can be no doubt of the  severity  of HIV infection. W ith th e  
exception of babies (see section 3.3), once a person is infected w ith HIV, 
he or she rem ains infected and infectious for life. I t  is e stim ated  th a t  
nine years after infection, 40 per cent of people will have developed AIDS, 
with only 10 per cent rem aining asymptomatic [31].
T he th ird  c r ite r io n , p re v e n ta b ility , is of g re a t  im p o rta n c e  in  
com bating  th e  sp re ad  of HIV. In  th e  absence of a vaccine or a cure , 
emphasis m ust be placed on halting the spread of the virus. Transm ission 
of HIV may be greatly reduced by behavioural changes. The acceptability 
of p ra c tis in g  ‘safe sex ’, by u sin g  condom s for p e n e tra tiv e  sex, w ould 
reduce the  spread of HIV and other sexually tran sm itted  diseases. The 
use o f ‘clean needles’, by injecting drug users, would likewise reduce the  
spread of HIV w ithin th is group. M aking such behavioural changes and 
susta in ing  them  is, a t present, generally held to be the key to containing 
the epidemic [41].
It is clear th a t on all th ree  criteria, HIV infection is an  extrem ely 
im p o r ta n t  p u b lic  h e a l th  is s u e , a n d  is  l ik e ly  to  r e m a in  so fo r th e  
foreseeable future.
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1.7 Government response to HIV infection
Throughout the  development of the HIV surveillance schemes, there  has 
been close collaboration betw een SCIEH and  the  Scottish  Office. The 
encouragem ent and financial support provided by the  Scottish Office has 
been invaluable in the  development and m aintenance of these  schemes. 
In addition, monies made available by the Scottish Office have been used 
to fund  public-education  cam paigns, special AIDS u n its  an d  needle- 
exchange schemes.
1.7.1 All-Party Parliamentary Group on AIDS
In  October 1986, an A ll-Party P arliam en tary  Group on AIDS (APPGA) 
w as se t up  to ra ise  aw areness of AIDS, to keep AIDS on th e  po litica l 
a g e n d a , a n d  to  "en courage  p o l ic ie s  b a se d  on r e l ia b le  so u rc es  o f  
information" [42]. In  1994, th is  group consisted  of 174 m em bers, 114 
from  th e  H ouse of Commons and  60 from th e  H ouse of Lords. I t  h a s  
provided a forum for various voluntary and sta tu to ry  bodies to exchange 
both information and views on wide-ranging aspects of HIV infection.
In M arch 1993, the AIDS Awareness T rust’ was launched w ith the 
objective of improving public education in issues related to AIDS and HIV 
infection. The tru s t provides financial support for the APPGA.
1.7.2 Ministerial task force
In  Ju ly  1991, a m in isteria l ta sk  force was set up, led by M r M. Forsy th  
(th en  M in is te r of S ta te  w ith  resp o n sib ility  for h e a lth  a t th e  S co ttish  
Office). The ta sk  force included experts from  th e  h e a lth  services, th e  
v o lun ta ry  sector, social services and o ther re lev an t fields. I t  in itia lly  
undertook to exam ine "measures to reduce the spread of HIV and AIDS  
and to ensure services were provided and co-ordinated to best advantage"
[43]. T he ta s k  force p u b lish ed  a re p o rt, in  M arch  1992 [41], w hich  
included recom m endations for h e a lth  education  and  for co-operation  
b e tw e e n  g ro u p s  w o rk in g  w ith in  H IV -re la te d  f ie ld s . T h e  H e a l th  
Education Board for Scotland (HEBS) were asked to take a m ajor role in 
all HIV-related educational initiatives.
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Issues highlighted under health  education included :-
(1) M aintaining public awareness of HIV and AIDS.
(2) Reviewing health  education in schools.
(3) T rain ing  on HIV/AIDS issues for teachers, police and  o thers 
involved in community education.
(4) E stablishing a liaison group to exchange views on HIV health- 
education issues.
To facilitate co-operation the task  force recommended :-
(1) A s tra teg ic  p lan n in g  group to be estab lish ed  in  each  h e a lth  
board, to co-ordinate H IV -related issues w ith in  th a t  h e a lth  
board.
(2) A national group to be established to co-ordinate H IV -related 
issues at a national level.
(3) Drug-related issues to be developed, including work in prisons.
(4) Voluntary HIV testing to be made more accessible.
1.7.3 Public health strategies
The im portance attached by the Government to the problems associated 
w ith HIV infection, was demonstrated in a policy statem ent issued by the 
Scottish Office, in 1992, entitled ‘Scotland’s Health: A Challenge to us All’
[44], by the specification of HIV/AIDS as a priority area.
A sim ila r docum ent, pub lished  by th e  D epartm en t of H ea lth  in  
1992, e n ti t le d  ‘T he H e a lth  of th e  N ation : A S tra te g y  for H e a lth  in  
E ngland’ [45], included HIV/AIDS and sexual h ea lth  as one of five key 
areas.
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1.8 Evaluation of surveillance schemes
E valuation of surveillance schemes is necessary to ensure th a t valuable 
resources are  used as efficiently as possible. The inevitable changes in 
h e a lth -re la ted  problem s are  reflected  in  changing  d a ta  req u irem en ts . 
W hile some surveillance schemes, originally of g rea t value, m ay become 
re d u n d a n t, o th e rs , o rig in a lly  of le s se r  v a lu e , m ay  a ssu m e  g re a te r  
im portance  (such as th e  m onitoring  of th e  u se  of pen tam id in e , in  th e  
USA, which led to the identification of AIDS [46]).
E valuation  of su rveillance schem es is ex trem ely  complex. The 
evaluation methods used in th is thesis (see chapter 8) concentrate on the  
u t i l i s a t io n  of in d iv id u a l schem es an d  on a c r i t ic a l  rev ie w  of t h e i r  
a ttribu tes. Evaluation of the finiancial benefits and costs of runn ing  the 
various HIV surveillance schem es described in  th is  th esis  w as deem ed 
outwith the scope of th is thesis and has not been carried out.
1.8.1 Utilisation of surveillance
The value of surveillance is inextricably  linked  to th e  use  m ade of th e  
data  collected. Surveillance data  are used for m any purposes, such as
(1) To determine the incidence and prevalence of a health  problem, 
and to detect changes in incidence as early  as possible so th a t 
appropriate action may be taken.
(2) To detect epidemics, outbreaks, or clusters of a health  problem.
(3) To e s tim a te  th e  m orb id ity  and  m o rta lity  a sso c ia ted  w ith  a 
health  problem.
(4) To identify those with a health  problem (and th e ir contacts) in 
order th a t they may be offered appropriate health  care.
(5) To improve understanding of the health  problem; for example
(a) To d e te rm in e  th e  p o p u la t io n  a t  r i s k  a n d  id e n t i f y  
vulnerable groups of people.
(b) To identify possible risk factors.
(c) To stim ulate ideas for research, e.g. to provide hypotheses 
of the aetiology of a disease.
(6) To help evaluate an intervention, e.g. vaccination or screening.
(7) To help plan future health  requirem ents.
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1.8.2 Attributes of a surveillance scheme
A p ra c tic a l approach  to ev a lu a tio n  of su rv e illan ce  schem es involves 
assessing  p a rticu la r a ttr ib u te s  common to m ost surveillance schem es, 
su c h  a s  s im p lic ity , f le x ib il i ty , a c c e p ta b i l i ty ,  s e n s i t iv i ty ,  
representativeness and tim eliness [47]. However, the relative importance 
of these a ttrib u te s  will vary betw een surveillance schemes; for example, 
tim eliness is of critical im portance in surveillance of infections such as 
in flu e n z a , w here  p ro m p t con tro l m e a su re s  a re  n ecessa ry , b u t  le ss  
im portan t in cancer surveillance. Additionally, in  certa in  surveillance 
schem es it  m ay only be p rac ticab le  to im prove som e a tt r ib u te s ,  e.g. 
sensitivity, a t the expense of others, e.g. simplicity.
(1) S im p licity
Surveillance schem es should be as sim ple as possible in  both  s tru c tu re  
and ease of operation, while still m eeting their objectives. In  particular, 
they should be as stream lined as is practicable and collect only necessary 
data.
(2) F lex ib ility
Surveillance schemes should be as flexible as possible in order to be able 
to adapt to changing needs. Changes occur naturally  as knowledge about 
the  health  event improves (e.g. changing AIDS definitions in  1985, 1987, 
and  1992 [25-27]). Changes m ay also be caused by other factors such as 
varying data  requirem ents. In general, simpler surveillance schemes will 
be more flexible.
(3) A cceptab ility
Surveillance schem es should be acceptable both  to th e  people who are  
operating the surveillance scheme, such as clinicians, laboratory staff and 
c lerical staff, and  to those  who are  u n d e r su rve illance . M easu res  of 
acceptability include participation ra tes, com pleteness of d a ta  on forms, 
reporting rates, and timeliness of reporting.
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(4) S en sitiv ity
T he se n s itiv ity  of a su rv e illan ce  schem e is i ts  a b ility  to id en tify  a ll 
occurrences of the health  event under surveillance. Sensitivity is affected 
by the likelihood th a t a person w ith the health  event seeks medical care, 
th a t the  hea lth  event is correctly diagnosed, and th a t it  is subsequently  
rep o rted  to th e  su rve illance  schem e. S en sitiv ity  m ay be affected  by 
heigh tened  aw areness of a hea lth  event, as well as in troduction  of new 
diagnostic  te s ts  or new trea tm e n ts . Surveillance schem es not of h igh  
sensitiv ity  m ay still be useful in m onitoring trends, provided th a t  th e  
sensitivity rem ains relatively constant. Sensitivity m ay be m easured by 
the completeness of case reporting.
(5) R ep resen tativen ess
A highly representative surveillance scheme will describe accurately the  
occurrence of a h ea lth  event over tim e, and  its  d is tribu tion  th roughou t 
th e  popu la tion . The re p re se n ta tiv e n e s s  of a su rv e illan ce  schem e is 
affected by sam pling biases which may exclude certain  sub-groups of the  
population or favour inclusion of other sub-groups. Change in  reporting  
practice is another factor affecting representativeness.
(6) T im eliness
Surveillance schem es should be able process inform ation as quickly as 
possible. There should be no undue delays between the  component p a rts  
of the surveillance system. Timeliness can best be assessed by the ability 
of th e  system  to ta k e  ap p ro p ria te  action  based  on th e  u rgency  of th e  
h e a lth  even t. F o u r tim e  p o in ts  a re  of p a r t ic u la r  im p o rtan c e  w hen  
considering timeliness, namely :-
(a) Time of onset of event.
(b) Time of diagnosis.
(c) Time of report to surveillance centre.
(d) Time of implementation of appropriate action.
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1.9 Methods
From  th e  s ta r t  of my resea rch  it  w as c lear to me th a t  w hile  th e  f irs t 
reco g n ised  cases of AIDS, an d  th e  e n su in g  d iscovery  of HIV, w ere  
extrem ely well docum ented, th e re  was a lack of docum entation  on th e  
surveillance schemes subsequently set up to m onitor the  spread of AIDS 
and HIV. However, few would argue th a t  docum entation  is necessary, 
therefore the  w riting and compilation of such docum entation should be 
u n d e r ta k e n  as soon  as  re s o u rc e s  p e rm it ,  p a r t i c u la r ly  s in c e  th e  
opportun ity  to collaborate w ith the  people who se t up th e  surveillance 
schem es will decrease w ith time. Access to sources of inform ation, such 
as inform al correspondence and g ran t applications, is also easiest while 
key personnel are still in post. Thus, for the  creation of docum entation, 
th e re  is a window of opportun ity  outside w hich th e  ta s k  m u st become 
much harder.
The sources of information available to me included
(1) D ocum entation
E arly  rep o rts  of AIDS and HIV w ere well docum ented in  publications 
such as M orbidity  and  M orta lity  W eekly Report, and  Science [1-3,5]. 
These early  reports were soon followed by various historical accounts of 
the early days of the epidemic, e.g. [46].
In  the 1980’s, few sources of documentation relating to surveillance 
of HIV in  Scotland w ere availab le, except for ro u tin e  rep o rts  of e arly  
c a se s  of A ID S a n d  HIV, an d  in fo rm a l c o rre sp o n d e n c e  a n d  g r a n t  
applications to funding bodies such as the Medical Research Council and 
the Scottish Office.
(2) P erson al C ontact
On my becoming a m em ber of the  AIDS/HIV team  a t SCIEH in  1991, I 
had  daily contact w ith the  people who were responsible for setting  up the  
A ID S/H IV -related su rveillance  schem es in  Scotland, and  w as able to 
discuss w ith them  the  beginning of each of these schemes. In  addition to 
this, informal team  m eetings gave me the opportunity to assess how the  
schemes were operating, while formal m eetings w ith colleagues working
22
in  AIDS/HIV throughou t Scotland gave me the  fu rth e r opportun ity  to 
assess how the schemes were perceived, and used, by other professionals. 
Scientific m eetings, such as in te rn a tio n a l AIDS conferences and  MRC 
workshops, allowed me to discuss, formally and informally, the  resu lts of 
HIV su rve illance  in  Scotland, and  com pare th ese  re s u lts  w ith  those  
obtained from sim ilar schemes elsewhere.
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Chapter 2
The AIDS Register
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2.1 Introduction to AIDS surveillance in the United Kingdom
In Septem ber 1982, fifteen months after the first reports appeared in the 
Morbidity and M ortality Weekly Report (MMWR) relating  to unexplained 
profound immune deficiency in young men [1-3], a national surveillance 
scheme was introduced for the purpose of monitoring the spread of AIDS in 
th e  U n ited  K ingdom . T his w as a jo in t in it ia tiv e  by SC IEH  and  th e  
Communicable Disease Surveillance Centre (CDSC), which is p a rt of the 
Public H ealth  Laboratory Service (PHLS). Clinicians are encouraged to 
report, to th is  surveillance scheme, any pa tien ts  who develop an AIDS- 
defining illness. The objectives of this surveillance scheme are
(1) To detect cases of AIDS in the United Kingdom, and to monitor 
trends in incidence.
(2) To assist research into the epidemiology of AIDS.
2.1.1 First AIDS-case definition
I t  was soon ap p aren t th a t  people suffering from unexplained  im m une 
deficiency were developing a wide range of infections and tum ours. To 
provide guidelines for surveillance purposes, a defin ition  of AIDS was 
compiled by the Centers for Disease Control, A tlan ta  (CDC), in 1982 [4]. 
This defines a case of AIDS as a person who has both
(1) A re lia b ly  d iagnosed  d isease  th a t  is, a t le a s t , m o d e ra te ly  
indicative of immune deficiency.
(2) No known underlying cause of immune deficiency.
The definition was made more specific by stating the diseases or conditions 
which were thought to be indicative of immune deficiency
(1) Kaposi’s sarcoma (KS)
(2) Pneumocystis carinii pneumonia (PCP)
(3) Some specific forms of meningitis
(4) Some specific forms of encephalitis
(5) O esophagitis due to cand id iasis, cytom egalovirus or herpes 
simplex virus
(6) Progressive multifocal leukoencephalopathy (PML)
(7) Chronic entercolitis (more than four weeks) due to cryptosporidiosis
(8) Unusually extensive mucocutaneous herpes simplex (of more than 
five week’s duration)
25
I t was recognised th a t there  would probably be m anifesta tions of AIDS 
which the definition did not cover, but a MMWR report [4] sta ted  th a t the 
"absence o f  a reliable, inexpensive, w ide ly  a v a ila b le  te s t  fo r  AID S, 
however, m ay m ake the w ork ing  case de fin it io n  the best cu rren tly  
available for incidence monitoring"
By 1985, a reliable tes t for detecting antibodies to HIV w as readily 
available, and other clinical p resen tations were known to be associated 
with immune deficiency. The first AIDS-case definition [4] was amended, 
in 1985, to encompass th is new knowledge. The new AIDS-case definition 
included a lis t of o ther signs of im m une deficiency, provided th a t  they  
occurred in  a person who had  developed antibodies to HIV [25,48,49]. 
These other signs included :-
(1) Disseminated histoplasmosis
(2) Isosporiasis
(3) Bronchial or pulmonary candidiasis
(4) Non-Hodgkin’s lymphoma
2.1.2 First reported AIDS cases in Scotland
By 31st December 1984, the  first th ree  cases of AIDS had  been reported  
to SCIEH. Two had presented with opportunistic infections, and one w ith 
PCP; all were m ales over 30 years of age. One was homosexual, one was 
a haemophiliac, and one had received a blood transfusion  abroad. Three 
years later, a t 31st December 1987, a to tal of 39 cases of AIDS had  been 
reported to SCIEH.
Table 2.01 shows the  epidemiological ch arac te ris tics  of th ese  39 
AIDS cases. It shows th a t 77 per cent of the  AIDS cases were diagnosed 
in  1986 or 1987, 67 per cent were hom osexual or b isexual m en, 82 per 
cent were over 30 years of age, and 51 per cent presented w ith PCP. Only 
4 IDUs (all female) were among these 39 AIDS cases.
2.1.3 Public Health Acts
T he P ub lic  H e a lth  Act of 1899 enforced  n o tif ic a tio n , to  th e  p ro p e r 
au thorities, of specified infectious diseases in the  UK. AIDS, however, 
h as not been added to the  lis t of notifiable diseases, in  the  UK [50]. In  
J a n u a ry  1989, M r D. M ellor (th en  M in is te r  of S ta te  for H e a lth ) , in  
response to a parliam entary  question on why AIDS had  not been m ade a
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notifiable disease, said
"The departm ent d id  not consider th a t there were any  
strong public health grounds for making AIDS a notifiable 
disease. To do so would be unlikely to improve the present 
reporting system or to assist health professionals in their 
work. Notification might also deter people from seeking 
help and so drive the infection underground." [51].
2.1.4 AIDS (Control) Act, 1987
On 15th M ay 1987, P arliam en t passed  th e  ‘AIDS (Control) Act, 1987’.
The requirem ents of th is act are
(1) Every h e a lth  board  in  Scotland m ust subm it a rep o rt to  th e  
Secretary of State.
(2) These reports will contain information specified in the  act, and 
such "other relevant information as the Secretary of State may  
direct".
(3) These reports will be published.
(4) The Secretary of S tate  may decide the form th a t the  report will 
take and the period it will cover. This period m ust be one year 
or under.
The first reports were to be made to the Secretary of S tate  and published
by 31st D ecem ber 1988. The in fo rm atio n  in itia lly  re q u e s te d  by th e
Secretary of State comprised
(1) The num ber of persons, known to each h ea lth  board, to have 
AIDS diagnosed in the previous twelve months.
(2) The cumulative num ber of AIDS cases in  each health  board.
(3) The num ber of AIDS cases, known to the  health  board, to have 
died in the previous twelve months.
(4) The cum ulative num ber of deaths am ong AIDS cases in  each 
health  board.
(5) H ealth  boards are  asked to give d e ta ils  of th e  fac ilitie s  and  
services for HIV testing, HIV prevention, counselling and care, 
available w ithin their respective areas.
(6) H e a lth  b o a rd s  a re  a sk e d  to  g ive th e  n u m b e r  of p e rs o n s  
employed (full and part-time) in providing these services, in the
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previous twelve months.
(7) H ealth  boards are asked to provide an estim ate of the  facilities 
and services they expect to provide in the next twelve months.
(8) H ealth  boards are asked to report w hat action has been taken, 
w ith in  th e  h e a l th  b o a rd , in  e d u c a tio n , t r a in in g  for H IV  
counselling, and treatm ent of HIV-infected people.
On an annual basis, SCIEH provides all health  boards w ith da ta  from the 
AIDS and HIV Registers to assist them  in the compilation of their reports 
to th e  S ecretary  of S ta te  for Scotland, in com pliance w ith  th e  Act. An 
example of such data  is given in Figure 2.01.
A m ap show ing the  location of th e  h e a lth  boards in  Scotland, is 
provided in the back pocket of th is thesis.
2.1.5 AIDS-case report form
To s ta n d a rd is e  A ID S -case  d a ta -c o lle c tio n  th ro u g h o u t  th e  U n ite d  
Kingdom, in  1987 a new reporting form was designed jo in tly  by SCIEH 
and CDSC. The information requested falls into five m ain sections :-
(1) Name of the  clinician reporting the  AIDS case, and  the  hospital or 
clinic from which the case is reported. The health  board of residence 
of the patien t is also requested.
(2) The date  of b irth , gender and ‘soundex code’ of th e  su rnam e of the  
patient.
To p r e s e rv e  p a t i e n t s ’ c o n f id e n tia l i ty ,  c l in ic ia n s  a re  
encouraged to use  ‘soundex codes’ as an  a lte rn a tiv e  to  u s in g  th e  
pa tien t’s surnam e. The soundex code is derived by following a set of 
rules to convert the surnam e to a letter followed by three digits. The 
le tte r  is sim ply the  first le tte r  of the  surnam e. Each soundex code 
represents a group of surnam es, w ith no soundex code being unique 
to  a p a r t ic u la r  su rn a m e , th u s  p re se rv in g  c o n fid en tia lity . T he 
soundex code can be derived by using  a set of w ritten  instructions, 
by a pre-program m ed calculator, or by using  a com puter program  
[52,53]. W hen th e  soundex code is u sed  in  conjunction  w ith  th e  
p e rso n ’s d a te  of b ir th , it  is possible to de tec t p robab le  d u p lica te  
reports which can then  be investigated.
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(3) All possible risk  factors for acquiring HIV are requested. In  some 
cases there will be more than  one way in which the person m ay have 
become infected; for instance, injecting drug users who are sexually 
active  m igh t have  acqu ired  th e  v iru s  sex u a lly  or th ro u g h  d ru g  
injecting.
To allocate people to risk  categories, a h ierarchical system  is 
used. This hierarchy is given in Table 2.02. The risk  is determ ined 
first by the risk activities of the patient, then  by the risk  activities of 
his or her partner(s). From Table 2.02, it can be seen th a t  a person 
who is an injecting drug  user, and a sexually  active heterosexual, 
will be classified as an injecting drug user.
While th is approach allows for consistency of classification, it 
w ill ten d  to over-estim ate  th e  num ber of persons who a re  in  th e  
categories a t the  top of the  hierarchy, a t the  expense of those lower 
down. Thus, the num ber of infections a ttribu ted  to IDU will appear 
higher (and the num ber a ttribu ted  to heterosexual risk  will appear 
low er) th a n  th ey  ac tu a lly  are . T his, in  tu rn , is lik e ly  to lead  to 
u n d e re s t im a tio n  of th e  e x te n t of h e te ro se x u a l s p re a d  of HIV, 
possibly  causing  u n w a rra n te d  com placency in  th e  h e te ro sex u a l 
population.
(4) D ates of la s t HIV-negative te s t resu lt, and  f irs t HIV-positive te s t 
resu lt (if available).
(5) All AIDS-defining conditions present a t tim e of AIDS diagnosis.
A hierarchical system, sim ilar to the one already described for 
risk  classification, is used to categorise clinical presentation a t AIDS 
diagnosis. This hierarchy is given in Table 2.03. From  th is  tab le  it 
can  be seen  th a t  a p e rso n  p re s e n tin g  w ith  b o th  KS a n d  H IV  
en cep h a lo p a th y  w ill be c lassified  as p re se n tin g  w ith  KS. Once 
again, th is hierarchical approach overestimates categories a t the  top 
of the hierarchy at the expense of those lower down.
2.1.6 United Kingdom collaboration on reporting of AIDS cases
All new AIDS cases, reported to e ither SCIEH or CDSC, a re  com pared 
w ith  those already reported  w ith in  the U nited  Kingdom, using  da te  of 
b irth , gender, and soundex code of surnam e to e lim inate  any duplicate
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reports. The hierarchies shown in Tables 2.02 and 2.03 are used  by both 
SCIEH and CDSC to obtain uniform ity of classification, throughout the  
UK, of bo th  r isk  and  AIDS p resen ta tio n . S ta ff  a t SC IEH  a n d  CDSC 
co-operate regu larly  to discuss surveillance issues and  p rep are  repo rts  
[54-57].
2.1.7 AIDS-case definitions (1987 and 1993)
In  S ep tem b er 1987, th e  o rig ina l d e fin itio n  of an  AIDS case  [4] w as 
expanded to include the m any more opportunistic infections which were 
th e n  know n to be a sso c ia ted  w ith  AIDS [26]. In  J a n u a ry  1993, th e  
C enters for Disease Control (CDC) again adopted a new definition of an  
AIDS case [27,58]. This definition included th ree  more AID S-indicator 
diseases :-
(1) Recurrent pneumonia within a 12 m onth period
(2) Pulmonary tuberculosis
(3) Invasive cervical cancer
However, the  m ain difference in the new CDC AIDS-case definition was 
the  inclusion of all HIV-infected adu lts w ith a CD4 count of un d er 200, 
regardless of the presence of an AIDS-indicator disease. This new AIDS- 
case  d e fin itio n  is su b s ta n tia l ly  w ider th a n  th e  p rev io u s  A ID S-case 
definition, w ith its introduction resulting  in  a large rise in the  num ber of 
AIDS cases reported in the USA [59]. CDC stated  th a t the use of the new 
definition would allow more people to be classified as AIDS cases which, 
in  tu rn , w ould allow  th em  access to a d d itio n a l m ed ica l a n d  socia l 
benefits.
A European working group rejected the CDC revision. The reasons 
they gave for th is were :-
(1) Lack of availability of CD4 m onitoring throughout Europe. In  
countries where CD4 m onitoring is available, there  is a lack of 
adequate quality assurance.
(2) The undesirable psychological effect, of being categorised as an 
AIDS case, on HIV-infected people who may feel quite well.
(3) In  Europe, unlike the USA, access to appropriate hea lth  care is 
not dependent on the person’s illness being classified as AIDS, 
so th e re  is  no a p p a re n t  m ed ica l b e n e f it  to  th e  p a t ie n t  in  
widening the AIDS-case definition to include low CD4 counts.
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However, the  E uropean w orking group did agree to add th e  th ree  new 
AID S-indicator d iseases to the  1987 definition [60,61]. One im portan t 
consequence of the  changes in the  1993 definition of AIDS, is th a t AIDS 
statistics from the USA and Europe are no longer directly comparable.
2.1.8 AIDS-case report form (1993)
T his new AIDS-case definition w as adopted in  th e  U nited  Kingdom  in  
J a n u a ry  1993 [61]. A new AIDS report form, including  th e  th ree  new 
AIDS-indicator diseases, was designed in the  sum m er of 1993. W ith the 
r e p r in t in g  of th e  form , th e  o p p o r tu n ity  w as ta k e n  to  m ak e  som e 
im provem ents to th e  design of th e  form. In  p a rticu lar, th e  sections on 
risk  category and AIDS presentation  were simplified, and a section was 
introduced to record the patien t’s initials. Three new sections were added 
to the form :-
(1) Clinical symptoms of HIV prior to the development of AIDS
(2) D eta ils  of p rophylactic  tre a tm e n t and  a n ti- re tro v ira l  d ru g  
therapy taken by the patien t before AIDS diagnosis
(3) Cause of death (where applicable)
A copy of the  new AIDS-case report form is included in the  back pocket of 
th is thesis.
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2.2 Reporting delay for AIDS cases
The tim e elapsing between the clinician diagnosing a case of AIDS, and 
reporting tha t case, is called the ‘reporting delay’. In Scotland, the median 
reporting delay is between three and six months. The reporting delay varies 
greatly among doctors, with some doctors preferring to wait until they have 
a batch of cases to report. There is little  doubt th a t the tim e required to 
complete the  AIDS-case reg istra tion  form is one of the  reasons for both 
under-reporting and delayed-reporting.
There is always the possibility th a t an AIDS case will be reported 
several years after diagnosis but, in Scotland, only eight cases of AIDS (1.5 
per cent) have ever been reported more than three years after diagnosis.
2.2.1 Rosenberg’s  correction for reporting delay
A computationally attractive method of adjusting AIDS figures for reporting 
delay w as developed by P. R osenberg [62], req u irin g  only th e  d a te  of 
diagnosis and the date of report, for each AIDS case. This method makes 
two assumptions :-
(1) The reporting delay is independent of the date of the AIDS diagnosis.
(2) The reporting delay is always less than three years.
The first assum ption is untrue, in th a t reporting delay was longer in the 
early years of AIDS (1983-1986) than it has been subsequently. This was 
mostly owing to the ra rity  of AIDS cases in Scotland a t th a t time, lower 
aw aren ess  of th e  m any p re sen ta tio n s  of AIDS, and  a less developed 
reporting  system . However, for cases reported from 1989 onwards, th is  
assumption has appeared to be reasonable.
The second assum ption has already been shown to be reasonable, 
since fewer than 2 per cent of all cases ever reported, in Scotland, have had a 
reporting delay of more than three years.
Applying Rosenberg’s correction to the  AIDS cases diagnosed in 
Scotland since January 1989, and reported to SCIEH by 31st December 1993 
(see Table 2.04), it can be shown that 9 per cent of AIDS cases are reported 
within one month of diagnosis, 57 per cent within three months, and 82 per 
cent within one year. Throughout section 2.2, Rosenberg’s method is used, 
whenever appropriate, to correct for reporting delay. The distribution of 
reporting delay is shown in Figure 2.02.
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2.3 Reporting of mortality from AIDS in Scotland
Deaths are reported to SCIEH in two ways :-
(1) Directly by the clinician m anaging the AIDS case.
(2) The Registrar General for Scotland (RGS) notifies SCIEH of all 
deaths in Scotland if the cause of death is likely to be related  to 
HIV infection.
Throughout the past ten  years, in Scotland, the death  toll from AIDS has 
risen steadily from 25 deaths having occurred by 31st December 1987, to 
346 d ea th s  by 30th  A pril 1994 [63]. F igure  2.03 show s th e  num ber of 
deaths, in  cases of AIDS reported  to SCIEH, by year of death . F igure  
2.04 shows the num ber of persons who are known to be dead, thought to 
be alive, or are of unknow n vital s ta tu s  (at 30th April 1994), by the  year 
of th e ir AIDS diagnosis. There are twelve persons whose v ita l s ta tu s  is 
not known (at 30th April 1994). Eleven of these persons have come from 
abroad and have subsequently returned home, and one has not been seen 
by his doctor since the  AIDS diagnosis was m ade in  A ugust 1991. Only 
two patien ts whose AIDS- defining illnesses were diagnosed before 1989 
(one in 1984 and one in 1987), are known to be still alive (at 30th April 
1994). All the other patients, who are assum ed still to be alive, have had  
their AIDS-defining illnesses diagnosed from 1989 onwards.
2.4 Completeness of AIDS-case reporting
Since some AIDS cases are not diagnosed, not reported, or are  reported  
late, the  cumulative num ber of reported AIDS cases will always be fewer 
th an  the actual num ber of cases. In Scotland, the ra te  of under-reporting 
of AIDS cases is estim ated  to be approxim ately ten  per cent [16]. This 
compares w ith an estim ate of 20 per cent under-reporting in England and 
Wales [56,64], and 15 per cent in the USA [65].
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2.5 Analysis of AIDS cases in Scotland
2.5.1 Year of AIDS diagnosis
By 30th A pril 1994, 512 AIDS cases had  been reported  to SCIEH [63]. 
Figure 2.05 shows these cases, by year of diagnosis. It shows a rise in the 
num ber of new AIDS cases diagnosed each year from 1988 to 1991, then  a 
fall in  1992. Figure 2.06 shows the expected num ber of AIDS cases, by 
year of diagnosis, once ad justm ent for repo rting  delay h as  been m ade. 
T he e s tim a te  for 1992 ap p ea rs  u n u su a lly  low, and  is th o u g h t to be a 
re su lt of prophylaxis and an ti-re trov ira l th e rap y  delaying th e  onset of 
AIDS [7,66]
2.5.2 Living AIDS cases
Every year, from 1986 onwards, the  num ber of new AIDS diagnoses has 
exceeded the  num ber of deaths from AIDS. This has been reflected in an 
annual increase in  the  num ber of persons w ith  AIDS who are  still alive
[7]. F igure 2.07 shows th a t in G reater Glasgow, Lothian, and  Tayside 
H ealth  Boards, the num ber of persons with AIDS who have been alive at 
the end of each calendar year, from 1990 to 1994, is rising through time.
2.5.3 Presentation at AIDS diagnosis
T able 2.05 shows th a t  50 per cent of AIDS cases have p resen ted  w ith  
PCP. O ther opportunistic infections (OOI) account for 29 per cent of all 
AIDS diagnoses. KS accounted for 10 per cent of th e  early  (pre 1988) 
AIDS diagnoses (see Table 2.01), b u t th is  has fallen to 6 per cent of the  
512 cases reported by 30th April 1994.
2.5.4 Risk category of AIDS cases
T able 2.05 show s th e  a llocated  risk  categories, by gender, for th e  512 
rep o rted  AIDS cases. I t  shows th a t  53 p er cen t of th e  m ale  cases a re  
classified as homosexual/bisexual, 31 per cent as IDUs, and 8 per cent as 
h e te ro sex u a l. T h is c o n tra s ts  w ith  th e  r isk  c lass ifica tion  for fem ales 
where 60 per cent are classified as IDUs, and 24 per cent as heterosexual.
F igure  2.08 shows th e  num ber of cases of AIDS diagnosed  each 
year, a ttr ib u te d  to e ith e r  hom osexual/b isexual or IDU tran sm iss io n .
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These figures are adjusted  for reporting  delay, and do not include those 
who are both homosexual/bisexual and IDU. This figure shows that, from 
1984 to 1988, the  predom inant route of infection of reported  AIDS cases 
was homosexual/bisexual. Since 1986, there  has been an increase in the  
num ber of reported AIDS cases a ttribu ted  to injecting drug  use. F igure
2.08 shows th a t the num ber of cases expected to be reported as diagnosed 
in 1993, after correcting for reporting delay, is g reater for those classified 
as IDUs th an  for those classified as homosexual/bisexual.
2.5.4.1 Heterosexual risk category
In  recent years, in te rest has focused on increasing repo rts of AIDS 
cases attributed  to heterosexual transm ission.
H eterosexual tran sm iss ion  is categorised  in to  th re e  h ie ra rch ica l 
groups
(1) ‘High risk ’ partner. Men or women who have had  sexual 
in te rc o u rs e  w ith  a p e rso n  in  a rec o g n ise d  h ig h  r is k  
c a te g o ry  su c h  a s  ID U , b is e x u a l ,  o r a r e c ip ie n t  o f 
HIV-infected blood or blood products.
(2) ‘Exposure abroad’. Men or women, not in  group (1), who 
have had sexual intercourse abroad.
(3) ‘Exposure United Kingdom’. Men or women who have had 
sexual intercourse in the  UK and are not in  groups (1) or 
(2).
H etero sex u a l tra n sm iss io n s  a re  c lass ified  accord ing  to th e  r isk  
ac tiv ities of th e  p a rtn e r, not the  HIV s ta tu s  of th e  p a rtn e r. T his 
lead s  to th e  anom aly  th a t  a pe rso n  m ay have  a p a r tn e r  who is 
known to be HIV infected, bu t the partner will not be categorised as 
a ‘h igh  r isk ’ p a rtn e r  un less he or she is in  a recognised h igh  risk  
category.
As with other hierarchies, th is approach will overestim ate the 
categories a t the top of the hierarchy (e.g. ‘high-risk p a rtn e r’), a t the 
expense of categories lower down (e.g. ‘exposure (UK)’).
Table 2.05 shows th a t fifty-six of the  AIDS cases reported  to 
SCIEH were classified as heterosexual. F ifteen (27 per cent) were 
categorised  as ‘h igh  r isk ’ p a rtn e r, tw en ty -seven  (48 p e r cent) as
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‘exposure abroad’, and ten  (18 per cent) ‘exposure UK’. T here  are  
fo u r c a se s  w h e re  th e  t r a n s m is s io n  r i s k  is  on ly  k n o w n  to  be 
heterosexual; these  cases are  under investigation  to classify them  
more specifically to one of the  heterosexual subgroups [63]. F igure
2.09 shows the expected num ber of AIDS cases a ttribu ted  to each of 
the  heterosexual risk  categories, by year of diagnosis (ad justed  for 
reporting delay). It shows a large increase in the  expected num ber 
of AIDS diagnoses in  1993, a ttr ib u te d  to ‘high r isk ’ p a rtn e rs , and  
also underlines the importance of ‘exposure abroad’.
2.5.5 Health board of residence at AIDS diagnosis
Figure 2.10 shows the num ber of AIDS cases, by health  board of residence 
a t the tim e of AIDS diagnosis. It shows th a t 44 per cent of all AIDS cases 
w ere res id en t, a t th e  tim e of th e ir  AIDS diagnosis, in  L o th ian  H ea lth  
Board, com pared w ith  24 per cent residen t in  G reater Glasgow H ealth  
Board, and 13 per cent in Tayside Health Board.
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2.6 Survival analysis
I t is clearly im portan t for the  patien t, the  clinician, and those allocating 
resources for pa tien t care, to know the expected survival ra te s  following 
AIDS diagnosis. Although it is valuable to estim ate survival ra tes based 
on d a ta  collected from those persons who have a lready  reached  AIDS 
diagnosis, some caution is required. The use of antiretroviral treatm ents, 
be tter pa tien t m anagem ent, and prophylaxis for opportunistic infections 
[67-71], have all played an im portant part in improving survival following 
infection w ith HIV. While it is reasonable to assum e th a t im provem ents 
in survival will continue, pre-AIDS survival m ay increase a t the  expense 
of post-AIDS survival, by the onset of AIDS being delayed to a la te r stage 
of immune deficiency at which survival rates rem ain poor [7,72].
2.6.1 Following-up of adult AIDS cases
Of the 498 adult AIDS cases reported to SCIEH by 30th April 1994, 334 
were known to have died [63]. Enquiries were made of the rem aining 164 
AIDS patien ts to ascertain when they last had their CD4 count m easured, 
or were last seen by medical staff.
If SCIEH had  not been notified of the  death  of a pa tien t, and th a t  
p a tien t had  undergone CD4 m onitoring in  the  period J a n u a ry  to A pril 
1994, th en  the  p a tien t was assum ed to be still alive a t 30th  A pril 1994. 
There were 133 patients in th is category.
E nqu iries w ere m ade of th e  rem ain ing  31 p a tie n ts  who h ad  not 
u n d erg o n e  CD4 m on ito ring  in  th e  period  J a n u a ry  to A pril 1994, by 
contacting the  clinicians who first reported them  to SCIEH. Five of the  
31 cases had  recently died, and their deaths had not yet been reported to 
SCIEH . E leven p a tie n ts  had  left the  country, and  h ad  th e ir  su rv iva l 
tim es ‘ censored’ a t the  date they left. W hen a survival tim e is ‘censored’ 
it m eans th a t the patien t is known to have survived for a t least th a t tim e 
w ith  AIDS. O nly one p a tie n t  h ad  no t been  seen  by h is  doctor since  
A ugust 1991, hence h is surv ival tim e w as censored a t th a t  da te . The 
o ther 14 p a tien ts  had  all been seen by th e ir  doctors in th e  previous six 
m onths, and  were assum ed to be still alive a t 30 A pril 1994. All cases 
thought to be alive a t 30 April 1994 had the ir survival tim es censored a t 
th a t date.
All d e a th  c e r tif ic a te s , rece ived  a t  SC IE H , w ere  e x am in e d  to
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identify cases where the cause of death did not seem to be directly related 
to HIV. Five persons, who were on the  AIDS Register, appeared  to have 
died  from  causes o th er th a n  AIDS. T hree  p e rso n s h ad  d ied  of d ru g  
overdoses, one of cirrhosis of the  liver, and one of ‘in h a la tio n  of gastric  
con ten ts’. These five AIDS cases had  th e ir  surv ival tim es censored a t 
their date of death.
Survival tim es, from date of AIDS diagnosis to date of death, were 
calculated for all who had died from AIDS, and from date of diagnosis to 
date of censoring, for the  rem ainder. Analysis was restric ted  to the  394 
AIDS cases diagnosed by 31st December 1992, since it  is though t th a t  
cases w ith shorter survival tend to be reported more quickly, thus under­
estim ating survival in recent years [55].
2.6.2 Results of univariate survival analysis
Each of the  variables used in the  survival analysis w as categorised into 
m utually exclusive groups. ‘Age (in years) a t AIDS diagnosis’ was divided 
in to  five groups; 15-24, 25-29, 30-34, 35-44, and  45+. ‘Year of AIDS 
d iag n o s is ’ w as d iv ided  in to  th re e  groups; p re  1988, 1988-1989, an d  
1990-1992. ‘Geographical region’ was divided into four groups according 
to the  health  board from which the  pa tien t w as first reported  as having 
AIDS; G reater Glasgow, Lothian, Tayside, and ‘other’. ‘Risk category for 
HIV tran sm iss io n ’ w as divided into five groups; hom osexual/bisexual, 
ID U , h e te ro se x u a l, h a em o p h iliac  or b lood p ro d u c ts , a n d  ‘o th e r  or 
unknown’. ‘AIDS presentation at diagnosis’ was divided into six groups :-
(1) PCP
(2) KS
(3) HIV encephalopathy
(4) W asting attributed  to HIV
(5) O ther opportunistic infection (OOI)
(6) Other-cerebral lymphoma, non-Hodgkin’s lymphoma and PML
F irstly , a ll v a ria b le s  w ere exam ined  in d iv id u a lly  to p roduce  a se t of 
univariate  analyses. For the univariate analyses, K aplan M eier survival 
cu rv es  [73,74] w ere ca lcu la te d , an d  th e  d iffe ren ce  b e tw ee n  c u rv es  
assessed using a log rank  test [75]. The analyses were carried out using 
SPSSPC+ [76], and th e  resu lts  sum m arised  in  Table 2.06. Following 
AIDS diagnosis, m edian survival for the  394 cases was 17 m onths. One
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year after AIDS diagnosis, 60 per cent were still alive; by two years, 37 
per cent were alive, and by th ree  years only 22 per cent w ere still alive. 
F igure  2.11 show s a sm oothed surv ival curve (based on th e  stepw ise  
K aplan M eier survival curve) from AIDS diagnosis to death. T here were 
significant differences in survival between age groups a t AIDS diagnosis, 
betw een presen tations a t AIDS diagnosis, and betw een h ea lth  boards of 
AID S d iagnosis . T hese  re s u l ts  a re  show n g rap h ica lly , for se lec te d  
categories, in Figures 2.12, 2.13 and 2.14.
2.6.3 Results of multivariate survival analysis
W hile u n iv a r ia te  an a ly ses  a re  in fo rm ative , i t  is im p o r ta n t to  m ake  
allowances for the effect of associations between the  variables by using  a 
m ultivariate analysis.
All the  variables used in the  univariate  analysis were en tered  into 
a Cox’s p roportional h a za rd ’s model, to p red ic t factors ind ep en d en tly  
associated  w ith  surv ival [74,77]. The analysis  w as ca rried  ou t u s in g  
BMDP procedure P2L [78].
The re su lts  of th e  ana ly sis  are  given in  T able 2.07. T h is tab le  
show s th e  re la tiv e  r isk  (RR) a sso c ia ted  w ith  each  of th e  c a teg o ries , 
compared to a baseline category, while m aking allowances for th e  effects 
of all the  other variables. This analysis shows th a t people aged 45 years 
or over have poor survival compared to those aged 15-24 years. The 95 
per cent confidence in terval (95% Cl) for the  relative risk  of survival for 
those aged 45 years or over, com pared w ith  those aged 15-24 y ears, is 
(1.4, 3.9).
P o o re r  su rv iv a l  w as fo und  to  be  a s so c ia te d  w ith  th o s e  w ho 
p resen ted  w ith HIV encephalopathy, HIV w asting syndrom e, or ‘o ther’; 
‘other’ being cerebral lymphoma, non-Hodgkin’s lymphoma or PML. The 
95% C l fo r th e  RR of s u rv iv a l  fo r th o s e  p r e s e n t in g  w i th  H IV  
e n c e p h a lo p a th y , c o m p a re d  to  th o s e  n o t - p r e s e n t in g  w ith  H IV  
en cep h a lo p a th y , is  (1.4, 19.9). S im ila r r e s u l ts  w ere  found  for ‘HIV 
wasting’ (95% Cl 1.6, 28.0) and for ‘other’ (95% Cl 2.3, 34.9).
T he in d e p e n d e n t e ffec ts  of age a n d  c lin ica l p r e s e n ta t io n  on 
survival, following AIDS diagnosis, have been well docum ented. These 
effects w ere no ted , e a rly  in  th e  HIV epidem ic, in  key  p a p e rs  on th e  
su rv iva l experiences of 5,833 AIDS p a tie n ts  in  New York [79], and  of 
4,323 AIDS p a tien ts  in San Francisco [80]. More recen t p apers  on th e
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survival experiences of 3,984 AIDS cases in th e  U nited  Kingdom  [55], 
2,135 AIDS p a tien ts  in B razil [81], and  3,204 AIDS cases in  A u stra lia  
[82], show th a t these variables are still significantly related to survival.
Gender, risk  category, and year of AIDS diagnosis were found not 
to be sta tistica lly  significant predictors of survival. Survival, following 
AIDS diagnosis, was found to be poorer in Tayside H ealth  Board th an  in 
Lothian H ealth Board. Possible explanations for th is are
(1) D ifferent diagnostic practices in  d ifferent regions lead ing  to 
earlier, or later, diagnosis of AIDS.
(2)Regional differences in treatm ent policies, such as the  early use 
of zidovudine, which might delay the progression to AIDS [83].
O ther stud ies have found th a t  survival differs am ong regions [55,84], 
although the reasons for th is are not clear. Additional da ta  are necessary 
to examine th is regional difference more closely, in particu lar CD4 counts 
a t tim e of AIDS diagnosis, and knowledge of trea tm en t practices in  the  
different hospitals in the different regions.
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2.7 AIDS predictions
2.7.1 AIDS predictions working groups
In June  1994, Dr R. Kendell (Chief Medical Officer for Scotland) convened 
a working group to be chaired by Professor D. Reid (director of SCIEH). 
The rem it given to th e  w orking group w as to estim ate , for each of th e  
years 1995 to 1999, the num ber of HIV-infected individuals, in  Scotland, 
who
”(■a) will develop AIDS or severe HIV immunodeficiency
(b) will require substantial health care because of their HIV  
infection." [8].
This was the fourth working group convened to predict future num bers of 
cases of AIDS and severe HIV-related disease in Scotland.
The first working group, chaired by Mr W. Tayler, was convened in 
1987, and  provided predictions of AIDS cases in Scotland from 1987 to 
1991 [18]. The second group, chaired by Dr B. McClelland, was convened 
in  1990, and provided predictions of AIDS cases and severe HIV-related 
disease from 1990 to 1993 [17]. The th ird  group, chaired by Professor D. 
Reid, was convened in 1992, and provided predictions of AIDS and severe 
HIV-related disease to 1995 [16].
2.7.2 Problems associated with AIDS predictions
Several factors m ake predictions of fu tu re  num bers of AIDS cases and 
cases of severe HIV-related disease difficult :-
(1) The very long and very variable incubation period from HIV to 
AIDS (median 10-11 years) [32,33].
(2) T hose  com ing fo rw a rd  for an  H IV  te s t  a re  a n  u n k n o w n  
proportion of all those infected with HIV.
(3) One of th e  prim ary  rou tes of infection is sexual, and  little  is 
known about m ixing p a tte rn s  w ithin , and  betw een, d ifferent 
sexual groups. There are problems in obtaining accurate da ta  
on sex u a l b ehav iou r, and  th e re  a re  f u r th e r  d if f ic u ltie s  in  
assessing the  influence of education and publicity on p a tte rn s  
of sexual behaviour. The lack of d a ta  on sexual behaviour has 
been redressed, to some extent, by the publication of the resu lts
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of studies of sexual behaviour [85-87].
(4) A dvances in  th e  u se  of a n t i r e t r o v i r a l  t r e a tm e n ts ,  b e t te r  
m anagem en t of p a tien ts , and  p rophylax is for o ppo rtun is tic  
infections, all affect survival following HIV infection [67-71].
Should new tre a tm e n ts  be in troduced  in  th e  nex t few 
years, they may have a significant effect on survival which, in 
tu rn , will affect predictions of AIDS and severe HIV infection 
[8].
However, regard less of the  problem s, predictions of fu tu re  AIDS cases 
and cases of severe HIV-related disease are essential, particularly  for :-
(1) P lan n in g  purposes, to ensu re  adequa te  resou rces a re  m ade 
available for patient care.
(2) T argeting  of education and support w here it is m ost needed, 
and where it will be most effective.
2.7.3 AIDS predictions - results and assessm ent
The second Reid working-group predictions were completed in  December 
1995 [8], using  the  methodology from the  previous repo rt [16,88]. The 
predictions were based on AIDS cases, and deaths, reported to SCIEH by 
M arch 1995 [89], together w ith estim ates of progression ra te s  from HIV 
to AIDS [68,90-94], and estim ates of the  cum ulative num ber of persons 
infected with HIV.
Predictions show th a t a gradual increase in new cases of AIDS is 
expected, from 140 cases in 1995 to 155 cases in 1999 [8]. The num ber of 
new AIDS cases, a ttribu tab le  to homosexual/bisexual risk  and  IDU risk, 
is expected to stay relatively constant, a t approximately 40 cases per year 
and  60 cases per y ear respectively. The num ber of new  AIDS cases, 
a ttribu tab le  to heterosexual risk, is expected to increase from 20 cases in 
1995 to 55 cases in 1999.
The predictions also show th a t the  num ber of persons w ith AIDS, 
and still alive, is expected to rise  from 240 in 1995 to 270 in  1999, w ith  
the largest increase occurring in the heterosexual group [8].
The p red ic tions of th e  second Reid w orking  group a re  g iven in  
Figure 2.15, together w ith the predictions of the  previous th ree  working 
g roups. F ig u re  2.15 show s th a t  th e  p re d ic tio n s , p ro d u ced  by each  
w ork ing  group, have  successively  decreased  and  have  becom e m ore
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accurate. It would, however, be unjust and over-simplistic to say th a t the 
previous working groups overestim ated the  scale of the  AIDS epidemic. 
T he e a r l ie r  p red ic tio n s  drew  th e  a tte n tio n  of th e  a u th o r i t ie s  to th e  
po ten tial severity  of the  problem. The reactions of these  au thorities, in 
the form of various public health  initiatives, have almost certainly played 
an  im p o rtan t role in  p rev en tin g  th ese  e a r lie r  p red ic tio n s from  be ing  
fulfilled.
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2.8 Distribution of AIDS data
Tables of cumulative and newly-reported AIDS cases are published every 
calendar q u arte r in a SCIEH publication ‘ANSWER’ (a copy of which is 
provided in the back pocket of this thesis). These tables show cumulative 
A ID S f ig u re s  by  h e a l th  b o a rd  of r e g i s t r a t io n ,  g e n d e r , p ro b a b le  
tran sm iss io n  rou te, and  v ita l s ta tu s . ANSWER is d is tr ib u ted , free of 
charge, to those who help to provide the  d a ta  in all the  HIV surveillance 
schem es co-ordinated a t SCIEH. ANSWER is produced monthly, th e  
o ther two issues in  each calendar q u a rte r  con ta in ing  o rig inal a rtic les  
concerning HIV in Scotland.
Tables of cum ulative and new ly-reported AIDS cases are  sen t to 
CDSC every ca lendar quarte r, to be included in  th e  U n ited  Kingdom  
quarterly  tables [57].
Tables of AIDS data  are supplied to the  Inform ation and S tatistics 
Division of the  N ational H ealth  Service in Scotland, for inclusion in  an 
annual publication on the health  of Scottish people [95].
In  a d d itio n  to  th e s e  r e g u la r  p u b lic a tio n s , A ID S f ig u re s  a re  
routinely presented a t meetings such as :-
1) AIDS co-ordinator’s meetings
2) HIV epidemiology and laboratory sub-committee (HEALS)
3) W est of Scotland AIDS advisory and information committee
4) SCIEH review meetings
Beginning in January  1996, staff a t SCIEH will produce an annual report 
consisting of an extrem ely comprehensive set of tab les of data , together 
w ith  figures and  explanatory  text, from all the  AIDS/HIV surveillance 
schemes co-ordinated at SCIEH [96].
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2.9 The future of AIDS surveillance
The m ain objective of the current AIDS surveillance scheme is to provide 
an  e s tim a te  of th e  num ber of persons, in  S co tland , who h ave  AIDS, 
together with their epidemiological characteristics.
In the early 1980s, when this surveillance scheme began, it was the 
only m eans of collecting data about the num ber of persons affected by th is 
newly-discovered and unexplained syndrome. However, the  discovery of 
HIV as the causative agent of AIDS, the development of HIV surveillance, 
and  the  grow th of immunological m onitoring, have all p layed a p a r t  in 
d isp lac in g  th e  im portance  of AIDS su rv e illan ce . T h is h a s  led  m any  
people to consider w hether or not AIDS surveillance is still im portant, or 
necessary. This issue is discussed further in  chapter eight.
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Chapter 3
The HIV Register
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3.1 Introduction to HIV and HIV testing
A lm o st from  th e  in i t ia l  re c o g n itio n , in  1981, of th e  sy m p to m s of 
unexplained im m une deficiency, which became known as AIDS [1-3], a 
viral cause seemed likely. The occurrence of AIDS among homosexual and 
bisexual men, injecting drug users who shared injecting equipm ent, and 
rec ip ien ts  of blood products (including haem ophiliacs), suggested  the  
presence of a virus which might spread through sexual contact or through 
blood products. These routes of transm ission  were a lready  fam iliar to 
epidem iologists, th rough previously acquired knowledge of h e p a titis  B 
v iru s  (HBV) w hich was known to be tra n sm itte d  by sexual con tact or 
through blood.
In 1982, a team  of researchers in France, led by Dr L. M ontagnier, 
removed some cells from a patient suffering from lymphadenopathy, then  
succeeded in isolating a virus from them. This virus appeared to be a new 
retrovirus, and was named ‘lymphadenopathy associated virus’ (LAV) [5].
One of th e  m ain  d iff ic u ltie s  faced  by th e  s c ie n t is ts  s tu d y in g  
retroviruses in 1982, was propagating the retrovirus. In November 1983, 
a team  of researchers in America, led by Dr R. Gallo, reported the scientific 
b reak th ro u g h  which allowed the  re tro v iru s  to be p ropagated  in large  
quantities [97]. The American team  named the retrovirus on which they 
were working, the ‘hum an T-cell leukaem ia virus - type th ree’ (HTLV-III). 
I t  la te r  em erged th a t LAV and HTLV-III were the  sam e retrov irus. In 
May 1986, a t the In ternational Committee on Taxonomy of V iruses, the  
retrovirus was renamed the ‘hum an immunodeficiency virus’ (HIV).
3.1.1 HIV antibody testing
By 1985, commercial test k its were available in N ational H ealth  Service 
(NHS) laboratories in Scotland, for te s tin g  blood for an tibodies to HIV. 
T he te s t ,  know n as an  ‘ELISA ’ te s t ,  is w idely  u sed  in  S co tlan d  for 
screening blood for antibodies to HIV [98]. If antibodies to HIV are found, 
th en  a confirm atory te s t is carried  out using  a d ifferen t technique. In 
Scotland, the confirmatory test most often used is known as ‘W estern blot’ 
[98]. The com bination of the  in itia l te s t  and  th e  confirm atory  te s t  is 
required  to be both very sensitive (ability to identify positives correctly) 
and very specific (ability to identify negatives correctly) [31].
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3.1.2 Implications of the window period for HIV
In  HIV  te s tin g , a m ajo r p rob lem  a rise s  as a r e s u l t  of th e  n a tu ra l ly  
occurring tim e-lag  betw een a person becom ing infected  w ith  HIV and  
develop ing  d e te c ta b le  an tib o d ie s  to H IV  T h is  p e rio d  is  c a lle d  th e  
‘window period’. An HIV-infected individual who has an HIV te s t while 
in  th is  window period, will not be iden tified  as HIV infected. As HIV 
tests  have improved, the length of the window period has shortened, w ith 
the current estim ate being approximately six weeks [99].
The presence of the  window period has im portan t im plications for 
the  Blood T ransfusion  Service (BTS). Since Decem ber 1985, all blood 
donated  to th e  NHS h as been screened for an tibod ies to HIV; anyone 
found to be HIV positive has been recalled  by th e  BTS for counselling. 
Recognising th a t routine screening of blood could not detect people in the  
window period, additional steps were taken to safeguard the  blood supply 
T he m ost im p o r ta n t  of th e s e  s te p s  w as to  in tro d u c e  a s e t  of 
guidelines to be implemented at each of the five BTS centres in Scotland. 
These guidelines have resu lted  in questionnaires being given to all new 
donors, draw ing th e ir a tten tion  to the  transm ission  rou tes of HIV. The 
questionna ires request those who belong to certa in  specified high  risk  
categories not to donate blood. However, some centres allow these donors 
to  d o n a te  b lood , b u t  th e  b lood  w ill n o t to  be  u se d . T h is  s a v e s  a 
hom osexual or bisexual m an, attend ing  a donor u n it w ith  h is peers, the  
potential em barrassm ent of being turned away w ithout donating blood.
However, even if th e  op tim istic  assum ption  is m ade th a t  th ese  
policies have been 100 per cent effective, following th e ir  in troduc tion  
betw een 1985 and  1986, th e re  is still a sm all b u t defin ite  r isk  of HIV 
infected blood entering  the  blood bank. This risk  comes from those who 
are not in (or do not admit to being in) the recognised high risk  categories 
for HIV, b u t  a re  H IV in fec ted  an d  a re  in  th e  ‘w indow  p e rio d ’. T he 
p ro b ab ility  of th is  h ap p en in g  is know n to  be in fluenced  by th re e  key 
param eters :-
(1) The incidence ra te  of new infection among those a t low-risk of 
HIV infection.
(2) The length of the window period.
(3) T he freq u en cy  w ith  w hich  donors r e tu r n  to  d o n a te  blood 
[100,101].
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In Scotland, th is risk  is thought to be very small, and has been estim ated  
to be less th an  1 in 100,000 [102]. However in  1986 a donor, who was in 
the  window period, donated HIV infected blood which was subsequently  
given to two recipients [103]. As a consequence, a t least one of th e  two 
r e c ip ie n ts  w as in fe c te d  w ith  HIV; th e  seco n d  p e rs o n  d ie d  o f h is  
underlying illness shortly after his transfusion.
In  1993, Dr B. McClelland, Director of the  South E ast of Scotland 
Blood T ransfusion  Service, approached Professor D. Reid, D irector of 
SCIEH, w ith a request to set up a working group to determ ine the  risk, to 
rec ip ien ts, of acqu iring  HIV and o ther infections from  blood provided 
through the BTS in Scotland. Recognising the  scale and complexity of the 
p ro b le m , th e  w o rk in g  g ro u p  a p p ro v e d  th e  a p p o in tm e n t  o f D r J . 
McMenamin, Research Fellow, to work on th is project [104-106].
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3.2 The HIV Register in Scotland
From the  s ta r t of HIV testing  in Scotland, in 1985, the  NHS laboratories 
have been inform ing SCIEH of all persons who te s t HIV positive. The 
confidentiality of data  relating to persons testing  HIV positive has always 
been of g rea t im portance. To p reserve  th is  confidentiality , th e  rep o rt 
from the  HIV testing  laboratory does not contain nam es, bu t sim ply the  
initials and the  soundex code of the surnam e (see section 2.1.5). Should a 
person tes t HIV positive on more than  one occasion, then  only the  earliest 
H IV  te s t  r e s u l t  is  r e ta in e d  on th e  re g is te r .  H ow ever, a d d it io n a l  
in fo rm ation  gained  on a subsequen t te s t, such as m ore accu ra te  r isk  
information or a change of name, is used to update the HIV Register.
3.2.1 HIV test request form
As p a r t  of a na tionw ide  p rogram m e to im prove and  s ta n d a rd is e  th e  
collection of epidemiological data  on all patients requesting an HIV test, a 
request form was designed. This form has been used throughout Scotland 
since 1989; a copy of the form is enclosed in the back pocket of th is  thesis.
From the  form it can be seen th a t the  inform ation requested  falls 
into several distinct sections
(1) Referral source: the name, address and signature of the  doctor 
authorising the request.
(2) P a t ie n t  d e ta ils : basic  ep idem iological in fo rm a tio n  on th e  
person being tested. Initials, soundex code of surnam e, gender, 
d a te  of b irth , na tionality , re s id en tia l in fo rm ation  and  clinic 
num ber are all requested.
(3) Specimen date.
(4) Principal reason for testing.
(5) R isk factor inform ation : th is  is a complex se t of qu estio n s 
designed to collect as much inform ation as possible about the  
person’s risk of acquiring HIV.
(6) Clinical information: clinical symptoms commonly associated 
w ith  HIV. T hese sym ptom s v a ry  w idely and  inc lude  fever, 
weight loss and persistent fatigue.
(7) Previous HIV test: information is requested on w hether or not 
th e  person  h as  had  a p revious HIV te s t. I f  a te s t  h a s  been  
taken, then  the time, place and laboratory reference num ber of
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the previous test are requested.
(8) A dditional inform ation: any fu r th e r  in fo rm ation  w hich th e  
clinician feels may be relevant.
3.2.2 Computer support for HIV surveillance
A database  was created by computing s ta ff a t SCIEH, using  a softw are 
package called DATAEASE [107]. This database was designed to enable 
s ta f f  to en te r  d a ta  quickly and accurately. I t m akes ex tensive  u se  of 
‘choice-fields’, selected by one or two keystrokes, thus avoiding the  need to 
type phrases such as ‘G reater Glasgow H ealth  Board’, hence m inim ising 
errors and inconsistencies.
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3.3 Revision of the HIV Register
During 1990, the late Dr G. Bath, formerly AIDS Co-ordinator for Lothian 
H ealth  Board, in stig a ted  a revision of the  L o th ian  H ealth  B oard HIV 
R egister, using  inform ation from local labora to ry  repo rts  and  hosp ita l 
records. This exercise proved th a t it was possible to improve substantially 
both the quality and quantity of the information held on th is HIV Register. 
An im portant contributory factor was th a t clinicians were becoming more 
confident that, by revealing dates of birth and soundex codes of surnam es of 
their HIV positive patients, they were not compromising confidentiality.
D uring 1991 and 1992, a revision of the  en tire  HIV R egister w as 
undertaken  by Dr B. Davis, then  R egistrar in Public H ealth  Medicine a t 
SCIEH, involving sta ff a t SCIEH and sta ff a t laboratories and hospital 
records offices throughout Scotland. The resu lts of the  Lothian reg ister 
revision were made available to SCIEH by Dr Bath, thus saving duplication 
of effort. The revision of the reg ister is described in detail in a separa te  
publication [108]. By the end of the revision process, the HIV Register had 
improved substantially. In particular, soundex codes of surnam es, which 
previously were m ostly unavailable, were known for 95 per cent of the  
cases, date of birth  was known for 98 per cent, gender for 99 per cent, and 
transm ission category for 92 per cent. A total of 447 records were removed 
from the database, either because they were duplicate records, or because 
they lacked both date of birth and soundex code. Summary tables, from the 
revised register, were first published in ANSWER in July  1992 [109].
An important outcome of the revision was the resulting improvement 
in the procedures for reporting HIV positive test results in infants. Babies, 
born to HIV positive mothers, carry m aternal antibodies th a t are detected 
by HIV testing. Approximately 84 per cent of these babies are not infected 
with HIV and, at a later stage, will test HIV negative because they will lose 
these m aternal antibodies [37]. It was recognised tha t these infants should 
not rem ain on the HIV Register if they subsequently tes t HIV negative. 
The B ritish  P aed ia tric  A ssociation Surveillance U n it (BPASU) of th e  
In s titu te  of Child H ealth  (ICH) m ain tains a reg is te r of all HIV infected 
children in the UK. Only those 22 infants who were confirmed by the ICH 
to be HIV infected were kept on the HIV Register, the other 95 infants were 
removed from the register. Reports of HIV positive tests , on infants, are 
now only included in the register after the ICH has confirmed th a t these 
infants are infected with HIV.
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3.4 Problems associated with the HIV Register
There are two major problems associated with in terp reta tion  of th e  cases 
on the HIV Register
(1) These cases represent HIV infection among those persons who 
choose to come forward for HIV testing.
Not everyone who is HIV infected will suspect th a t  they 
are infected or will wish to be tested, therefore the  reg ister will 
u nderestim ate  the  num ber of persons who are  HIV infected. 
The reg is te r therefore cannot be used  as a d irec t e s tim ate  of 
HIV prevalence.
(2) It is not known w hether a person testing  HIV positive h as  been 
recen tly  infected w ith  HIV, or h as been  in fec ted  for severa l 
years.
T he fac t th a t  a pe rson  te s tin g  HIV po sitiv e  h a s  been  
infected for an unknown time, m eans th a t newly-reported HIV 
positive test results cannot be interpreted as new infections.
The first problem has been partially  resolved by the  provision of a range 
of un linked  anonym ous tes ting  (UAT) studies, which are  no t subject to 
the participation bias of voluntary testing (see chapter five).
The second problem has been helped by the introduction of the  CD4 
Study (see chapter six). This enables the m atching of people on the  HIV 
Register to their CD4 count, if th is has been m easured a t the  tim e of their 
first positive HIV test. Hence, for m any of the  persons now te s tin g  HIV 
positive, th e ir level of im m une deficiency m ay be ascertained  from th e ir 
CD4 count a t the tim e of their HIV test.
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3.5 Analysis of the HIV Register
An a n a ly s is  of th e  HIV R eg is te r w as c a rr ie d  ou t u s in g  a ll th e  d a ta  
available on the  2,129 HIV positive persons reported  to SCIEH by 30th 
June  1994 [6].
3.5.1 Age group and gender of persons tested
Figure 3.01 shows the gender and age group, a t tim e of test, of the  2,129 
HIV positive  persons, 75 per cent of whom  are  m ale. T he m odal age 
g roup  of p e rso n s  te s t in g  HIV p o sitiv e  is  20-24 y e a rs  (28 p e r  cen t), 
followed by the  25-29 year age group (22 per cent). All age groups, from 
0-4 years to over 65 years, are represented.
3.5.2 Setting of HIV test request
The setting  in which people requested HIV tests  has only been routinely 
documented since the  introduction of the  s tandard  request form in  1989. 
T ab le  3.01 show s th a t  37 per cen t of te s t  re q u e s ts  h ave  been  m ade 
th ro u g h  th e  h o sp ita l se ttin g , 20 per cen t th ro u g h  th e  g en ito -u rin a ry  
m edicine (GUM) se tting , 16 per cent th rough  th e  general p rac titio n er 
(GP) setting, and 11 per cent through the counselling clinic setting.
3.5.3 Reason for HIV test request
There a re  m any reasons for people to seek, or to be recom m ended by a 
doctor to have, an HIV test :-
(1) Concern th a t  the ir behaviour has exposed them  to the  r isk  of 
acquiring HIV.
(2) Concern th a t  accidental injury, such as a need lestick  injury, 
has exposed them  to HIV.
(3) Physical sym ptom s m ay have developed th a t  a re  associated  
with HIV.
(4) Learning (or suspecting) th a t a partner is HIV positive.
(5) T ra v e llin g  to  p a r ts  of th e  w orld  w h ich  re q u ire  p ro o f of a 
negative HIV test before allowing entry [110].
(6) Requiring an HIV test for insurance purposes.
(7) Screening for HIV before renal dialysis or organ/semen donation.
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The rea so n  w hy a person  req u e s te d  an  HIV te s t ,  h a s  a lso  only  b een  
routinely documented since the introduction of the standard  request form 
in 1989. Table 3.01 shows that, for persons tested  between Ja n u a ry  1989 
and Ju n e  1994, the  modal reason for requesting an HIV tes t was ‘p a tien t 
concerned’ (42 per cent) followed by ‘doctor concerned’ (35 per cent).
3.5.4 Health board of residence by health board of test request
Table 3.02 shows the health  board of residence of the person being tested, 
by the health  board from which the HIV test was requested (health board 
of request). H ealth  board of residence is known for 68 per cent of those 
tested; health  board of request is known for all cases. Table 3.02 shows 
th a t  48 p e r cen t of a ll HIV positive  te s ts  have  been  re q u e s te d  from  
Lothian H ealth  Board, 22 per cent from G reater Glasgow H ealth  Board, 
and  16 per cent from Tayside H ealth  Board. The o ther h e a lth  b o ard s 
together account for only 14 per cent of all HIV positive tests. Table 3.02 
shows clearly th a t most people have an HIV tes t in the ir health  board  of 
residence.
3.5.5 Year of HIV specimen
The HIV R egister contains th ree  different da tes p e rta in in g  to th e  HIV 
p o s itiv e  te s t .  T h ese  a re : th e  d a te  th e  b lood  sp e c im en  w as ta k e n  
(specimen date), the  date  the  blood specimen was tested  (test date), and 
the  date  the  resu lt was reported to SCIEH (report date). In  m ost cases, 
these three dates are w ithin a few days of one another. However, in  some 
instances, blood specimens, previously held in storage, were la te r  te s ted  
for antibodies to HIV; under such circum stances the  specim en da te  m ay 
precede the test date by several years.
Figure 3.02 shows the  num ber of persons testing  HIV positive, by 
th e  y ea r of specim en. From  1981 to 1983, 84 specim ens te s te d  H IV 
positive. Between 1984 and 1987, the num ber of HIV positive specim ens 
rose from 250 in 1984 to 325 in 1986, before falling to 248 in  1987. Since 
1987, the  num ber of HIV positive specimens has fluctuated betw een 125 
and 175 per year.
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3.5.6 Health board by year of specimen
Figure 3.03 shows the num ber of positive HIV tests resu lting  from those 
te s ts  requested  w ith in  Lothian, G reater Glasgow, and T ayside H ealth  
Boards, by year of specim en. T his shows clearly  th a t , w ith in  L o th ian  
H ealth Board, a large num ber of persons tested HIV positive in the  period 
before 1986, com pared w ith  e ith e r G rea te r Glasgow H ea lth  B oard  or 
Tayside H ealth  Board. Since 1988, the num ber of positive HIV tes ts  has 
been relatively stable, a t approximately 50 per year from those requested 
in Lothian H ealth  Board, and approximately 25 to 35 per year from those 
requested in each of G reater Glasgow and Tayside H ealth Boards.
3.5.7 Risk category for HIV infection
W here a person has more th an  one ‘risk  activity’ for HIV infection, it is 
usually not known which of the possible routes of infection was the actual 
route. This is the  case w ith sexually-active IDUs, who m ight have been 
infected either through sharing needles or through sexual contact. In  the 
H IV  R eg is te r , th e  h ie ra rc h ic a l  ap p ro ach  ta k e n  to  c la s s if ic a tio n  is 
consistent w ith th a t taken  in the  AIDS Register, by first identify ing the  
risk  activities of the patient, and then  those of the partner(s) (see section 
2.1.5 and Table 2.02).
Ninety-seven per cent of the persons who tested  HIV positive have 
been assigned a r isk  category. Table 3.03 shows th a t  49 per cen t have 
been classified as IDU, 29 per cent as hom osexual/bisexual, and  14 per 
cent as heterosexual.
3.5.7.1 Risk category by year of specimen
T able 3.04 show s each r isk  category  by y ea r of specim en , w hile  
F ig u re  3 .04  show s on ly  th e  h o m o se x u a l/b is e x u a l, ID U , a n d  
heterosexual risk  categories by year of specimen. Figure 3.04 shows 
a high num ber of HIV positive tests among IDUs betw een 1984 and 
1987, w ith a lower, relatively stable, num ber thereafter (between 30 
a n d  50 t e s t s  p e r  y e a r ) . I t  a lso  sh o w s t h a t  th e  n u m b e r  of 
hom osexuals/b isexuals te s tin g  HIV positive  h a s  been  re la tiv e ly  
stable and, since 1989, has been slightly g reater th an  the  num ber of 
ID U s te s tin g  HIV positive . The n u m b er of HIV p o s itiv e  te s ts
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a ttr ib u te d  to h e te ro sexual r isk  in creased  sh a rp ly  in  1986, th e n  
increased more steadily until 1992, before dropping slightly in 1993.
3.5.7.2 Risk category by year of specimen (Greater Glasgow HB)
Figure 3.05 shows the major risk  categories, by year of specimen, for 
te s ts  req u ested  w ith in  G rea te r Glasgow H ealth  B oard. I t  show s 
t h a t ,  s in c e  1984, th e  n u m b e r  of H IV  p o s i t iv e  t e s t s  a m o n g  
homosexuals/bisexuals has been greater th an  those among IDUs or 
heterosexuals, with the exception of 1986 and 1987 when there were 
s lig h tly  m ore HIV positive  te s ts  am ong ID U s. S ince 1989, th e  
num ber of HIV positive tests among homosexuals/bisexuals has been 
more than  twice th a t of any other risk category.
3.5.7.3 Risk category by year of specimen (Lothian HB)
Figure 3.06 shows the major risk categories, by year of specimen, for 
te s ts  requested  w ithin Lothian H ealth  Board. It shows th a t  there  
were 195 HIV positive tes ts  among IDUs in  1984, 107 in 1985 and 
70 in 1986. Throughout the same period, there were 70 HIV positive 
tests among homosexuals/bisexuals. Since 1987, the  num ber of HIV 
positive te s ts  am ong those in  all th ree  m ajor r isk  categories h a s  
been sim ilar a t 10 to 25 per year.
3.5.7.4 Risk category by year of specimen (Tayside HB)
Figure 3.07 shows the major risk  categories, by year of specimen, for 
te s ts  requested  w ith in  Tayside H ealth  Board. I t  shows a sim ila r 
p a tte rn  to Lothian, bu t on a sm aller scale, w ith  m ost HIV positive 
te s ts , before 1987, being am ong IDUs. However, un like  Lothian, 
th e r e  h a v e  b e e n  v e ry  few  H IV  p o s i t iv e  t e s t s  a m o n g  
homosexuals/bisexuals, a t only 2 to 3 per year.
3.5.7.5 Injecting drug user (IDU) risk category
F igu re  3.04 em phasises th e  scale of th e  sp read  of HIV  infec tion  
among injecting drug users. Figures 3.05 and 3.06 show th a t m ost 
of th ese  te s ts  w ere requested  w ith in  L o th ian  H ealth  B oard, w ith  
re la tiv e ly  few req u ested  w ith in  G rea ter Glasgow H e a lth  Board.
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M any papers have been published on th e  epidem ic of HIV am ong 
injecting drug users in Edinburgh [111-114].
Since Glasgow and Edinburgh are  both large cities, only 70 
kilom etres apart, w ith regular, rap id  transport links betw een them , 
there  has been m uch debate about the  rap id  spread  of HIV among 
th e  estim ated  3,000 IDUs in E dinburgh in  th e  early  1980’s [115], 
co m p ared  w ith  th e  re la t iv e  lack  of sp re a d  of H IV  am ong  th e  
estim ated 10,000 IDUs in Glasgow a t th a t tim e [116-118]. There is 
no d o u b t t h a t  th e  c it iz e n s  of G lasgow  b e n e f i te d  th ro u g h  th e  
know ledge and  experience  acc u m u la te d  from  th e  ep idem ic  in  
E dinburgh. This enabled tim ely im plem entation  of p reven ta tive  
measures, in Glasgow, such as needle exchange program m es [119].
3.5.7.6 Heterosexual risk category
In  recen t years, th e re  has been an  increase in  th e  num ber of HIV 
positive te s t resu lts  from people whose risk  activity  is classified as 
heterosexual (see Table 3.04). The num bers in th is  he terosexual 
category have risen since 1985, and are now sim ilar to the num ber of 
IDUs and hom osexuals/bisexuals te s tin g  HIV positive, a t a round  
25-50 new  te s ts  p e r year. T h is  h a s  s t im u la te d  a g re a t  d e a l of 
in terest [120-126].
Table 3.03 shows th a t 31 per cent, of the 294 persons who are 
classified  as he terosexual, have a p a rtn e r  who is in  a recognised 
high risk  category. This 31 per cent includes persons who have had  
sex with IDUs, or with those infected through blood factor trea tm en t 
or blood transfusion, or women who have had sex with bisexual men. 
T hirty  per cent of those classified as heterosexual are  classified as 
‘other p a rtn er (abroad)’; they have no other identified risks, b u t are 
thought to have been infected with HIV through sexual intercourse 
abroad. Twelve per cent are  classified  as ‘o th er p a r tn e r  (U nited  
Kingdom)’, and 27 per cent are classified as ‘not known’. Figure 3.08 
shows th e  heterosexual classifications by year of specim en; since 
1985, there has been a rise in the num ber of persons in the  ‘high risk  
p a r tn e r’ category. Of those whose infection is a ttr ib u te d  to ‘o ther 
p a rtn er (abroad)’, num bers have varied between 8 and 16 cases per 
year, but with no obvious pattern. ‘Other partner (United Kingdom)’ 
has alw ays been the  sm allest of the  heterosexual categories, w ith
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between 1 and 8 cases per year.
In 1993, Ms F. Raeside (a research nurse at SCIEH) began the 
t a s k  of in v e s tig a tin g  th o se  w hose r is k  c a teg o ry  w as coded as 
‘heterosexual - not known’ or ‘unknown’, to ascertain if these persons 
m ig h t be re-c lassified . In itia lly , th is  in v e s tig a tio n  m ade u se  of 
medical records and contacts with doctors. Only if the  p a tien t’s risk  
could not be classified through any of these information sources, was 
permission sought from the clinician to interview the patient.
By 30th Ju n e  1994, 148 persons who Had been classified as 
‘heterosexual - not known’ or ‘unknown’ were re-classified. Twenty- 
one per cent were found to be hom osexual or bisexual, 30 per cent 
w ere  in je c t in g  d ru g  u s e rs ,  a n d  18 p e r  c e n t w e re  fo u n d  to  be 
heterosexual with high risk partners [6,127].
3.5.7.7 Mother to child transmission of HIV
T ab le  3.04 show s th a t  th e  n u m b er of HIV p o s itiv e  spec im ens, 
a ttribu ted  to mother-to-child transm ission, ranged from zero to five 
cases per year. This does not necessarily  m ean th a t  th is  category 
will continue to contribute few cases to the  overall epidemic. The 
increase in HIV infection, a ttributed  to heterosexual spread, has led 
to an  increase  in the  repo rted  num ber of HIV positive specim ens 
among women, most of whom are of childbearing age. Hence, th is  
m ay lead to an  increase in  the  num ber of pregnancies am ong HIV 
po sitiv e  wom en. In  tu rn , th is  m ay re s u lt  in  an  in c re a se  in  th e  
num ber of babies born to HIV positive women, although the decision 
faced  by su ch  w om en, as to  w h e th e r  or n o t to  c o n tin u e  th e i r  
pregnancies, is likely to be influenced by cu rren t knowledge of the  
combined effects of treatm ent, pregnancy and HIV progression [128].
3.5.7.8 Transmission of HIV to haemophiliacs
Haemophilia is an inherited bleeding disorder caused by a deficiency 
of a blood com ponent know n as ‘factor V III’. H aem ophiliacs a re  
tre a te d  by reg u la r injections of factor V III ob tained  from  severa l 
thousand  individual blood donations. In  th e  years preceding HIV 
testing , batches of factor VIII were contam inated  by HIV infected 
blood, thereby infecting the haemophiliacs who received them . Since
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A pril 1985, factor VIII has been sub jec ted  to h e a t  tr e a tm e n t  to 
inactivate HIV without reducing the effectiveness of the factor VIII.
W hen th e  p lig h t of th e  HIV in fec te d  h a e m o p h ilia c s  w as 
re c o g n ise d , th e  H aem o p h ilia  S o c ie ty  p la c e d  p r e s s u r e  on th e  
G o v e rn m en t to  p rov ide  f in an c ia l c o m p e n sa tio n  for th e  1,215 
haem ophiliacs, in the  UK, who were known to have been infected 
w ith  HIV. In  1987, the  Governm ent announced  th a t  te n  m illion 
pounds would be m ade available to th e  M acF arlane  T ru st, to be 
adm in istered  for the  benefit of those HIV infected haem ophiliacs 
and their families. The Government made an additional donation of 
24 million pounds to the M acFarlane T rust in November 1989. The 
H aem oph ilia  Society’s cam paign for com pensa tion  w as fin a lly  
dropped in December 1990, when the Government gave a fu rther 42 
m illio n  p o u n d s  to  th e  T ru s t. T h ro u g h o u t th e  c a m p a ig n  for 
co m p en sa tio n , th e  G overnm ent a d m itte d  t h a t  i t  h a d  a m o ra l 
responsibility to those haemophiliacs who had  become infected, bu t 
denied th a t it had been negligent [129].
Table 3.04 shows the number of HIV positive tests, by year of 
specimen, for haemophiliacs in Scotland. It shows th a t, by 1985, of 
th e  74 h aem o p h iliacs , 66 (89 p er cen t) w ere  know n to  be H IV  
positive. Since 1990, only one haem ophiliac has new ly-tested HIV 
positive.
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3.6 Reporting of mortality from HIV infection
Like deaths from AIDS, pre-AIDS deaths are  reported  to SCIEH in two 
ways
(1) Directly by the doctor responsible for the patien t’s care.
(2) T he R e g is tra r  G enera l for S co tlan d  n o tif ie s  S C IE H  of a ll 
d ea th s, in  Scotland, w here th e  cause of d ea th  is likely  to be 
related to HIV infection.
T he in fo rm a tio n  on cause  of d ea th , w hich  is reco rd ed  on a form  of 
particu lars (FOP) for each death, is often inadequate to ascertain  if HIV 
has been a principal cause of death. Doctors will often describe the  cause 
of death  in vague term s, in order to spare the  deceased person ’s fam ily 
the possible em barrassm ent of having AIDS or HIV specified as a cause of 
death  [130]. In  a cohort of AIDS patien ts, in  New York, of w hich 2,834 
deaths were reported, 13 per cent of the death certificates did not mention 
either HIV or AIDS as a cause of death [131].
In Scotland, conditions such as chronic viral illness, recurren t chest 
in fec tions, g en e ra lised  debility, pneum onia  an d  b i la te ra l  b ro n ch ia l 
pneum onia, a re  regu larly  w ritten  on FO Ps as causes of d e a th  in  HIV 
positive people, with no mention being made of HIV or AIDS. To obtain a 
m ore  a c c u ra te  cau se  of d ea th , th e  R e g is tra r  G e n e ra l for S c o tla n d  
a rranged  th a t  FOPs would contain a specific box which doctors should 
tick if they were willing to provide, in confidence, more information on the 
cause of death, were th is to be requested by the R egistrar General. This 
arrangem ent has enabled more accurate inform ation to be collected, and 
AIDS or HIV to be specified as a cause of death  in cases w here it  had  not 
previously been recorded.
By 30th June  1994, 536 deaths of persons on the HIV Register had  
been reported to SCIEH [6]. Figure 3.09 shows the  num ber of deaths of 
persons on th e  HIV Register by year of death . I t  can be seen  th a t  th e  
num ber of deaths rose steadily each year, from 13 in 1986 to 61 in  1990, 
th en  alm ost doubled to 120 in 1991. In 1992 and 1993, th e  num bers of 
deaths were approximately 100 per year.
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3.7 Survival analysis
The ideal survival analysis would look at the tim e elapsing betw een HIV 
infection and death  (or censoring). Unfortunately, w ith the  exception of 
som e h a em o p h ilia c s  and  blood tra n s fu s io n  re c ip ie n ts , th e  tim e  of 
infection is usually  unknown. Another difficulty lies in  de te rm in ing  to 
w hat extent HIV infection contributes to m any of the deaths, especially of 
injecting drug users [132,133]. Date of HIV te s t is a poor su b s titu te  for 
da te  of HIV infection. Some people will seek an  HIV te s t because they  
have been a t risk  of HIV infection, o thers because they  have developed 
symptoms th a t may be associated with HIV At the tim e of testing, some 
will have recently become HIV infected, others will have been infected for 
m any m onths or years. From the information available through the  HIV 
R egister, recen t infections cannot be d istin g u ish ed  from  e a r lie r  ones. 
U sing the  date  of the  first HIV positive te s t will alw ays u n d e re s tim a te  
survival tim e from HIV infection to death.
Despite these caveats, some survival analysis is appropriate. The 
population studied, in June  1993, included adults aged 15 years or more 
whose HIV positive specim ens pre~dated 31st D ecem ber 1992. T here  
were 1,668 HIV positive adults in the study.
In  th is  analysis, survival tim e was defined as th e  tim e from the  
date  of the  earliest HIV positive blood sam ple (known to SCIEH) to the  
date  of death  (or censoring). Those whose deaths were not recorded, had  
their survival times censored at 30th June 1993.
3.7.1 Results of univariate analysis
Each of the  variables used in the survival analysis was categorised. ‘Age 
(in years) a t firs t HIV positive specimen’ w as divided in to  four groups, 
15-24, 25-34, 35-44, and  45+; ‘r isk ’ w as d iv ided  in to  four ca teg o ries , 
homosexual/bisexual, IDU, heterosexual, and ‘other’; ‘health  board of tes t 
request’ was divided into four groups, Greater Glasgow, Lothian, Tayside, 
and  ‘O ther’. K aplan M eier survival curves [73] w ere calcu lated  u sing  
SPSSPC+ [76], and the difference between the curves assessed using a log 
rank  test [75].
The re su lts  of the  un ivariate  analysis a re  sum m arised  in  Table 
3.05, which shows th a t five years after first tes tin g  HIV positive, 82 per 
cent of the  population are still alive, by ten  years th is has fallen to 62 per
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cent. Since few HIV positive tests have resu lted  from blood specim ens 
taken  before 1983, survival rates beyond ten  years are not estim ated. A 
smoothed survival curve for the whole group, based on the  K aplan M eier 
survival curve, is given in Figure 3.10.
There are differences in survival between the  categories of all four 
v a ria b le s . In  p a rtic u la r, IDUs appear to h av e  b e tte r  su rv iv a l th a n  
homosexuals/bisexuals (shown in Figure 3.11), younger age groups survive 
longer th a n  older age groups (shown in F igure  3.12), fem ales surv ive 
longer th an  males, and those requesting HIV testing  in  L othian H ealth  
Board survive longer than  those from other health  boards.
3.7.2 Results of multivariate analysis
T he m ain  prob lem  w ith  u n iv aria te  a n a ly s is  is th a t  it  c a n n o t m ake  
a llow ances for th e  effect of associations b e tw een  th e  v a r ia b le s . To 
in v es tig a te  th e  independen t effect of each v a riab le , on su rv iv a l, it  is 
n ecessary  to use m u ltiv a ria te  analysis. All the  v a riab le s  used  in  th e  
univariate analysis were entered into a Cox’s proportional hazards model, 
to p red ict factors independently associated w ith  surv ival [74,77]. The 
analysis was carried out using BMDP procedure P2L [78].
The results of this analysis are summarised in Table 3.06, and show 
th a t those who are aged over 35 years have poor survival compared to those 
in the baseline group of 15-24 years. The 95 per cent confidence interval 
(95% Cl) for the relative risk (RR) of survival for those aged 35-44 years, 
compared with those aged 15-24 years is (1.5, 2.7); for those aged 45 years or 
over, compared with the same baseline group, it is (1.5, 3.0).
Being homosexual/bisexual was significantly associated with poorer 
survival than  tha t of the baseline heterosexual category, w ith the 95% Cl 
for RR being (1.1, 2.3). However, survival of IDUs was not significantly  
d ifferen t from th a t  of the  heterosexual category. C om paring  su rv iva l 
between the IDU and homosexual/bisexual categories, shows th a t survival 
in the IDU category is twice as long.
Those who were first tested for HIV in areas outside Greater Glasgow 
or Lothian Health Boards, show poorer survival. For those in Tayside the 
95% Cl for RR is (1.2, 2.0) compared with the baseline of Lothian; for those 
in the ‘other’ category it is (1.1, 2.0). Although survival of females appears 
to be longer th a n  th a t  of m ales, the d ifference w as no t s ta t is t ic a l ly  
significant once the effect of the other variables was taken into account.
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The independent effect of age on survival from HIV infection is well 
documented in other papers; in particular, in a study of IDUs in Edinburgh 
[92], a study of people infected by blood transfusions in Sweden [134], and a 
study of HIV-infected homosexuals and heterosexuals in Italy  [135]. The 
effect of risk  activity  on survival from HIV infection is shown in stud ies 
from Edinburgh [68] and Italy [135].
3.8 Distribution of HIV data
Tables of HIV data  are published quarterly in ‘ANSWER’, showing newly- 
reported and cum ulative HIV infections, by risk  category, gender, age, 
and  health  board; a copy of ANSWER is provided in the  back pocket of 
th is thesis.
L ike A ID S d a ta ,  su m m a ry  d a ta  from  th e  H IV  R e g is te r  a re  
routinely presented a t meetings attended by professional people working 
in HIV-related fields (see section 2.8).
In addition to this, SCIEH provides an information service, on HIV 
su rv e illa n c e  d a ta  h e ld  a t  SC IE H , to  p eo p le  from  a w ide  ra n g e  of 
disciplines, such as public health officials, students and the media.
S taff a t SCIEH have often been asked to provide inform ation  in  
response to parliam entary  questions, in particu lar regarding the  num ber 
of persons thought to have been infected w ith HIV as a resu lt of blood, or 
blood products, provided by the  N ational H ealth  Service (NHS). These 
persons inc luded  haem oph iliacs liv ing  in  S co tland  who h a d  becom e 
infected with HIV after receiving infected ‘Factor VIII’ [129].
3.9 The future of the HIV Register
T he  HIV R e g is te r  is  a n  e x tre m e ly  im p o r ta n t  c o m p o n e n t of H IV  
s u rv e i l la n c e  in  S c o tla n d , p la y in g  a c ru c ia l  ro le  in  b o th  r o u t in e  
publications, such as ANSWER [136], and in special studies such as AIDS 
predictions [8,16-18]. Its value has been increased even more by linkage 
to  o th e r  s u rv e i l la n c e  sc h e m e s  su c h  a s  th e  CD 4 S tu d y  a n d  th e  
Denominator Study.
I t  is  c le a r  t h a t  th e  H IV  R e g is te r  w ill c o n tin u e  to  h a v e  a 
fundam ental role in HIV surveillance for the foreseeable future.
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Chapter 4
The Denominator Study
4.1 Introduction to the Denominator Study
W hile  th e  H IV  R eg is te r p lays an u n d e n ia b ly  im p o r ta n t  ro le  in  th e  
surveillance of HIV infection in Scotland, it is often difficult to in te rp re t 
because little  is known about the population being tested . For example, 
an  in c re a se  in  th e  n um ber of rep o rted  H IV p o sitiv e  p e rso n s  m ig h t 
represen t a genuine increase in prevalence of HIV, or reflect an  increase 
in the num ber of persons coming forward for HIV testing [137].
4.1.1 Origin of the Denominator Study
In 1988, the ‘Scottish National Collaborative HIV Sero-testing Study’ was 
co-ordinated at SCIEH, with the financial support of the Home and Health 
D epartm ent of the Scottish Office [39]. The aim of the  study is to collect 
epidemiological d a ta  on all persons coming forward for an HIV test. All 
National Health Service HIV testing laboratories participate, except those 
devoted exclusively to the  processing of blood donations. The study  is 
colloquially referred to as the ‘Denominator S tudy’ because, w ith in  th is 
study, HIV positive results (the numerator) are interpreted in conjunction 
with all HIV test results (the denominator).
A sim ilar study, but less extensive, involving eighteen HIV testing  
laboratories in England and Wales, was introduced a t CDSC in 1986 [138].
4.1.2 Request form for the Denominator Study
A request form, designed specifically for th is study, is used w henever an 
HIV te s t is requested . A description of th is  form  w as given in  section 
3.2.1, and a copy is provided in the back pocket of th is thesis.
T he u se  of a comm on req u e s t form  h e lp s  to  s ta n d a rd is e  d a ta  
collection, but some difficulties remain
(1) The absence of requested inform ation is difficult to in te rp re t; 
e.g. the absence of clinical information m ay m ean th a t either no 
clinical symptoms were present, or th a t symptoms were present 
bu t not recorded.
(2) D ecisions m ay be m ade subjectively  by th e  c lin ic ian ; e.g. a 
p e rso n  re q u e s tin g  a te s t, for in su ra n c e  p u rp o se s , m ay  be 
p resu m ed  by th e  c lin ician to be h e te ro se x u a l w ith  no r is k  
factors for HIV.
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4.1.3 Support for the Denominator Study
The HIV testing  laboratories which are expected to te s t more th an  1,500 
specim ens each year, are called the ‘p rincipal lab o ra to rie s’, w hile th e  
o th ers  a re  called th e  ‘sm all labora to ries’. C lerical officers have been  
appointed, by SCIEH, to work in each principal laboratory, to collate the  
HIV tes t results, and to enquire about incomplete, absent or im plausible 
information. The names and locations of these laboratories are found in 
Figure 4.01 and Table 4.01.
Concurrent w ith the development of the  request form, com puters 
w ere purchased  and installed  in all p rincipal labora to ries, to  help th e  
clerical officers m anage their data. To enable da ta  to be en tered  quickly 
and  accurately, a da tabase  was designed a t SCIEH, u s in g  a so ftw are  
p a ck a g e  c a lle d  DATAEASE [107], an d  in s ta l le d  on e ac h  of th e s e  
com puters. This database makes extensive use of ‘choice-fields’, which 
allow tex t (such as ‘G reater Glasgow’) to be en te red  by only one or two 
keystrokes, thereby minimising errors and inconsistencies in data-entry.
HIV positive te s t resu lts , from all labo ra to ries , a re  rep o rted  to 
SCIEH, promptly, by telephone. Once a m onth, all te s t re su lts  from the  
principal laboratories are transferred electronically to SCIEH. The small 
laboratories post their HIV test request forms and tes t resu lts  to SCIEH 
on a regular basis.
67
4.2 Analysis of data from the Denominator Study (1989-1992)
4.2.1 Number of HIV tests and repeat tests
For the  purposes of this analysis, ‘repeat te s ts’ are defined as subsequent 
te s ts  for th e  sam e person w ithin a calendar year. The m ain  reason  for 
repeat testing  is to ensure tha t a person still tes ts  HIV negative after the 
window period (see section 3.1.2).
Following com puter-entry of all th e  HIV te s t d a ta  for a calendar 
year, th e  d a ta  a re  exam ined to iden tify  persons h av in g  re p e a t te s ts . 
Figure 4.02 shows th a t repeat tests account for approxim ately 8 per cent 
of all tests.
In Ju ly  1993, a data analysis was undertaken , covering the  period 
1989 to 1992. Haemophiliacs and children, people who had been recorded 
as ‘know n HIV p o sitiv e s’, and  people w hose age or g e n d e r w as n o t 
recorded, w ere excluded from the analysis. In  any one ca len d a r year, 
repeat tests were excluded unless seroconversion occurred betw een tests, 
when the positive test result was included instead of the  earlier negative 
tes t result. The study population consisted of 46,673 test results.
4.2.2 Year of HIV test
Table 4.02 shows th a t the number of persons tested, per year, rose by 35 
per cent from 9,651 in 1989 to 13,049 in 1992. I t  also shows th a t the  ra te  
of persons testing  HIV positive has decreased from 13.0 per 1000 tested  
in 1989 to 9.8 per 1000 in 1992.
However, caution should be shown in in terpreting  these results, in 
p a r t ic u la r  a fall in  th e  ra te  of persons te s tin g  HIV po sitiv e  does no t 
necessarily imply th a t prevalence of HIV is falling [137].
4.2.3 Testing rates in population groups of known size
A lthough  i t  is  v a lu ab le  to analyse  v a r ia tio n s , th ro u g h  tim e , in  th e  
ch arac te ris tic s  of those persons (belonging to a p a rtic u la r  category or 
group) who requested HIV tests, the analysis m ay be enhanced by tak ing  
into account the to tal number of persons in th a t  group. W hile th is  is not 
possible for variables where the numbers in each category are not known, 
such as r isk  category, it is certain ly  possible for v a riab les  such as age
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group, gender and health board of residence.
4.2.3.1 Age group and gender of persons tested
Table 4.03 shows the number of persons tested, the  num ber tested  
per 1000 population , the num ber te s tin g  HIV positive , and  th e  
num ber testing  HIV positive per 1000 tested . Population d a ta  for 
S c o tla n d  a re  based  on e s tim a te s  p ro v id ed  in  S c o ttish  H e a lth  
Statistics (1994) [139].
Table 4.03 shows that, for both males and females, the  20-24 
year age group showed the highest ra te  of persons seeking an HIV 
test; for males, 7.7 per 1000 population sought testing, compared with
5.2 per 1000 for females. However, it is im portant to realise th a t high 
ra te s  of tes tin g  do not necessarily m ean high ra te s  of te s tin g  HIV 
positive. The highest rates of testing  HIV positive, for both m ales 
and females, were found in the 25-29 year age group a t 18.8 per 1000 
tested, for males, compared with 11.6 per 1000 for females.
High ra te s  of testing  HIV positive, w ith in  a group, ind icate  
th a t more persons in that group should be encouraged to seek testing. 
The above resu lts  suggest th a t more testing  should be encouraged 
among men in the 25-29 year age group.
4.2.3.2 Health board of residence of persons tested
Table 4.03 shows the number of tes ts  by health  board of residence. 
The highest ra te  of testing was found in  Lothian w ith  5.5 te s ts  per 
1000 population per year, followed by Greater Glasgow with 3.7 tests 
per 1000. The highest rate  of testing  HIV positive w as in  Tayside 
w here 19.1 of every 1000 tes ts  were positive, followed by L o th ian  
with 17.5 per 1000. Lower rates were found in Greater Glasgow with 
8.4 positive tests per 1000 tests, and Grampian with 4.7 per 1000.
These results suggest th a t more testing  should be encouraged 
in persons from both Tayside and Lothian Health Boards.
4.2.4 Reason for HIV test request
T he reason  for th e  te s t  request is recorded for 99 p e r cen t of p e rso n s 
te s ted ; figu re  4.03 shows th e  th ree  m ain  rea so n s  given. ‘S c reen in g ’ 
includes HIV testing for purposes of travel, insurance, renal dialysis, and
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organ/sem en donors or recipients. In the  ‘patien t concerned’ group, there  
w as a 104 per cent rise  in the num ber of persons tes ted  per year, from 
4,411 in 1989 to 8,985 in 1992. The modal reason for testing  was ‘patien t 
concerned’ (57 per cent of persons tested), followed by ‘screening5 (23 per 
cent).
4.2.5 Setting of HIV test request
Figure 4.04 shows th a t the modal se tting  from which people requested  
HIV te s ts  w as th e  general p rac titioner (GP) se tting . T ests req u ested  
th rough  GUM clinics increased by 117 per cent, from 1,636 in  1989 to 
3,554 in 1992. Tests requested through counselling clinics increased by 
132 per cent, from 694 in 1989 to 1,616 in 1992.
4.2.6 Risk category for HIV infection
The approach  used  to categorise people by r isk  behav iour only differs 
from th a t described in  Table 2.02 in th a t the  heterosexual risk  category 
has been simplified by referring to those who are ‘heterosexual (high risk  
partner)’ as ‘heterosexual (high risk)’ and the rem ainder as ‘heterosexual 
(low r is k ) ’. S ev en ty -e ig h t per cen t of th e  peop le  b e in g  te s te d  w ere  
assigned a r isk  category. Of those persons assigned a r isk  category, 58 
p e r  cen t w ere  a t t r ib u te d  to h e te ro se x u a l (low risk ) , 11 p e r  c en t to 
h e te r o s e x u a l  (h ig h  r is k ) , 15 p e r  c e n t to  ID U , 10 p e r  c e n t  to  
homosexual/bisexual, and 6 per cent to ‘other’ risk.
F ig u re  4.05 show s th a t  th e  n u m b er of p e rso n s  te s te d , in  th e  
heterosexual (low risk) category, rose by 77 per cent from 3,567 in 1989 to 
6,324 in  1992. Figure 4.06 shows that, between 1989 and 1992, the  ra te  
o f t e s t in g  H IV  p o s itiv e  w as r e la t iv e ly  s ta b le  in  th is  c a te g o ry , a t  
approxim ately 3.4 per 1000 tested. Although fewer persons tes ted  were 
in  the  IDU and hom osexual/bisexual risk  categories, the  ra te  of te s tin g  
HIV positive , in  th ese  categories, w as m uch h ig h e r a t 28.9 p e r 1000 
te s te d  a n d  42.9 p e r 1000 respectively . In  th e  h o m o sex u a l/b isex u a l 
category, th e  high ra te  of men tes tin g  HIV positive suggests  th a t  i t  is 
extrem ely im portan t to encourage more hom osexual or b isexual m en to 
come forward for testing.
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4.3 Characteristics associated with testing HIV positive
4.3.1 Introduction to logistic regression
In  Ju ly  1993, a logistic regression analysis w as ca rried  out u s in g  th e  
study  population described in section 4.2.1. The aim s of th is  analysis 
were
(1) To in v es tig a te  which c h a rac te ris tic s , of th o se  seek in g  HIV 
testing, are associated with testing HIV positive.
(2) To p rov ide  an  e s tim a te  of th e  p ro b a b ility  of te s t in g  H IV  
positive, for an individual person.
T he lo g is tic  m odel specifies th e  p ro b a b ility  of a n  e v e n t o c cu rrin g , 
depending on the  values of a set of explanatory variab les [140]. In  th is  
analysis, the event of interest is the HIV test result. The logistic model is 
u se d  to  in v e s tig a te  th e  effect of th e  e x p la n a to ry  v a r ia b le s  on th e  
probability of testing  HIV positive, and also to estim ate the probability of 
a person testing  HIV positive for any given set of explanatory variables. 
T he a n a ly s is  w as ca rried  out u sin g  th e  s ta t is t ic a l  p ro ced u re  PROC 
LOGISTIC from SAS [141].
The following explanatory variables w ere chosen for inclusion in 
th e  logistic reg ression  model. Risk category, gender, p resence of HIV 
related clinical symptoms, year of HIV test, age group a t tim e of HIV test, 
health  board of te s t request, reason for HIV test, and setting  of HIV te s t 
request.
4.3.2 Example of logistic regression using gender
Logistic regression, a t its sim plest, looks a t each exp lanato ry  variab le  
separately. The following example illu s tra te s  logistic regression  using  
gender
P (HIV positive) = exp (a)/{l+exp(a)} 
where a = bQ + bx x
with x = 0 if the person is male, 
or x = 1 if the person is female.
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U sing th e  d a ta  on gender from the  study  population , th e  logistic 
reg ression  provides m axim um  likelihood es tim ates  for b Q and  b lf 
giving:
b0 = -4.293 and bx =-0.6307 
Thus:
P (HIV positive) = 0.013 for a male 
P (HIV positive) = 0.007 for a female.
4.3.3 The odds ratio in logistic regression
The param eters in a logistic regression model may be expressed in term s 
of the odds ratio.
The odds of being HIV positive are :-
P (HIV positive) / P (HIV negative).
Using the example of section 4.3.2 :-
The odds of being HIV positive for a male are:
[exp (a) / {1 + exp (a)}] / [1 / {1 + exp (a)}]
= exp (a) where a = b0
Similarly, the odds of being HIV positive for a female are:
[exp (a) / {1 + exp (a)}] / [1 / {1 + exp (a)}]
= exp (a) where a = bQ + b1
Thus the odds ratio (OR) for females, compared to males, is: 
exp (bQ + bx) / exp (bQ)
= exp (bx)
= exp (-0.6307)
= 0.53
The value exp (bx) is called the ‘odds ratio (unadjusted)’. I t is unadjusted  
in  th e  s e n s e  t h a t  g e n d e r is th e  on ly  e x p la n a to ry  v a r ia b le  in  th e  
re g re s s io n , an d  is th e re fo re  u n a d ju s te d  for th e  e ffec t o f a n y  o th e r  
explanatory variable.
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4.3.4 Reference categories for logistic regression
Each of the  explanatory variables chosen for the  logistic regression was 
trea ted  as a categorical variable. In logistic regression, a s ta tem en t can 
only be m ade about the  effect of a p a rticu la r category by com paring it 
w ith  another category. For each variable, therefore, it was necessary to 
designate a particular category (the reference category) to be the  one with 
which th e  o ther categories were com pared. This w as chosen to be th e  
category which had  the largest num ber of tests, w ith the  exception of age 
group and year of test. For age group, the youngest age group was chosen 
to be the reference group; for year of test, the  earliest year was chosen.
T he re s u lts  of th ese  logistic  reg re ss io n s , for each  e x p la n a to ry  
variable separately, are given in Table 4.04.
4.3.5 Multivariate logistic regression
So far, th e  analysis has explored th e  association  betw een  each of th e  
explanatory variables and the probability of testing  HIV positive. I t was 
l im ite d  to  look ing  a t  each  v a r ia b le  se p a ra te ly . I t  is  im p o r ta n t  to  
investigate  the  effect of each variable on th e  probability  of te s tin g  HIV 
p o sitiv e , w hile  allow ing  for th e  effects of a ll th e  o th e r  e x p la n a to ry  
v a r ia b le s . T h is is  p a r tic u la r ly  im p o r ta n t  if  th e re  a re  a sso c ia tio n s  
betw een th e  explanatory  variab les w hich m ight confound th e  re su lts . 
Using the  general logistic regression equation [140], gives the  odds ratio  
ad ju sted  for th e  effect of the  other exp lanato ry  variab les. T hese odds 
ratios, and  th e ir 95 per cent confidence in te rvals (95% Cl), a re  given in 
the last two columns of Table 4.04.
4.3.6 Results of multivariate logistic regression
There were statistically  significant odds of testing  HIV positive, for each 
of the  risk  categories, compared to the  reference category ‘heterosexual 
(low r isk ) ’, once all th e  o ther ex p lan a to ry  v a ria b le s  w ere  ta k e n  in to  
account. The 95 per cent confidence in te rval (95% Cl) for th e  ad justed  
odds ratio  {OR(adj)} for ‘homosexual/bisexual’ was (5.56, 10.05), for ‘IDU’ 
(2.92, 5.32), and for ‘heterosexual (high risk)’ (2.22, 4.41).
The odds of te s tin g  HIV positive in  T ayside H ealth  B oard  w ere 
sim ilar to the  odds of testing HIV positive in Lothian H ealth  Board, b u t
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were lower in  the rest of Scotland.
The reasons for test ‘doctor concerned’ and  ‘confirm atory te s t’ were 
both independently  associated with higher odds of tes tin g  HIV positive, 
compared w ith those whose reasons for testing  were ‘pa tien t concerned’. 
Those who w ere te s te d  for screening pu rposes, such  as in su ra n ce  or 
trave l, w ere independently  associated w ith  lower odds of te s tin g  HIV 
positive, compared with the reference category ‘patien t concerned’.
The se tting  of the test request was also independently  associated 
with higher odds of testing HIV positive, for those from hospital settings, 
GUM clinics, or counselling clinics, compared to those requesting an  HIV 
te s t from  th e ir  GPs. The h igher odds associated  w ith  th e  counselling  
clinic are probably explained by the fact tha t, in  Scotland, there  are only 
th r e e  c o u n s e l l in g  c lin ic s , a ll of w h ich  a re  a t t a c h e d  to  h o s p i ta l s  
specialising in the treatm ent of HIV.
T he  p re se n c e  of c lin ica l sym ptom s w as a lso  in d e p e n d e n tly  
associated with higher odds of testing HIV positive.
Fem ales appeared to be associated w ith lower odds of testing  HIV 
positive, un til adjustm ent was made for the  o ther explanatory  variab les 
when it  w as shown th a t  males and fem ales w ere equally  likely  to te s t  
HIV positive.
Sim ilarly, la te r  years of tes tin g  appeared  to be assoc ia ted  w ith  
lower odds of te s tin g  HIV positive, u n til ad ju stm en t w as m ade for th e  
other explanatory variables, when it was shown th a t year of tes tin g  had  
no significant effect on testing HIV positive.
4.3.6.1 Multivariate logistic regression: interactions
The previous m ultivariate analysis was taken  forward by including 
in te rac tio n  te rm s in the  general logistic reg ress ion  equation ; for 
exam ple, gender by health  board, gender by source of te s t request, 
risk  category by gender, and risk category by source of te s t request. 
T h e  in te r a c t io n s  in v o lv in g  r i s k  c a te g o ry  w e re  fo u n d  to  be  
statistically  significant, hence a separate  m ultivariate  analysis was 
carried  out for the  three m ain risk  categories; injecting drug  users, 
homosexual/bisexual males, and heterosexuals.
For hom osexuals and  b isex u a ls , th e  odds of te s t in g  H IV  
positive were sim ilar in Lothian H ealth Board and G reater Glasgow 
H ea lth  Board, b u t were significantly  low er elsew here  (P < 0.05 ;
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OR(adj) = 0.5). Significantly h igher odds of te s tin g  HIV positive 
w ere found a t counselling  clinics (OR(adj) = 3.6) an d  h o sp ita ls  
(OR(adj) = 2.0) compared with persons tes ted  by GPs. The odds of 
te s tin g  HIV positive  were s ig n ifican tly  h ig h e r  for p e rso n s  who 
ex h ib ited  c lin ica l sym ptom s com pared  w ith  th o se  w ho d id  n o t 
(OR(adj) = 4.0). The odds of testing  HIV positive rose significantly 
from age 20-24 (baseline for OR) to age 35-39 (OR(adj) = 3.0), th en  
fell by age 40-44 (OR(adj) = 1.04). The odds of tes ting  HIV positive 
rem ained relatively constant over the tim e period.
For injecting drug users, the odds of testing  HIV positive were 
sim ilar in  Lothian H ealth Board and in  Tayside H ealth  Board, b u t 
w ere  s ig n if ic a n tly  low er e lsew h ere  (P< 0 .05 , O R (ad j) = 0 .2). 
S ig n ifican tly  h igher odds of te s tin g  HIV positive  w ere  found  a t 
counselling clinics (OR(adj) = 3.1) and GUM clinics (OR(adj) = 2.8) 
com pared w ith  persons tes ted  by GPs. T he odds of te s tin g  HIV 
positive were significantly higher for persons who exhibited clinical 
sy m p to m s com pared  w ith  th o se  w ho d id  n o t (O R (adj) = 2 .7). 
F em ales w ere significantly  less likely  to te s t  HIV positive  th a n  
m ales  (OR(adj) = 0.49). The odds of te s t in g  H IV  p o sitiv e  ro se  
significantly from age 20-24 (baseline for OR) to age 30-34 (OR(adj) 
= 2.5), th en  fell by age 40-44 (OR(adj) = 1.39). The odds of te s tin g  
HIV positive remained relatively constant over the tim e period.
For th e  heterosexual risk  category, th e  odds of te s tin g  HIV 
po sitiv e  w ere s im ila r in  L o th ian  H e a lth  B oard  a n d  in  T ay sid e  
H ealth  Board, b u t were significantly low er elsew here  (OR(adj) = 
0.5). Significantly higher odds of testing HIV positive were found in 
the  hospital se tting  (OR(adj) = 2.9) and the  GUM clinics (OR(adj) = 
1.8) compared with persons tested by GPs. The odds of tes ting  HIV 
positive were significantly higher for persons who exhibited clinical 
sym ptom s compared with those who did no t (OR(adj) = 2.6). The 
odds of te s tin g  HIV positive were re la tive ly  constan t over all age 
groups and for both m ales and fem ales. The odds of te s tin g  HIV 
positive rem ained relatively constant over the  tim e period.
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From  th ese  ana ly ses  by risk  category, sev e ra l p o in ts  a re  w orth  
highlighting :-
(1) Although the highest odds of testing  HIV positive are found in 
the  counselling clinic setting , for hom osexual/b isexuals and  
in jecting  d rug  users, the  h ighest odds for h e te ro sex u a ls  a re  
found in the hospital setting. This suggests th a t those who are 
infected heterosexually  m ay not be aw are of be ing  a t r isk  of 
HIV infection  u n til sym ptom s a rise  w hich req u ire  h o sp ita l 
treatm ent. If th is is true, then it is particu larly  im portant th a t 
h o sp ita l c lin ic ian s rem ain  a le r t  to  th e  p o ss ib il i ty  of th e i r  
pa tien ts being at risk of HIV infection, and persuade p a tien ts  
to have an HIV test.
(2) W hile th e  overall ad justed  odds of te s tin g  HIV positive  a re  
equal for m ales and females, there  are differences betw een the  
risk  categories. In the injecting drug  user category, m ales are  
tw ice as likely  to te s t HIV positive  as fem ales, w hile  in  th e  
h e te ro sex u a l category, fem ales a re  m ore like ly  to  te s t  H IV  
positive (OR(adj) = 1.31). The reasons for th is  are  unclear and 
should be investigated further, possibly by ru n n in g  sep ara te  
logistic regressions for m ale and fem ale in jecting  d rug  u se rs  
and heterosexuals.
(3) The heterosexual category differs from the other two categories 
with age having little effect on the odds of testing  HIV positive. 
There is no typical age group for those infected heterosexually, 
un like  th e  o ther two risk  categories w ith  th e  typ ically  older 
HIV-infected homosexual and typically  younger HIV-infected 
in jecting drug  user. This again  underlines th e  im portance of 
hospital clinicians being alert to the possibility of the ir patien ts 
being at risk  of HIV infection, regardless of typical stereotypes.
4.3.7 Probability of testing HIV positive
The estim ated  probability  of any p a tien t te s tin g  HIV positive  m ay be 
calculated from the values of the coefficients of the relevant explanatory 
variab les used  in  the  m ultivariate  logistic regression , as show n in  th e
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following three examples :-
Example 1
During a visit to a GUM clinic in Glasgow in 1990, a thirty-year-old 
m ale hom osexual requested  an  HIV te s t  because h is  doctor w as 
concerned th a t his clinical symptoms m ight be HIV related . U sing 
the coefficients of the explanatory variables in Table 4.05 gives 
P (HIV positive) = exp (a) / (1+ exp (a)} 
where
a = -7.263 + 2.012 - 0.908 + 1.135 + 0.613 + 1.653 + 1.342 - 0.036 
= -1.452
Thus P (HIV positive) = 0.234/1.234
= 0.19
Example 2
As example 1, except th a t the patient had no clinical symptoms, 
a = -7.263 + 2.012 - 0.908 + 1.135 + 0.613 + 1.653 - 0.036 
= -2.795
Thus P (HIV positive) = 0.061/ 1.061
= 0.06
Example 3
As example 2, except tha t the reason for testing was ‘patien t 
concerned’.
a = -7.263 + 2.012 - 0.908 + 0.613 + 1.653 - 0.036 
= -3.930
Thus P (HIV positive) = 0.02/ 1.02
=  0.02
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4.4 The future of the Denominator Study
T he D en o m in a to r S tudy  collects d a ta  on a ll H IV  te s ts  in  S co tlan d , 
currently approximately 15,000 tests each year. To m anage th is data, the 
study utilises substantial resources, since clerical officers and com puters 
are required in the principal laboratories. The tim e taken  for each year’s 
d a ta  to be published, together with the poor qua lity  of inform ation  on 
m any of the  request forms, raises questions about the  fu ture  direction of 
th is  surveillance scheme. These issues are discussed fu rth er in  chap ter 
eight.
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Chapter 5
Unlinked Anonymous Testing
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5.1 Unlinked Anonymous Testing (UAT)
Prior to 1989, surveillance of HIV in Scotland relied on the  results of HIV 
tests performed only with the informed consent of the patient.
B etw een 1987 and 1989, several rep o rts  w ere p u b lished  w hich 
showed th a t estim ating the prevalence of HIV from d a ta  provided solely 
by v o lu n ta ry  tes ting , such as the HIV R egister and  th e  D enom inator 
Study, was inadequate and undesirable [142-144].
Another report, produced by the Social Services Com mittee for the  
UK G overnm ent [145], sta ted  th a t th ere  was an  u rg en t need for m ore 
reliable d a ta  on the  prevalence of HIV in the  U nited  Kingdom. Several 
epidemiologists argued tha t a system of anonymous screening was the  :-
"...most practical, most accurate and most ethical means of 
gauging the prevalence of HIV in the population as a whole 
an d  its  emergence in groups curren tly  con sidered  low  
risk..." [145].
One of the  m ain obstacles to UAT concerned the  ethical im plications of 
te s tin g  a p e rso n ’s blood for HIV w ithou t th a t  p e rso n ’s know ledge or 
consent. However, in 1989, the S tandards C om m ittee of th e  G eneral 
Medical Council reported that no fundamental ethical principle is breached 
by th e  p r in c ip le s  of UAT [146]. T h is re p o r t  p av ed  th e  w ay  for th e  
introduction of unlinked anonymous testing (UAT) for HIV infection within 
specific population groups, such as antenatal and GUM clinic attenders.
5.1.1 Principles of UAT
U nlinked  anonym ous testing  involves the  te s tin g  of res id u e  from  any 
specimen th a t has been taken from a person for some other purpose. The 
residue is irreversibly unlinked from any person-identifiable inform ation 
(e.g. nam e, ad d ress  or da te  of b irth ) before be in g  te s te d , so th a t  i t  is 
impossible to link the  resu lt with a particu lar person, th u s  fulfilling the  
k ey  r e q u ire m e n t  of UAT th a t  th e  a n o n y m ity  of th e  in d iv id u a l  is  
preserved. The purpose for which the specimen was initially  taken  m ust 
not be compromised in any way by UAT.
Inform ation m ust be available describing th e  purpose of th e  UAT 
scheme, and stating  th a t anyone may be tested for HIV, anonymously and
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w ithout prior consent, unless th a t person chooses not to partic ipate . To 
th is effect, those implementing UAT schemes are required to ensure th a t 
p o ste rs  a re  on display, and leaflets availab le, to people a t a ll cen tres  
w here UAT is being carried out. Such lite ra tu re  is available in several 
languages; one of the leaflets is provided in the  back pocket of th is thesis.
Partic ipation  in a UAT scheme does not affect a person’s r ig h t to 
request an HIV test, should one be wished.
5.1.2 The main advantages and disadvantages of UAT
The main advantage of UAT is that it is virtually free of participation bias 
since perm ission to tes t is not actively sought, therefore very few people 
object to participating. Another advantage is th a t surveillance is relatively 
inexpensive, since the patient cannot receive the test result, and therefore 
counselling is redundant. Hence, large num bers of people are  able to be 
tested relatively cheaply, making this a particularly appropriate method of 
surveillance for a large population.
The main disadvantage of UAT is that the patient is unable to benefit 
directly, since the patient cannot be informed of the test result. However, 
knowledge of prevalence of an infection within a group of people is beneficial 
to the group as a whole. If the prevalence of the infection is low, the members 
of the group will be reassured by this; if the prevalence is high, then  the 
group may be targeted and encouraged to come forward for further testing.
Another disadvantage of UAT is tha t only limited information, from 
the original specimen, is perm itted to rem ain linked to the  residue. For 
exam ple , it  is accep tab le  to re ta in  th e  p a t ie n t ’s gender, age g roup , 
geographical region and calendar quarter of test, but not the date of birth, 
name, address or date of test.
Vigilance is always necessary, when presenting  resu lts  of UAT, to 
ensure that deductive disclosure cannot occur. For example, a man in the 80- 
84 year age group, from Grampian Health Board, testing HIV positive, would 
almost certainly compromise that individual’s identity!
5.1.3 Government approval for UAT in UK
A fter m uch consu lta tion  and debate on th e  legal and  e th ica l issu es of 
UAT, Kenneth Clarke (then Secretary of State for Health) announced, in 
November 1988, th a t
81
"The Government sees no legal obstacle to such (anonymous) 
testing . From the layman's poin t of view, we also see no 
eth ical objection to the testing for scien tific purposes of 
blood samples taken properly in the first place for another 
purpose from a patient no longer id e n tif ia b le [42].
A year la ter, in  November 1989, V irginia Bottom ley (then  M in ister for 
H ealth ) announced th a t  UAT would begin in  th e  U n ited  K ingdom  in  
Jan u ary  1990; she said :-
"The surveys will be a valuable tool in assessing prevalence 
o f  H IV  in th is  cou n try , p a r t ic u la r ly  a m o n g s t th e  
heterosexual population for whom we lack inform ation.
These surveys will help us make more accurate predictions 
of the numbers o f people throughout the population  who 
w ill become infected. This will help us to plan  and target 
both our prevention activities and services for those who 
are infected." [9].
5.1.4 Network of UAT studies for HIV, in Scotland
Since 1990, five UAT surveillance schemes, for HIV in  Scotland, have 
been introduced. They form a netw ork of com plem entary stud ies, each 
providing data  on HIV prevalence. The five studies are :-
(1) GUM Study: A study  of m en an d  w om en a tte n d in g  GUM 
clinics in Glasgow and Edinburgh.
(2) H o sp ita l S tudy : A s tu d y  of m en  a t te n d in g  tw o G lasgow  
hospitals, as in-patients or out-patien ts, or a ttend ing  one of a 
small num ber of general practitioner clinics in Glasgow.
(3) G uthrie  Study: A study of m others of new -born babies. This 
study covers the whole of Scotland.
(4) Fam ily Planning Study: A study of women attend ing  a family 
planning centre in Glasgow.
(5) A ntenatal Study: A study of women attending an tenatal clinics 
in Edinburgh and Dundee.
A sim ilar netw ork of studies, co-ordinated a t CDSC, w as in troduced  in  
England and Wales [40,147-149].
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5.2 GUM Study
The GUM study started , in October 1990, in  th ree  GUM clinics based a t 
E d in b u rg h  Royal Infirm ary , Glasgow Royal In firm a ry  an d  G lasgow  
S o u th e rn  G enera l H ospita l. This s tu d y  w as in it ia lly  fu nded  by th e  
Medical Research Council (MRC) before being funded by SCIEH.
The purpose of the study is to estim ate the  prevalence of HIV, and 
to detect changes in  prevalence, through tim e, am ong m en and  women 
attending GUM clinics.
Since people a ttend ing  GUM clinics often p resen t w ith  sexually  
transm itted  diseases (STDs), these people are thought to be more likely to 
have more sexual partners, and therefore to be a t higher risk  of acquiring 
HIV infection th an  the general population. If there  is an  increase in  the  
heterosexual spread  of HIV, then  it is likely to be ap p aren t firs t in  th is  
setting.
Persons attending one of these GUM clinics, and who have a blood 
sa m p le  ta k e n ,  a re  in c lu d ed  in  th e  s tu d y  i f  i t  is  e i th e r , t h e i r  f i r s t  
a ttendance  in  a calendar quarter or, th e ir  firs t a ttendance  w ith  a new 
STD.
In  la te  1992, the  study was expanded to include GUM clinics in 
Aberdeen, Falkirk, Stirling, Dundee and Perth.
Results from the study have been presented a t in ternational AIDS 
conferences in Amsterdam and Berlin [150,151].
5.2.1 GUM Study: data collected
(1) GUM clinic attended
(2) Gender and age group
(3) Time period of specimen taken (in calendar quarters)
(4) The HIV sta tus of the patient, if known
(5) Any objection, by the patient, to being tested for HIV
(6) Patien t’s risk factors for HIV
(7) P artner’s risk factors for HIV (and HIV sta tu s if known)
(8) Diagnostic codes of current STDs
(9) Information about nationality of pa tien t and partner(s)
An exam ple of th e  survey form is included  in  th e  back  pocket of th is  
thesis.
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5.2.2 GUM Study: results
An analysis of all tests conducted throughout the  period 1st October 1990, 
to 30th Ju n e  1994, shows tha t the num ber of persons tested  per calendar 
quarter, in  both Glasgow and Edinburgh, has stayed relatively  constant 
(see Figure 5.01 and Table 5.01). However, owing to the  study design, it 
is not possible to tell how many different people have been tested  overall.
T here  w ere 58 objections to p a rtic ip a tin g  in  th e  study, 20 from  
Edinburgh and 38 from Glasgow. Twenty-six objections took place in the  
f i r s t  six  m o n th s  of th e  study  (0.5 p er cen t), b u t  th is  fell to  only tw o 
objections in the first six months of 1994 (0.05 per cent).
Table 5.01 shows th a t 16,103 tests were carried out in  Edinburgh, 
com pared w ith  18,289 in  Glasgow. T here w ere 146 HIV positive  te s t  
resu lts in  Edinburgh, and 96 in Glasgow, over th is  tim e period. The ra te  
of p e rso n s  te s tin g  HIV positive (per 1000 te s te d )  in  E d in b u rg h  w as 
greater th an  th a t in Glasgow, in almost all calendar quarters, averaging 
9.1 per 1000 and 5.2 per 1000 respectively.
Table 5.02 shows the  num ber of te s ts  classified by r isk  category, 
gender, and location of GUM clinic. Although the  num ber of tes ts  among 
IDUs a t GUM clinics in Glasgow was higher th an  in Edinburgh, the  ra te  
of HIV positive tests, per 1000 tests, was substan tia lly  lower in  Glasgow 
a t 8 per 1000, compared with 142 per 1000 in  Edinburgh. Tests am ong 
ID U s in  E d in b u rg h  accounted  for 0.8 p e r  c en t of th e  to ta l  te s ts  in  
Edinburgh, bu t 13 per cent of the HIV positive te s ts  there . By contrast, 
tes ts among IDUs in Glasgow accounted for 1.3 per cent of the  to tal tes ts  
there, and 2 per cent of the HIV positive tests.
The num ber of te s ts  among hom osexuals/bisexuals in  E dinburgh 
and Glasgow were of sim ilar magnitude, as were the  ra tes  of testing  HIV 
positive, a t 54 per 1000 in Edinburgh and 48 per 1000 in Glasgow.
Tests among homosexuals/bisexuals in  Edinburgh accounted for 9 
per cent of the  Edinburgh HIV tests, but accounted for 55 per cent of the  
HIV positive results there. Similarly, in Glasgow they accounted for only 
7 per cent of the HIV tests, but 63 per cent of the  HIV positive results.
The num ber of HIV tests, on those classified as heterosexual risk , 
w as h igher in m ales th a n  in females, in  both  E d inburgh  and  Glasgow. 
However, in  Edinburgh, the rates of HIV positive tes ts , per 1000 tes ts , 
were very sim ilar for males and females, a t 3.0 per 1000 and 3.5 per 1000 
respectively . In  Glasgow, the  ra te s  w ere h ig h e r for m ales, a t 2.6 pe r
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1000, compared with 1.0 per 1000 for females.
T h ere  is, how ever, th e  u n av o id ab le  p rob lem  a sso c ia te d  w ith  
classifying people, especially males, into risk  categories, namely th a t they 
may withhold the tru th  about their sexual activities, thus being classified 
as h e te ro se x u a l w hen they  are  e ith e r hom osexual or b isex u a l. T h is  
p o ten tia l b ias m eans th a t  the  tru e  ra te  am ong h e te ro sex u al m ales is 
likely to be lower th a n  th is  study shows. The skill and  a ttitu d e  of th e  
d o c to r in te rv ie w in g  th e  p a tie n t  a t  th e  GUM c lin ic  m ay  a ffe c t th e  
willingness of the patien t to reveal risk factors for HIV transm ission.
All persons a re  asked, a t consu lta tion , if  th ey  know  th e ir  HIV 
s ta tu s ; those  who say  they  are HIV positive  a re  c lassified  as ‘know n 
positives’. In  the  analysis, table 5.02 shows w hether or not th e  person 
te s tin g  HIV positive  w as a known HIV positive . In  E d in b u rg h , th e  
num ber of known HIV positives, in the  IDU and  hom osexual/bisexual 
categories, exceeded the number of unknown HIV positives. This was not 
th e  case in  the  heterosexual category, w here unknow n HIV infections 
outnum bered known HIV infections by two to one, in males, and th ree  to 
one, in  fem ales. O verall, in  E d inbu rgh , th e re  w ere  75 know n H IV 
positives and 70 unknown HIV positives.
In  Glasgow, in  th e  hom osexual/bisexual category  th e  unknow n 
infections outnum bered known infections by th ree  to one, in heterosexual 
m ales by approxim ately six to one, and in heterosexual females by two to 
one. T here  w as very  little  infection, know n or unknow n, am ong th e  
Glasgow IDUs. Overall, in  Glasgow, there  were 22 known HIV positives 
and 73 unknown HIV positives.
O ne of th e  a im s of the  GUM S tu d y  is to  s tu d y  t r e n d s  in  H IV  
prevalence over a period of time. The re su lts  of the  analysis showed a 
relatively stable situation with no substantial changes in HIV prevalence 
in any of the risk categories, in either Glasgow or Edinburgh.
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5.3 Hospital Study
In  O ctober, 1991, a one-year p ilo t s tu d y  w as in i t ia te d  a t  SC IE H  to 
estim ate the prevalence of HIV infection among people, aged 16-49 years, 
attending  two Glasgow hospitals, or attending a few GP clinics th a t were 
u sin g  th e  b iochem istry  labora to ries of th e se  h o sp ita ls . All p a tie n ts  
a tten d in g  these  cen tres, who have a blood sam ple  tak e n  for u re a  and  
electrolyte testing, are eligible for the study. Repeat samples, provided by 
any one person within a twelve week period, are excluded from the study.
The pilot phase of this study was financed by the MRC, thereafter, 
financial responsibility passed to SCIEH.
From 1st May 1993, the study was restricted  to males, since it was 
recognised th a t the GUM, Guthrie, antenatal and family planning studies 
were already providing sufficient HIV-prevalence data for females.
Results from the study have been presented a t in ternational AIDS 
conferences in A m sterdam  and B erlin , and  a t an  MRC w orkshop  in 
M anchester in 1995 [152-154].
5.3.1 Hospital Study: data collected
(1) Hospital biochemistry departm ent (Glasgow Royal Infirm ary or 
Stobhill General Hospital)
(2) Gender and age group
(3) Time period of specimen taken (in calendar quarters)
(4) The HIV sta tus of the patient, if known
(5) Any objection, by the patient, to being tested for HIV
(6) Medical section patient is attending i.e.
General practitioner (GP)
General medical 
O ther
5.3.2 Hospital Study: results
The re su lts  of th is  study, for m ales only, covering th e  tim e  period  1st 
October 1991, to 30th June 1994, are sum m arised in Table 5.03.
In  th is tim e period, 17,130 specimens were tested a t Glasgow Royal 
Infirmary, compared with 9,942 specimens a t Stobhill G eneral Hospital, 
Glasgow. Among those tes ts  from Glasgow Royal Infirm ary , 201 HIV
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positive tes ts  were found, compared with only 10 from Stobhill G eneral 
Hospital. This gave an average rate, per calendar quarter, for Glasgow 
Royal Infirm ary, of 11.7 HIV positive te s ts  p e r 1000 tes ted , com pared 
with a ra te  of 1.04 per 1000 for Stobhill General Hospital.
Table 5.04 shows the  resu lts  for each hosp ita l, c lassified  by th e  
m edical section  being  a tten d ed  by th e  p a tie n t  a t th e  tim e  th e  blood 
specim en was taken. Extremely high ra tes  of tes ting  HIV positive were 
found  in  th e  G en era l M edical section  a t  G lasgow  Royal In firm ary , 
averaging  49.7 per 1000 tests. The ra te s  for Stobhill G eneral H ospital 
were all lower than  those found at Glasgow Royal Infirmary. The highest 
ra te  a t Stobhill was found in the General M edical section w ith  2.1 HIV 
positive tests per 1000 tests; the other medical sections had  ra tes of under 
1 per 1000 tests.
T able 5.04 also shows the  d is tr ib u tio n  of th e  HIV positive  te s t  
resu lts among the different medical sections, a t Glasgow Royal Infirmary, 
by knowledge of HIV status. In the General Medical section, where most 
of the  HIV positive resu lts were concentrated, the  known HIV positives 
o u tn u m b ered  th e  unknow n HIV positives by a fac to r of ten . O f th e  
rem a in in g  21 HIV positive resu lts, only 8 w ere know n HIV positives. 
Only ten  HIV positive results were found among those tested  a t Stobhill 
General Hospital, four of which were from known HIV positives.
Throughout th is analysis there has been a m arked difference between the 
re su lts  from th e  two hospitals. The num ber of HIV positive specim ens 
(most of which were from known HIV positive persons) taken  a t Glasgow 
Royal Infirm ary, has been greater (by a factor of 20) th an  the  num ber of 
HIV positive specim ens taken  at Stobhill G eneral H ospital. However, 
t h i s  is  a lm o s t  c e r ta in ly  b ro u g h t a b o u t by  th e  W est o f S c o tla n d  
haem ophilia un it being based at Glasgow Royal Infirmary. Haem ophilia 
p a tie n ts  a re  frequen tly  referred  to o ther m edical sections w ith in  th e  
h o sp ita l for tre a tm e n t and, if they  a re  HIV in fec ted , w ill u su a lly  be 
classified as ‘known positives’.
T he  r e s u l ts  from  S to b h ill G e n e ra l H o s p ita l  a re  l ik e ly  to  be 
representative of the prevalence of HIV infection among m ales (excluding 
h a e m o p h ilia c s )  a t te n d in g  h o sp ita l , a n d  show  no c h a n g e  in  H IV  
p rev a len ce  over th e  s tu d y  period. The re s u l ts  from  G lasgow  Royal 
Infirm ary are, however, likely to reflect trends in the health-care needs of 
the HIV infected haemophiliac cohort in the W est of Scotland.
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5.4 Guthrie Study
In Scotland, blood samples taken from babies, between 8-14 days old, are 
routinely tested  for an  inherited disorder which, un less trea ted , usually  
leads to severe b rain  damage. This test, the  G uthrie  tes t, m easures the  
am ount of phenylketonuria in a spot of blood tak en  from th e  heel of th e  
baby. All the blood samples, from babies throughout Scotland, are sent to 
one laboratory, a t Stobhill General Hospital in Glasgow, for testing.
In Jan u ary  1990, a UAT programme was started , to study changes 
in prevalence of HIV infection among the m others of new-born babies in 
Sco tland . T his w as based  on HIV te s tin g  of re s id u a l blood from  th e  
G uthrie  te s t [155,156]. Babies born to HIV infected m others will have 
antibodies to HIV in their blood, but th is does not necessarily m ean th a t 
the  baby is infected w ith HIV (see section 3.3). T hus, te s tin g  res idua l 
blood from the  G uthrie test only provides the  HIV s ta tu s  of th e  m other, 
not th a t of the baby.
A lthough each te s t specimen comes from a d ifferen t baby, some 
m others are counted more than  once in any one calendar year, e ither by 
having a m ultiple b irth  or by having another baby w ithin a calendar year.
T his UAT stu d y  differs from all th e  o th er UAT s tu d ie s  in  th a t  
babies are  unable to object to their blood being tested  for HIV, although a 
m other may object on her baby’s behalf.
5.4.1 Guthrie Study: data collected
(1) F irst p a rt of postcode of mother’s residence
(2) M other’s age
(3) Baby’s gender and calendar quarter of b irth
5.4.2 Guthrie Study: results
The resu lts of the  Guthrie Study are presented for the  four years 1990 to 
1993. Table 5.05 shows th a t the num ber of te s ts  per calendar quarter, 
and the  ra te  of HIV positive tests, have shown little  variation throughout 
the study period. Overall, 77 of the 262,508 specimens were HIV positive, 
giving a ra te  of 0.3 per 1000 tests.
T ab le  5.06 show s the  num ber of m o th e rs  re s id e n t in  Glasgow, 
E dinburgh and Dundee, by HIV te s t resu lt and  y ear of te s t. For each
88
location, averaging the  ra tes of HIV positive tes ts , over th e  four years, 
shows Edinburgh had a rate  of 1.7 per 1000 tests , Dundee had  1.3, and 
Glasgow had 0.12. The rate for the rest of Scotland was sim ilar to th a t of 
Glasgow at the low rate  of 0.13 per 1000 tests.
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5.5 Antenatal Study
In  D ecem ber 1988, an  HIV su rv e illan ce  schem e w as in tro d u c e d  to 
estim ate  HIV prevalence among women a tten d in g  a n te n a ta l clinics in 
E d in b u rg h  an d  D undee. In  th is  sc h em e , w om en  w ho a g re e d  to  
p a r tic ip a te  in  HIV te s tin g  were given a choice of e ith e r  a nam ed , or 
an o n y m o u s, HIV te s t  [157]. R esu lts  from  th is  schem e h a v e  b een  
p resen ted  a t in ternational AIDS conferences in  A m sterdam  and B erlin  
[150,151].
In  Ju ly  1993, th is ‘mixed’ surveillance schem e w as replaced  by a 
solely UAT surveillance scheme, again  of wom en a tten d in g  a n te n a ta l  
c lin ics in  E d in b u rg h  and  Dundee, th e  ob jec tive  b e in g  to  d e te rm in e  
changes, through time, in HIV prevalence among these women.
T h e  fo llo w in g  s tu d y  r e s u l ts  r e f e r  to  th e  m o re  r e c e n t  UAT 
surveillance scheme.
5.5.1 Antenatal Study: data collected
(1) Clinic attended
(2) Woman’s age group
(3) Time period of specimen taken (in calendar quarters)
(4) Woman’s risk factors for HIV
(5) P artner’s risk factors for HIV
(6) Any objection, by the woman, to being tested  for HIV
(6) Setting from which the blood was taken
(7) Woman’s choice for ongoing pregnancy or planned term ination
5.5.2 Antenatal Study: results
Table 5.07 shows the num ber of persons in the  A ntenatal Study, in  both 
Dundee and Edinburgh, from 1st July 1993 to 30th Ju n e  1994; in Dundee 
there were 3,749 HIV tests, and in Edinburgh, 15,258 tests.
Averaged over all the  calendar q u a rte rs  in  th is  sam e period, th e  
ra te  of te s tin g  HIV positive was rem ark ab ly  s im ila r in  th e  two te s t-  
c e n tre s , a t  1.3 pe r 1000 te s ts  in D undee, a n d  1.2 p e r 1000 te s ts  in  
Edinburgh. Table 5.07 shows that, although few women w ere IDUs, or 
p a rtn e rs  of IDUs, these  categories con ta ined  m ost of th e  wom en who 
tested  HIV positive. In Dundee, there were 5 HIV positive specimens; 4
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were from IDUs, and 1 from a partner of an  IDU. In  Edinburgh, 19 HIV 
p o sitiv e  spec im ens w ere found, in c lu d in g  6 from  ID U s an d  5 from  
partners of IDUs.
Am ong women who were assum ed to be a t low r isk  of HIV, i.e. 
n e ither they nor the ir partners were IDUs, there  were very few cases of 
HIV. In  th is  low-risk category, no HIV positives w ere found in  Dundee, 
and only 8 in Edinburgh (0.52 per 1000 tests).
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5.6 Family Planning Study
In  Jan u ary  1992, a UAT study was sta rted  a t a family planning  clinic in 
Glasgow, w ith the  aim of monitoring changes in HIV prevalence am ong 
women attending  the clinic. The study was initially  funded by the MRC 
before becom ing funded by SCIEH. All women a tten d in g  th e  clinic for 
pregnancy testing, for the first time in a calendar year, and who subm it a 
urine specimen, are included in the study.
This study has a complementary role to the G uthrie and A ntenatal 
S tudies. The Fam ily P lanning  Study includes women who th in k  they  
m ay be pregnant, while the Antenatal Study is restric ted  to women who 
are pregnant, and the  G uthrie Study to those who have given b irth  to a 
baby.
5.6.1 Family Planning Study: data collected
(1) Age group of the woman
(2) Time period of specimen taken (in calendar quarters)
(3) Any objection, by the woman, to being tested for HIV
(4) F irst p a rt of the postcode of woman’s residence
(5) Result of pregnancy test
5.6.2 Family Planning Study: results
Table 5.08 shows th a t  9,929 specim ens w ere te s te d  for HIV betw een  
Ja n u a ry  1992 and Ju n e  1994. Only two of these  specim ens w ere HIV 
positive; one in the  calendar quarter April to Ju n e  1992, the  other in the  
quarter April to June  1993. Averaging the  num ber of HIV positive te s ts  
per 1000 tests , over all calendar quarte rs  in  th is  period, gives the  very 
low ra te  of 0.2 per 1000 tests.
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5.7 UAT: summary of results
F ig u re  5 .02  show s su m m ary  r e s u l t s  from  a ll  th e  UAT sc h e m e s  
co-ordinated a t SCIEH, based on da ta  collected from Ja n u a ry  1992 to 
June  1994. It shows th a t high prevalences of HIV are found in the GUM 
and Hospital Studies, with over 5 HIV positives per 1000 tests, compared 
with the other UAT studies showing under 2 per 1000 tests. The reasons 
for th is may include
(1) People attending GUM clinics and hospitals are  likely to be a t 
higher risk of having HIV infection th an  people w ith no need to 
attend  (see section 5.2).
(2) The G uthrie, A ntenatal and Fam ily P lann ing  S tud ies do not 
include males, thereby excluding the homosexual risk  category.
5.8 UAT: comparison of results with Denominator Study
The Denominator Study gives an HIV prevalence ra te  of 11 HIV positives 
per 1000 tes ted , which, as expected, is su b s ta n tia lly  h ig h er th a n  any  
re su lts  from th e  UAT studies. However, the  prevalence ra te  from th e  
D e n o m in a to r  S tu d y , for th o se  p e rs o n s  c la s s i f ie d  a s  low  r i s k  
heterosexuals, is 4 per 1000 tested, which is lower th a n  th e  prevalence 
ra tes found in  the  GUM and Hospital Studies, bu t h igher th a n  the  ra te s  
found in  the A ntenatal, Guthrie and Family Planning Studies.
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5.9 UAT: comparison with England and Wales
In January  1995, staff at CDSC produced a comprehensive report on the 
results of UAT surveillance schemes, in England and Wales, from the years
1990 to 1993 [149]. This report contains results from similar GUM, Guthrie 
and hospital surveillance schemes.
Results from 1992 and 1993, co-ordinated a t CDSC for the  GUM 
Study, are separated into three groups: C entral London, London and the 
South East (excluding Central London), and England and Wales (excluding 
London and the South East). Very high HIV prevalence rates are found in 
Central London (49 HIV positives per 1000 tests), compared with the other 
two regions (4 per 1000 and 3 per 1000 respectively). From Table 5.01, it 
can be seen th a t  the  HIV prevalence ra te s , from  th e  GUM S tudy  in 
Scotland, are comparable to those found in England and Wales (excluding 
Central London).
R esu lts from the  G uthrie  S tudy  (from  y e a rs  1990 to 1993), in  
England and Wales, show an HIV prevalence ra te  of 2 per 1000 te s ts  in 
London and the South-East, compared with under 0.4 per 1000 tests in the 
rest of England and Wales. From Table 5.06, it can be seen th a t the ra tes 
from the Guthrie Study, in Edinburgh and Dundee, are sim ilar to those in 
London and the South East, while the rates in Glasgow are sim ilar to those 
in the rest of England and Wales.
Results of a hospital study from two London hospitals (from years
1991 to 1993), show that HIV prevalence rates among all patients receiving 
hospital care (excluding obstetrics) was 11 per 1000 tests, compared w ith 
11.7 per 1000 tests found in a comparable study in one Glasgow hospital, 
and 1 per 1000 tests in another Glasgow hospital (see Table 5.03).
5.10 The future of UAT surveillance
The growth of UAT surveillance, in the early 1990s, has led to a network of 
UAT surveillance schemes. Many of these schemes have been modified at 
the end of their pilot phase; some have been curtailed, others expanded. 
W hile acknowledging th a t each UAT schem e has its  own m erits , it is 
nevertheless worthwhile to evaluate the relative importance of each scheme, 
and to question if they are all necessary. These issues are addressed further 
in chapter eight.
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Chapter 6
The CD4 Study
6.1 Staging system for HIV infection
T he p rog ression  of HIV infection is c h a ra c te r ise d  by im m unolog ical 
changes and increasingly severe clinical m anifestations which reflect the  
g radual de terio ration  of the immune system  [31]. S tag ing  system s for 
HIV  in fec tion  have  evolved as know ledge of th e  p ro g ress io n  of H IV  
infection has improved. Of the earlier staging system s [11,12], one of the  
best know n is the  W alter Reed staging system , adopted by th e  U nited  
S tates Army in 1985 [10].
A s tag in g  system  provides a fram ew ork  for d iv id ing  th e  w hole 
spectrum  of HIV infection into mutually exclusive stages. In particular
(1) It helps to identify interm ediate stages of disease progression 
between the asymptomatic stage and AIDS.
(2) I t  provides guidelines which m ay be used  for such even ts as 
commencing (or ceasing) therapy, or drug trials.
(3) I t  f a c i l i ta te s  com m unica tion  b e tw e e n  v a r io u s  g ro u p s  of 
professionals in HIV-related fields by providing a fram ework in 
w h ic h  a ll  H IV  p o s itiv e  p eo p le  a re  a b le  to  be  c la s s if ie d  
consistently.
6.1.1 WHO staging system for HIV infection
In Ju ly  1990, the World Health Organization (WHO) produced an in terim  
proposal for a stag ing  system  for HIV infection and  d isease  [13]. T his 
system  is applicable to HIV positive people aged th ir te e n  or over. The 
p rog ression  of HIV infection in  ch ild ren  an d  a d u lts  is d iffe ren t bo th  
clinically and immunologically, so it is inappropria te  for them  to sh a re  
the same staging system.
T he WHO s ta g in g  system  h a s  two axes, one c lin ica l a n d  one 
immunological (see Table 6.01). The immunological axis is based on the  
absolute num ber of T4 cells per cubic m illim etre of blood. This value is 
commonly referred  to as the CD4 count. The absolu te  num ber of CD4 
cells is calculated, from three separate laboratory m easurem ents, using  
the formula
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CD4 count = (WCC) x (%lymphocytes) x (%CD4 lymphocytes) 
where:
WCC = white cell count
%lymphocytes = percentage of WCC th a t are lymphocytes 
%CD4 = percentage of lymphocytes th a t are CD4 lymphocytes
For example, if a person has a WCC of 5.4xl09/L, of which 22 per cent are 
lymphocytes, and 35 per cent of these lymphocytes are CD4 lymphocytes, 
then
CD4 count = 5.4 x 109/L x 0.22 x 0.35 
= 0.416 x 109/L 
= 416 x 106/L
This is commonly referred to as a CD4 count of 416.
T he CD4 co u n t of a h e a lth y  p e rso n  is  a ro u n d  1000 ce lls  p e r  cub ic  
m illim etre of blood. Following HIV infection, the  CD4 count tends to fall, 
w ith time, by approximately 40 - 80 cells per cubic m illim etre of blood per 
year on average [13], although individual counts may fluctuate widely.
In the  WHO staging system the immunological axis is divided into 
three categories, A,B and C
(1) Stage A: CD4 count greater than  500
(2) Stage B: CD4 count between 200 and 500
(3) Stage C: CD4 count less than  200
The clinical axis has four m utually  exclusive categories, s tages 1 to 4, 
corresponding to a list of physical or clinical conditions associated w ith  
HIV.
Stage 1 m eans th a t, a t the tim e of the  CD4 request, th e  p a tien t is 
asym ptom atic, or h as  an acute re tro v ira l infection, or h a s  p e rs is te n t 
generalised lymphadenopathy (PGL).
S tage 2 (early  HIV infection) includes conditions such as herpes 
zoster and recurrent infections of the upper respiratory tract.
S tag e  3 ( in te rm e d ia te  HIV in fec tion ) em b races  su ch  c lin ica l 
conditions as oral candidiasis, oral h a iry  leukop lak ia  and  pu lm onary  
tuberculosis.
S tag e  4 ( la te  HIV infection) in c lu d es  p a t ie n ts  w ith  an  AID S
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defining illness, in addition to those pa tien ts  whose illness has confined 
them  to bed for a considerable part of the m onth preceding the  date of the 
CD4 request.
P atien ts may have symptoms th a t put them  in stage 2 a t one clinic 
v is it, b u t be asym ptom atic  (stage 1) a t th e  nex t. T he W HO s ta g in g  
system  classifies people according to highest stage ever reached, so these 
pa tien ts  would rem ain  in clinical stage 2 despite being asym ptom atic a t 
the tim e of their la ter visit.
W hen the  CD4 count is combined w ith clinical inform ation, th ere  
a re  tw elve categories th a t cover the  en tire  spectrum  of HIV infection. 
Those in  th e  1A category (clinical stage 1 and  im m unological stage  A) 
being relatively healthy, compared with those in the 4C category (clinical 
s ta g e  4 a n d  im m unolog ical s tag e  C), w hose HIV in fe c tio n  is  m ore  
a d v a n c e d . T h is  sy s te m  h a s  been  u se d  a n d  v a l id a te d  by  a W HO 
international collaborating group [158].
6.1.2 WHO staging system in Scotland
In  N o v e m b er 1990, a p ro p o sa l w as  p u t  fo rw a rd  to  in t r o d u c e  a 
co llabora tive  su rveillance  scheme, for HIV in fec ted  a d u lts  rece iv ing  
h e a lth  care  in  Scotland, based  on th e  WHO s ta g in g  system . Such a 
scheme began in Scotland in November 1991, after consultation with HIV 
im m unologists and clinicians. Its purpose is to discover th e  num ber of 
HIV positive ad u lts  curren tly  receiving im m unological m onito ring  in  
S c o tla n d , to g e th e r  w ith  in fo rm a tio n  on th e i r  c u r r e n t  c lin ic a l a n d  
immunological health. This surveillance scheme is colloquially referred 
to as the ‘CD4 Study’.
6.1.3 Surveillance form for the CD4 Study
A th ree -p art request form, for those persons undergoing im m unological 
m onitoring in Scotland, was designed at SCIEH in order to standard ise  
d a ta  co llec tion  for th is  su rve illance  schem e. A copy of th is  form  is 
p ro v id e d  in  th e  b a ck  pocket of th is  th e s is .  T he  c l in ic ia n , w ho is  
requesting  the  lymphocyte count, completes th e  top copy of the  form a t 
th e  tim e  of c o n su lta tio n , reco rd in g  th e  c lin ic a l sy m p to m s p re s e n t  
according to h is or he r medical judgm ent. The top copy of th e  form  is 
kep t by th e  clinician, w ith the other two copies being  forw arded to th e
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H IV  im m uno logy  la b o ra to ry , to g e th e r  w ith  th e  b lood  sa m p le  for 
lym phocyte an a ly sis . The second copy of th e  form  is re ta in e d  by th e  
laboratory . The th ird  copy, which contains in fo rm ation  from  both  th e  
clinician and the laboratory, except for the patien t’s name, is forwarded to 
SCIEH.
As w ith the  other surveillance schem es adm in istered  by SCIEH, 
the  confidentiality of each person is m aintained by collecting only lim ited 
information on identity, such as date of birth, initials and soundex code of 
surnam e.
6.1.4 Computer support for the CD4 Study
A req u est form is completed every tim e a CD4 count is requested  and, 
since HIV positive people are m onitored regularly , severa l form s will 
probably be completed for each person in the study.
C oncurren t w ith  th e  designing of th e  req u est form , a com puter 
relational database was designed in DATAEASE [107] to track  all records 
fo r each  p e rso n  in  th e  study , and  to c o lla te , for each  p e rso n , su ch  
sum m ary information as highest clinical stage ever reached, most recent 
CD4 count, and date of most recent CD4 count.
6.1.5 Addition of risk category and death information
Since th e  person ’s nam e will usually  be w ritte n  on th e  top copy of th e  
request form, it was decided th a t HIV risk  factor inform ation should not 
be collected; instead, risk  inform ation is sought from th e  HIV Register. 
T his enables r isk  category to be en tered  onto th e  CD4 da tab ase  w hile 
preserving the patien t’s confidentiality.
In fo rm ation  about d ea th s of HIV infec ted  persons, received  a t 
S C IE H  from  e i th e r  th e  R e g is tra r  G e n e ra l for S c o tla n d  (RGS) or 
clinicians, is also recorded on the CD4 database.
6.1.6 Interpretation of immunological axis
T h e re  a re  s e v e ra l  w ays of u s in g  th e  CD4 d a ta  to  r e p r e s e n t  th e  
im m unological s ta te  of those under m onitoring. I t m ay be argued  th a t  
the  best choice will depend on the context in which the  d a ta  are likely to 
be used
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(1) If  the  d a ta  are to be used for allocation of resources, such as 
provision of out-patient facilities, hospital beds and staffing, it 
m ay be appropriate to look at the w orst scenario by tak in g  the  
lowest CD4 count within the time period of interest.
(2) If  the  d a ta  are being used to assess a p a tie n t’s su itab ility  to 
en ter a drug trial, then the most recen t CD4 count is likely to 
be the most appropriate.
(3) I f  th e  d a ta  are  be ing  u sed  to d e sc rib e  th e  im m u n o lo g ica l 
condition of the population in any given tim e period, it  m ay be 
appropria te  to use the  average CD4 count (averaged over all 
counts in the time period).
For th e  purpose of describing the staging of th e  population  in  any  one 
year, it was decided to use the average CD4 count in  th a t  calendar year, 
together w ith the most severe stage ever reached. The tables and figures 
referred to, throughout this chapter, use th is system  of representation.
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6.2 Results of the CD4 Study in Scotland
In  Ju n e  1994, an analysis was carried  out to com pare th e  stag ing , in  
1992, of those HIV positive adults who had the ir CD4 count m easured in 
1992, w ith  th e  s tag in g , in  1993, of th o se  who h a d  th e i r  CD4 co u n t 
m easured in 1993.
6.2.1 WHO staging of HIV positive adults (1992)
The staging, for the  928 HIV positive adu lts  who had  th e ir  CD4 count 
m easured in 1992, is given in Table 6.02.
At the  tim e of the ir last CD4 count m easurem ent in  1992, 40 per 
cent of these 928 adults were in clinical stage 1, 16 per cent were in stage 
2 (e a rly  H IV  in fec tio n ), 25 p e r cen t in  s ta g e  3 ( in te rm e d ia te  H IV  
infection), and 15 per cent in stage 4 (late HIV infection). The rem aining 
4 per cent had  no clinical information recorded on any of the ir forms, and 
thus were unable to be clinically staged.
T aking the  average of all CD4 counts, m easured  during  1992, for 
each of th e  928 persons, 15 per cent had  an  average CD4 count of over 
500, 44 per cent had an average count of between 200 and 500, and 39 per 
cent had an average count of under 200. The rem aining 2 per cent had  no 
CD4 count recorded on any of their forms.
From  Table 6.02, it can be seen th a t the  modal cell is IB w ith 209 
persons (22 per cent). The distribution  of people in  the  stag ing  system  
reflects the  association between high clinical staging and low CD4 counts. 
No person  in  stage  4 had  an average CD4 count of over 500. Of those  
persons with an average CD4 count of greater th an  500, 71 per cent were 
in  clinical stage 1, while, of those people w ith average CD4 count of less 
th a n  200, 70 per cent were in clinical stages th ree  or four (in term ediate  
or late HIV infection).
6.2.2 WHO staging of HIV positive adults (1993)
The staging, for the  942 HIV positive adults, who had  th e ir  CD4 count 
m easured in 1993, is given in Table 6.03 and represented in Figure 6.01.
At the  tim e of the ir last CD4 count m easurem ent in 1993, 39 per 
cent of these 942 adults were in clinical stage 1, 15 per cent were in stage 
2 (e a rly  H IV  in fec tio n ), 20 pe r cen t in  s ta g e  3 ( in te rm e d ia te  H IV
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infection), and 17 per cent in stage 4 (late HIV infection). The rem aining 
9 per cent had  no clinical information recorded on any of the ir forms, and 
thus were unable to be clinically staged.
T aking the  average of all CD4 counts, m easured  during  1993, for 
each of th e  942 persons, 17 per cent had  an  average CD4 count of over 
500, 42 per cent had an average count of between 200 and 500, and 40 per 
cent had an average count of under 200. The rem aining 1 per cent had  no 
CD4 count recorded on any of their forms.
It is apparen t th a t the results in  Tables 6.02 and 6.03 are alm ost 
id e n tic a l,  show ing  a s ta b le  p o p u la tio n -p ro file  for th o se  w ho w ere  
m onitored during  1992 and 1993. However, i t  can be seen from Figure 
3.09 th a t  approxim ately 100 HIV positive persons died in  1992, hence, 
th is  s ta b i l i ty  in  p o p u la tio n -p ro file  m ask s  s u b s ta n t ia l  c h a n g e s  a t  
individual level.
6.2.3 Regional variations in WHO staging (1993)
Figures 6.02, 6.03 and 6.04 show the distribution of WHO staging applied 
to all p a tien ts  m onitored, during 1993, a t im m unology labo ra to ries in  
Edinburgh, Glasgow and Dundee. These laboratories all show a different 
distribution of staging: in Edinburgh, the modal stage was IB with 27 per 
cent of the  481 persons monitored there; in Glasgow, the modal stage was 
the  most severe stage, 4C, with 24 per cent of the  215 persons monitored; 
in  D undee, 3C w as th e  m odal stage w ith  20 p er cen t of 144 persons. 
F rom  th e s e  fig u res , i t  ap p ea rs  th a t  th o se  p e rso n s  c u rre n t ly  u n d e r  
m onitoring in Glasgow and Dundee are more likely to be a t an  advanced 
sta te  of HIV disease than  those in Edinburgh.
6.2.4 Risk category variations in WHO staging (1993)
F igu res 6.05, 6.06 and  6.07 show th e  d is tr ib u tio n  of WHO stag in g  as 
applied to the three m ain risk categories. The m ost strik ing  difference is 
in the homosexual/bisexual category where 26 per cent of the  181 persons 
are in stage 4C, compared with 12 per cent of the  IDU, and 12 per cent of 
the  heterosexual, categories. From these figures it appears th a t, of those 
p e r s o n s  u n d e rg o in g  CD4 m o n ito r in g , th o s e  c la s s i f ie d  a s  
homosexual/bisexual (males) are more likely to be a t an advanced stage of 
HIV infection th an  those classified as either IDU or heterosexual.
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6.3 Log-linear modelling of risk, region and severity 
of HIV infection
The associations among geographical region, risk  category and severity of 
HIV infection are complex. A sta tistica l technique known as log-linear 
modelling may be used to investigate such associations among categorical 
variables, by exam ining the num ber of en tries in d istinct categories of a 
multi-dimensional table [140]. In October 1993, th is analysis was carried 
o u t u s in g  d a ta  co llec ted  from  th o se  p e rso n s  u n d e r  im m u n o lo g ica l 
monitoring during 1992.
For th is analysis only, each of the twelve cells of the  WHO staging 
system  w as classified as either ‘severe’ HIV infection or ‘m odera te’ HIV 
infection. Using the WHO staging in Table 6.01, cells 1A, 2A, 3A, IB, 2B 
and 3B became ‘moderate’ HIV infection, and cells 1C, 2C, 3C, 4A, 4B and 
4C becam e ‘se v e re ’ HIV in fec tion . T he ‘se v e re ’ H IV  c la s s if ic a tio n  
conformed to the AIDS definition adopted in the United S tates of America 
in January  1993 [27,58].
The th ree  immunology laboratories in  E dinburgh, Glasgow and  
D undee w ere used  as a surrogate  for the  th re e  geographical reg ions. 
A n a ly s is  w as r e s t r i c te d  to  th e  th r e e  m a in  r i s k  c a te g o r ie s ,  
homosexual/bisexual, IDU, and heterosexual, giving a study population of 
720 (see T ab le  6.04). A form al an a ly s is  w as c a rr ie d  o u t u s in g  th e  
s ta t is t ic a l  p rocedure  HILOGLINEAR from  th e  A dvanced S ta tis t ic s  
module of SPSSPC+ [159].
T able 6.05 show s the  95% confidence in te rv a l (95% Cl) for th e  
estim ates of the  m ain effects and two-way in terac tions produced by the  
lo g -lin ea r m odel. The values of the  p a ra m e te rs  for th e  m a in  effects 
confirm  w h a t is a lready  well known about th e  HIV popu la tion  u n d e r 
m onitoring in Scotland; namely, th a t there are more HIV positive people 
in Edinburgh th a n  e ither Glasgow or Dundee, th a t  th ere  are  m ore HIV 
p o s i t iv e  p e o p le  w hose  r is k  a c t iv i ty  is  th o u g h t  to  b e  ID U  th a n  
hom osexual/bisexual or heterosexual, and more ‘m oderate’ HIV infection 
th an  ‘severe’ HIV infection.
Of much greater interest than  the m ain effects, are the  interactions 
be tw een  region, risk , and  severity  of HIV infection . T he in te ra c tio n  
param eters indicate the change between the effects of the variables taken  
individually and taken  collectively. They rep resen t the  additional effect 
associated with a particular combination of values.
103
Table 6.05 shows th a t statistically  significant associations occur 
betw een region and risk  category; in particu lar, it  shows th a t  Glasgow 
h as more HIV positive hom osexuals/bisexuals th an  expected, and  th a t  
D u n d e e  h a s  few er th a n  e x p ec te d . T h e re  a re  s t r o n g  s t a t i s t i c a l  
a sso c ia tio n s betw een  r isk  category and  se v e rity  of H IV  infec tion ; in  
particu la r, hom osexuals are more likely to have ‘severe’ HIV infection, 
while IDUs are more likely to have ‘m oderate’ HIV infection. Despite the  
statistically  significant association between region and risk  category, and 
betw een risk  category and severity of HIV infection, Table 6.05 shows 
th a t  the  association between region and severity  of HIV infection is not 
statistically significant.
Some issues are raised by the results of these interactions :-
(1) The higher than  expected number of HIV-infected male homosexuals 
in Glasgow indicates th a t th is is the  m ost im portan t transm ission  
route in th is  area, while the relatively low level of infection am ong 
the IDU and heterosexual risk categories suggests th a t these routes 
have been less im portant. This scenario is com pletely reversed  in 
Dundee, with injecting drug u§e and heterosexual sex being the  key 
ro u te s  of tra n sm iss io n , and  hom osexual sp re a d  b e in g  of l i t t le  
im portance. These results emphasise the  need to p lan  HIV-related 
services, such as prevention campaigns, to suit the different needs of 
the different areas.
(2) T he h ig h e r  th a n  expected  n u m b er of peop le  w ith  sev e re  HIV  
infection among those infected homosexually, and  th e  lower th a n  
expected num ber people with severe HIV infection among the  other 
risk categories, have important consequences for future patien t care. 
Although, a t present, the majority of those infected by injecting drug 
use, or heterosexually , are still re la tiv e ly  well, th ese  people will 
becom e less h e a lth y  as th e ir  in fec tion  p ro g resses. T hus, in  th e  
future, these risk categories will need increasing levels of care. This 
will have im portant consequences for the  fu ture  costs of care which 
w ill be s ig n ific an tly  increased , p a r t ic u la r ly  in  E d in b u rg h  an d  
D undee w ith  th e ir  h igher proportion of people in fected  e ith e r  by 
injecting drug use or heterosexually.
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6.4 HIV positive adults alive and under monitoring
Table 6.06 shows, for those HIV positive adults not known (at 31/12/94) to 
have died, the time period and value of their most recent CD4 count. These 
results include all CD4 counts reported to SCIEH by 15th February, 1995. 
The last time period, January to June 1995, is necessarily incomplete.
In Table 6.06, it is shown th a t 912 persons (81 per cent) had th e ir 
CD4 count measured between 1st January 1994 and 15th February 1995, of 
whom 216 persons had their CD4 count m easured in the first six weeks of 
1995. There were 80 persons (7 per cent) who las t had th e ir CD4 count 
measured in 1992. These people may have died, and the death not reported 
to SCIEH, or have moved away from Scotland.
Table 6.07 shows the same information as Table 6.06, but categorised 
by the health  board from which the most recent CD4 count was requested. 
This ‘health  board of request’ is known for 1,098 persons (97 per cent). In 
Lothian Health Board, 486 persons (83 per cent) have had their CD4 count 
m easured  since 1st Ja n u a ry  1994, com pared w ith  195 (81 per cent) in 
Greater Glasgow Health Board, 143 (74 per cent) in Tayside Health Board, 
and 25 (83 per cent) in Grampian Health Board.
Table 6.08 shows the same information as Table 6.06 but categorised 
by risk . Risk categories have been assigned (see section 6.1.5) to 1,027 
persons (91 per cent). Since 1st January 1994, 251 (88 per cent) of the HIV 
positive persons in the homosexual/bisexual category have undergone CD4 
monitoring, compared with 430 (81 per cent) of those in the IDU category, 
and 140 (77 per cent) of those classified as heterosexual risk.
6.5 The future of the CD4 Study
A lthough  th e  CD4 S tudy  is re la tive ly  new, it h as  a lre ad y  becom e an  
e x tre m e ly  im p o r ta n t  com ponent of HIV s u rv e illa n c e  in  S c o tla n d . 
Information from the scheme is regularly requested by staff a t the Scottish 
Office who are  in te res ted  in the allocation of resources for H IV -related 
issues in Scotland [8].
However, as the study comes to the end of its pilot phase, there are 
concerns re la tin g  to i ts  perform ance th a t  need  to be a d d re ssed . In  
p a r t ic u la r , th e  q u a lity  of the  c lin ical d a ta  is poor and  d a ta -e n try  is 
unnecessarily laborious. These issues are discussed further in chapter eight.
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Chapter 7
Computer Linkage of HIV Surveillance Schemes
106
7.1 Linkage of HIV surveillance schemes
T here is enorm ous potential to increase the  inform ation available from 
th e  su rv e illa n c e  of HIV in  S co tland , by l in k in g  th e  rec o rd s  in  th e  
individual HIV surveillance schemes. This potential arises because, over 
a period of time, an HIV infected person is likely to appear in  more th an  
one s u rv e i l la n c e  sch em e, as th e  fo llo w in g  h y p o th e t ic a l  e x a m p le  
illustrates:-
A wom an IDU te s ts  HIV negative in  M arch 1989, te s ts  HIV 
positive in Jan u ary  1990, has her first CD4 count m easured in  
February 1990, and has an AIDS-defining illness diagnosed in 
M a rc h  1994. T h is  w om an  w o u ld  a p p e a r  f i r s t  in  th e  
Denominator Study, then the HIV Register, the  CD4 Study and 
finally the AIDS Register.
If each HIV surveillance scheme has sufficient common identifiers, such 
as d a te  of b ir th , in itia ls , and  soundex code of su rn am e, to enab le  i ts  
records to be linked to those in the other surveillance schemes, then  it  is 
possib le  to b u ild  up  a profile, over a pe riod  of tim e , of HIV  p o sitiv e  
individuals. The uniformity of the use of identifiers, such as initials, date 
of b irth , and soundex code of surname, together w ith the centralisation of 
all th e  surveillance da ta  on computer a t SCIEH, m akes th is  ta sk  m uch 
easier th an  it would be otherwise.
However, unless the  data-sets to be linked are  of a sim ilarly  high 
quality , and  th e  linkage is carried  out w ith  considerab le  care, it  m ay 
p resen t m isleading information. In particular, if  th ere  are transcrip tion  
erro rs in  key identifiers such as date of b irth , or if people are  known by 
different surnam es in different data-sets, then  links will be missed. This 
m ay  le a d  to  an  o v e re s tim a tio n  of th e  n u m b e r of d if fe re n t  p e rso n s  
contained in the new combined data-set.
A lthough the  AIDS Register and the  CD4 Study have always had  
good iden tifie rs , it w as not u n til the  revision  of th e  HIV R eg ister w as 
completed in 1992 [108], th a t the identifiers in  th a t surveillance scheme 
became of a sufficiently high quality to link it w ith the other surveillance 
schemes. Since 1993, much time and effort has been expended by staff a t 
SCIEH to identify people who are in more than  one scheme.
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7.2 Merger of the HIV and AIDS Registers
The first link to be made occurred in 1994, between the HIV Register and 
th e  AIDS Register. These two files w ere in itia lly  linked, th e n  m erged 
in to  one file, the  HIV/AIDS Register, thereby  providing m any benefits. 
The following are some examples
(1) D a ta  e n try  is sim plified . M ost people te s t  HIV p o sitiv e  before  
developing an AIDS-defining illness. Such a person will have an  
HIV positive record, on the HIV/AIDS Register, a lready containing 
inform ation such as initials, soundex code of surnam e, da te  of b irth  
and probable transmission category. Hence, the record only needs to 
be u p d a te d  w ith  add itional in fo rm atio n  p e r t in e n t  to  th e  AIDS 
diagnosis, e.g. da te  of onset of f irs t A ID S-defining illness. I f  th e  
person subsequently  dies, then th e  da te  of d ea th  needs only to be 
entered in one combined file, instead of two separate files.
If  a person has not previously tested  HIV positive, th en  th is  
w ill now be m ore noticeable th a n  before th e  m erger, p ro m p tin g  
enqu iries to be m ade, through th e  rep o rtin g  c lin ician, about any  
previous HIV test which the person may have had.
(2) D ata  held on the  HIV Register m ay be found to be out of date , e.g. 
th e  p e rso n  m ay now be know n to  be hom osexual, or m ay  h ave  
changed nam e or address. With a m erged file, it is easier to update  
the person’s record with this new information.
(3) The m erging of the  two files allows other questions to be answ ered 
more easily, for example
(a) How many persons infected with HIV have progressed to AIDS?
(b) How m an y  p e rso n s  in fec te d  w ith  H IV  h a v e  d ie d  b e fo re  
developing an AIDS-defining illness?
7.2.1 Results from merger of HIV and AIDS Registers
Table 7.01 shows HIV positive persons and th e  year of th e ir  f irs t HIV 
positive specimen, categorised by w hether or not they have been reported 
to SCIEH as AIDS cases. Of the 2,209 HIV positive reports received a t 
SCIEH by 31st December 1994 [38], it can be seen th a t 604 (27 per cent)
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have been reported as AIDS cases.
H ow ever, c o n tra ry  to  e x p e c ta tio n s , T a b le  7 .01 sh o w s l i t t l e  
difference betw een the  percentage of reported AIDS cases am ong those 
p e rso n s  know n to be HIV positive in  th e  e a rly  1980s, an d  th o se  no t 
known to be HIV positive until the early 1990s. For instance, 25 per cent 
of people who were known to be HIV positive, in  1984, have progressed to 
AIDS, compared with 23 per cent of those who were first known to be HIV 
positive ten  years later, in  1994. The figure of 25 per cent is a t variance 
w ith published figures which show that, ten  years after infection, 50 per 
cent of HIV infected people will have progressed to AIDS [31].
T h is a p p a re n tly  slow progression  from  HIV to AIDS m ig h t be 
artificial. Possible explanations are
(1) Some people on th e  HIV/AIDS R eg is te r  m ay no lo n g er be 
resident in Scotland.
(2) Some people m ay have had  HIV te s ts  u n d e r false  n am es or 
d a te s  o f b i r th .  F o r su ch  p e o p le , i t  is  u n l ik e ly  t h a t  a n y  
subsequent AIDS reports will be capable of being  m atched  to 
th e ir  o rig inal HIV positive te s ts . T hese people m ay ap p ea r 
twice on the HIV/AIDS Register, w ith their earlier HIV-positive 
test results possibly never being updated.
Table 7.02 shows inform ation rela ting  to deaths reported  to SCIEH  by 
3 1 st D ecem ber 1994. Of those who w ere know n to  be H IV  p o sitiv e  
betw een 1983 and 1988, approxim ately 10 per cent have died w ithou t 
either having developed an AIDS defining illness, or w ithout having being 
reported to SCIEH as an AIDS case.
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7.3 Computer linkage of HIV/AIDS Register and CD4 Study
From the beginning of the CD4 Study, the  HIV Register has been used to 
p rov ide risk -ca teg o ry  in fo rm ation  for a ll p a tie n ts  in  th e  CD4 Study. 
Since the nam e of the patien t is on the surveillance form used to request 
a CD4 c o u n t, in  o rd e r  to  p re s e rv e  c o n f id e n tia l i ty  i t  w as d e em ed  
in ap p ro p ria te  to record risk  factors for HIV on th e  sam e req u est form. 
Instead , ascertainm ent of the  HIV risk  category, for a person new to the  
CD4 Study, involves searching the HIV Register for the  person’s record, 
then  copying the relevant information to the  corresponding record in the  
CD4 S tu d y  d a ta b a s e . T h is  tim e -c o n su m in g  p ro c e d u re  c re a te s  a 
tem porary link between the person’s records in both the HIV Register and 
the  CD4 Study database, but the link is broken after the risk  information 
has been copied.
It was clear th a t it would be desirable to make th is link perm anent. 
C om puter linkage of the  HIV/AIDS R egister and CD4 S tudy  da tab ase  
w as s ta r te d  in  J u ly  1994, u s in g  th e  com m on id e n tif ie rs  of in i t ia ls ,  
soundex of su rnam e and date  of b irth , to m ake the  link. The form at of 
th e  CD4 S tudy  d a ta b ase , w hich collects a ll CD4 co u n ts  for a ll H IV  
positive persons, m akes a single register, for all HIV/AIDS d a ta  and  all 
CD4 data, too cumbersome to be easily m anipulated.
In  o rd e r  to  sim p lify  th e  l in k a g e  p ro cess , each  p e rso n  in  th e  
HIV/AIDS R eg ister is a llocated a un ique  se ria l n um ber (HIV record  
num ber), similarly, each person in the  CD4 Study is allocated a unique 
serial num ber (CD4 record number). When a patien t in the  CD4 Study is 
iden tified  in  th e  HIV/AIDS Register, th en  th e  CD4 record  num ber is 
copied to the  HIV/AIDS Register, and the  HIV record num ber copied to 
th e  CD4 su m m ary  record. T hus, th ese  reco rd  n u m b ers  e s ta b lish  a 
perm anent link between the two files, which rem ain separate, unlike the  
new linked HIV/AIDS Register, which is now held as one com puter d a ta  
file.
The m ain im petus for linking the two surveillance schemes is to provide 
answers to questions such as
(1) W hat proportion of HIV positives in  each h e a lth  board , and  
thought to be still alive, are currently under CD4 monitoring?
(2) Do persons who have only recently been tested  as HIV positive 
have high or low CD4 counts?
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7.3.1 HIV positives under CD4 monitoring
Table 7.03 shows th a t of the  1,591 HIV positive persons th o u g h t to be 
alive, 960 (60 pe r cent) a re  known to be in  th e  CD4 Study. In  a ll b u t 
th ree  health  boards, the num ber of people included in the  CD4 S tudy is 
g rea ter th an  the  num ber not included in the  study; the  th ree  exceptions 
b e in g  D um fries and  Galloway, H ig h lan d , and  G ram p ian . T he  low 
participation ra tes  in these three health  boards m ay be a consequence of 
th e  p rac tical difficulties of tran spo rting  blood specim ens, from rem ote  
locations to th e  immunology laboratories, quickly enough for th e  CD4 
count m easurem ents to be viable.
From Table 7.03 it can be seen th a t there are 631 persons who have 
tested  HIV positive, are thought to be alive, but are not in the CD4 Study. 
F u rther investigation is required to ascertain if these people are residen t 
in Scotland and receiving care.
7.3.2 CD4 counts at first positive HIV test
T h e  in t e r p r e t a t i o n  of CD4 c o u n ts , a t  H IV  d ia g n o s is ,  is  n o t  
s tra ig h tfo rw a rd . The ex ten t to w hich in d iv id u a l doctors succeed  in  
persuading HIV positive people to encourage the ir p a rtners to have HIV 
te s ts  (commonly called ‘contact trac ing ’), w ill affect th e  va lues of CD4 
counts a t HIV diagnosis. If  p a rtn e rs  te s t HIV positive, th en  th e ir  CD4 
count a t HIV diagnosis will alm ost certainly be h igher th a n  if th ey  had  
w a ited  u n til  th ey  h ad  o th er reaso n s to seek  HIV te s tin g . S im ila rly , 
h ig h er CD4 counts will occur if doctors encourage wom en, a tte n d in g  
a n te n a ta l  clinics, to have HIV tests . A ttitu d es  to co n tac t-trac in g  and  
a n te n a ta l  te s tin g  m ay d iffer betw een  doctors, h o sp ita ls  an d  h e a l th  
boards, m aking the  in terpretation  of CD4 counts, a t HIV diagnosis, very 
difficult.
7.3.3 Results from linkage of HIV/AIDS Register and CD4 Study
In  Ja n u a ry  1995, using the HIV/AIDS Register linked to the  CD4 Study 
database, an analysis was carried out to examine the CD4 counts, a t tim e 
of HIV diagnosis, of persons first te s tin g  HIV positive in  1994. For 95 
persons (69 per cent of the 138 persons first testing  HIV positive in  1994), 
an  HIV te s t and a CD4 count m easurem ent had  been conducted w ith in
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one m onth of each other.
Table 7.04 shows the CD4 counts for these 95 persons, classified by 
health  board of CD4 request, risk category and gender. In particular, it is 
seen th a t 48 of the  95 persons (50 per cent) had  a CD4 count of less th an  
200, suggesting th a t they were at a late  stage of HIV infection, and  had  
probably been infected with HIV several years before being identified as 
HIV positive. In  contrast, 18 persons (19 per cent) had  a CD4 count of 
over 500, suggesting th a t they were in the early stages of HIV infection.
Table 7.04 also shows th a t the largest group of new ly identified  
HIV cases consisted of 28 hom osexual/bisexual m en from Lothian. Of 
th e se  28 m en, 7 h a d  CD4 counts of less th a n  200 a t HIV d iag n o sis , 
com pared w ith 7 who had CD4 counts of over 500. The second-largest 
group consisted of 19 homosexual/bisexual m en from G reater Glasgow, of 
whom 9 had  CD4 counts of under 200 at HIV diagnosis, and 2 had  counts 
of over 500.
In  L oth ian , 15 new HIV cases w ere a ttr ib u te d  to h e te ro sex u a l 
transm ission, compared with 6 in G reater Glasgow and 9 in  Tayside. In 
each health  board, there appeared to be a m ixture of early-stage and late- 
stage  HIV infection among those classified as he te ro sexual risk , w ith  
sim ilar levels of immune deficiency in both males and females.
The sm allest risk  category was IDU, w ith 7 cases in Lothian, 5 in 
greater Glasgow and 8 in Tayside. Most persons in th is category had  low 
CD4 counts, suggesting tha t infection took place some years before. There 
were 3 m ale IDUs with counts of over 500, 2 in Tayside and 1 in  G reater 
Glasgow, suggesting th a t there were a few early-stage infections in these 
groups.
A copy of a poster, presented at an MRC workshop in  M anchester in 1995, 
show ing CD4 counts a t HIV diagnosis [160], is p rov ided  in  th e  back  
pocket of th is thesis.
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7.4 Other computer linkage involving HIV surveillance data
Increasing computerisation of surveillance records a t SCIEH, and a t other 
centres, has increased the opportunity to create links between data  held at 
d if fe re n t lo ca tio n s . T h is p rov ides g re a te r  p o te n tia l  for a d d it io n a l  
information to be extracted from data already gathered.
When linkage of data held at SCIEH with data held in other centres 
is proposed, it is necessary to be extremely careful to consider all possible 
consequences of tha t linkage. In particular, there is a need to ensure th a t 
the confidentiality of the HIV surveillance data  is preserved. Doctors who 
report AIDS cases, HIV positive test results and CD4 counts to SCIEH, do 
so in confidence, using soundex codes for surnames to protect their patients’ 
identities. It is clearly wrong to use this data in such a way th a t pa tien ts’ 
names or addresses might be identified.
D ata, held within SCIEH, containing individual dates of b irth  and 
soundex codes, should not be made available to anyone outside SCIEH, 
except under very strict guidelines and with appropriate ethical approval.
In  th e  p a s t  few y ea rs , SCIEH h as ap p ro ach ed  (and  h a s  been  
approached by) other centres, with proposals to link the HIV Register with 
other data sources. In each case, a protocol has been agreed, and appropriate 
ethical committee approval sought, before the linkage has begun.
Two such linkages have already taken place
(1) Linkage of the HIV Register with data on all deaths in Scotland, 
betw een  1980 and 1991, held by th e  R e g is tra r  G en era l for 
Scotland.
T his has im proved the  record  of d e a th s  am ong those  
persons listed in the HIV Register, in p a rticu la r by providing 
information on the cause of death [14].
(2) L inkage of the  HIV Register w ith S co ttish  m orb id ity  record 
(SMR) data collated on SMR-1 forms from 1981 to 1993.
SMR-1 form s a re  com pleted  every  tim e  a p a t ie n t  is 
d isch a rg ed  from  a w ard  in  a S c o ttish  h o sp ita l  (ex c lu d in g  
psychiatric wards and obstetric wards). They are also completed 
every tim e a person changes co n su ltan t or is tra n s fe r re d  to 
an o th e r h o sp ita l [15]. T his h a s  en ab led  in fo rm a tio n  to be 
genera ted  on the  use of hosp ital resources by those  who a re
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known to be HIV positive. This includes inform ation such as 
n um ber of h o sp ita l adm issions, len g th  of s ta y  and  type  of 
hospital. This information is clearly of great importance to those 
responsible for the planning of resources for patient care.
7.5 Computer linkage ■ the future
I t  is  e v id e n t th a t  co m p u te rs  w ill co n tin u e  to  p la y  a n  in c re a s in g ly  
im portan t role in the  collection of data. This, in tu rn , c reates a clim ate 
th a t is ideal for computer linkage.
Results from computer linkage often point the  way forward to new 
areas of research :-
(1) The re su lts  in Table 7.02 suggest th a t  th e re  should  be m ore 
active following-up of the people who tested  HIV positive in the  
early  1980’s, and who have apparen tly  not yet reached  AIDS 
diagnosis, or died. A first approach m ight be to m ake enquiries 
as to w he ther, or not, any  of th e se  people a re  know n to be 
registered as AIDS cases in England or Wales.
(2) The results in Table 7.03 suggest th a t it m ight be worthwhile to 
contact the  health  boards th a t show low participation  ra te s  in  
th e  CD4 S tudy , in  o rd er to in v e s t ig a te  th e  e x te n t  of th e  
immunological monitoring received by pa tien ts in these health  
boards.
(3) T he  r e s u l t s  in  T ab le  7 .04 h a v e  im p lic a t io n s  fo r h e a l th  
education policies aimed a t reducing th e  sp read  of HIV. The 
r e s u l ts  in d ic a te  th a t  p re v e n ta t iv e  c a m p a ig n s  sh o u ld  be 
m aintained, or strengthened, to encourage behavioural changes 
among homosexual/bisexual men.
Follow ing th e  success of th e  linkage be tw een  th e  HIV R eg is te r  and  
SMR-1 data , p lans are  being made to link th e  HIV R egister w ith  o ther 
SMR data-sets, including SMR-2 (m aternity  discharge records), SMR-4 
(m en ta l h e a lth  in -p a tie n t adm ission /d ischarge records), and  SMR-6 
(cancer registration) [15].
114
Chapter 8
Evaluation of HIV Surveillance at SCIEH 
(1984-1994)
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8.1 Evaluation of HIV surveillance
In  th e  f irs t six chap ters  of th is  thesis, th e  p rin c ip a l HIV su rv e illan ce  
schem es co-ord inated  a t SCIEH, betw een 1984 and  1994, h av e  been  
e x a m in e d  in  d e p th . In  th is  f in a l c h a p te r ,  e a c h  of th e  p r in c ip a l  
su rv e illan c e  schem es is eva lua ted  for a t t r ib u te s  such  as sim plic ity , 
flexibility, acceptability, sensitivity, rep resen ta tiveness and tim eliness. 
The schem es are  also evaluated for the ir ab ility  to help to answ er key 
questions on the  spread  of HIV. Finally, th is  chap ter re tu rn s  to issues 
p re v io u s ly  r a is e d , in  th e  f i r s t  six  c h a p te r s ,  a b o u t th e  in d iv id u a l  
surveillance schemes.
Throughout th is  chapter, I have expressed my own view s on th e  
value of certa in  aspects of HIV surveillance in  Scotland. T hese views 
have been formed over the past five years, not in isolation, bu t after m any 
discussions w ith clinicians, epidemiologists and  sta tis tic ian s w orking in 
the field of HIV surveillance.
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8.2 Evaluation of attributes of HIV surveillance
In  M ay 1988, CDC pub lished  gu idelines for e v a lu a tin g  su rv e illan c e  
systems [47]. In th is report (see section 1.8.2) the  following a ttribu tes are 
listed as being im portant to a surveillance system :-
(1) Simplicity
(2) Flexibility
(3) Acceptability
(4) Sensitivity
(5) Representativeness
(6) Timeliness
8.2.1 Evaluation of attributes of the AIDS Register
The objective of the  cu rren t AIDS surveillance schem e is to provide an 
estim ate of the num ber of persons, in Scotland, who have AIDS, together 
with their epidemiological characteristics.
C linicians throughout Scotland, who recognise th a t a  p a tien t has 
a n  A ID S -d e fin in g  i l ln e s s , a re  e n c o u ra g e d  to  c o m p le te  a n  A ID S- 
re g is tra tio n  form  and  forw ard it to  SCIEH. T his schem e re lie s  on a 
p a tien t w ith  AIDS seeking medical help, th e  clinician recognising th a t  
th e  illness is an  AIDS-defining illness, and  the  clinician rep o rtin g  it  to 
SCIEH.
Since almost all people who develop an AIDS-defining illness seek 
m edical help, the  level of under-reporting of AIDS cases is though t to be 
low, having been estim ated at approximately ten  per cent [8]. Hence, the 
sensitivity of the system is very high.
From clinical da ta  collected by the CD4 Study, it is recognised th a t 
the AIDS-registration scheme appears to work well in  the  hospitals th a t 
tre a t  a large num ber of AIDS patien ts, since these  hosp ita ls  a re  more 
likely to be fam iliar with AIDS-defining illnesses and the  AIDS-reporting 
schem e. However, th is  m ay not be the  case in  h o sp ita ls  w here  AIDS 
p a tien ts  are  rare ly  seen, and consequently the  reporting  system  is less 
well known. Hence, there  m ay be a b ias in favour of th e  la rg e r  AIDS 
centres in Edinburgh, Glasgow, and Dundee. However, despite th is  bias, 
th e  A ID S-reporting scheme ra tes highly for being rep re sen ta tiv e  of all 
AIDS cases in Scotland.
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T he A ID S -reg is tra tio n  schem e u n d o u b tab ly  su ffe rs  from  th e  
complexity of the current AIDS definition, which consists of a long list of 
AIDS-defining illnesses [4,26,27]. In addition, the AIDS-registration form 
is tim e consum ing to com plete, lead ing  often to a considerab le  delay  
betw een a clinician diagnosing a case of AIDS and reporting th a t case to 
SC IE H . T here fo re , th e  A ID S -reg is tra tio n  schem e r a te s  poorly  for 
simplicity, acceptability and timeliness.
The A ID S -reg istra tion  schem e h as  proved th a t  i t  is ex trem ely  
flexible by coping with three changes in the AIDS-case definition between 
1985 and 1993 [25-27].
8.2.2 Evaluation of attributes of the HIV Register
The purpose of the HIV-registration scheme is to provide estim ates of the  
num ber of persons, in Scotland, who are infected w ith HIV, together w ith 
their epidemiological characteristics.
HIV surveillance re lies on the  HIV -infected person  agreeing  to 
have an  HIV te s t, and  also relies on th a t  te s t  re su lt be ing  rep o rted  to 
SCIEH. However, m any HIV-infected people will not suspect th a t  they  
are  infected, especially if they are asymptomatic, therefore they  will not 
seek an  HIV test, hence th is  scheme is likely to under-rep resen t people 
who are HIV infected and asymptomatic. Estim ates from the  GUM Study 
show  th a t  for every  two p ersons know n to be HIV in fec te d  th e re  is 
another HIV-infected person whose infection is not known [8]. Therefore, 
th is scheme rates poorly for both sensitivity and representativeness.
This surveillance scheme runs very smoothly, since there  are  few 
la b o ra to r ie s  in  S co tland  w here  HIV te s tin g  is c a rr ie d  ou t, and  it  is 
relatively easy for laboratory staff promptly to report their HIV-antibody- 
positive te s t resu lts  to SCIEH. This scheme ra te s  highly for simplicity, 
acceptability, flexibility and timeliness.
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8.2.3 Evaluation of attributes of the Denominator Study
The purpose of the Denominator Study is to provide information about all 
those seeking HIV testing in Scotland, regardless of their test result.
This scheme shares many of the a ttribu tes of the  H IV -registration 
scheme. Like the  HIV Register, it relies on people seeking an  HIV te s t 
an d  th e re fo re  sh a re s  th e  sam e problem s of re p re s e n ta tiv e n e s s  an d  
sensitivity.
W ith alm ost 15,000 HIV tests carried out in  Scotland every year, 
th is  su rveillance  schem e is much less sim ple to opera te  th a n  th e  HIV 
R egister, requ iring  su b s tan tia l resources, p a rticu la rly  in  s ta ffin g  and  
computing. It is also much less timeous, with a long tim e delay (up to 18 
m on ths) be tw een  HIV te s ts  being  c a rried  ou t and  th e  r e s u l ts  b e in g  
published.
8.2.4 Evaluation of attributes of UAT
UAT surveillance was introduced in 1990 to provide unbiased estim ates 
of HIV prevalence, in  selected population groups, over a period of tim e. 
There are  five such UAT schemes in Scotland, all of them  operating  in a 
sim ilar way.
Since partic ipa tion  ra te s  are extrem ely high, these  su rveillance  
schemes are all highly representative of the population groups targeted , 
w ith  in itia l doubts about the  acceptability of th e  schem es [145] hav ing  
been  show n to be unfounded . However, se v e ra l of th e  schem es a re  
ex trem ely  lim ited  in th e ir  geographical spread ; such as th e  H osp ita l 
S tudy which is lim ited to two Glasgow hospitals, th e  Fam ily  P lan n in g  
S tudy which is lim ited to one Glasgow clinic, and  th e  A n ten a ta l S tudy 
which is lim ited to Glasgow and Edinburgh.
These schem es are all relatively sim ple to operate, and  tim eous, 
w ith resu lts being available at SCIEH within a few m onths of the  person 
a ttend ing  the  participating  clinic. However, the  schem es ra te  poorly for 
flexibility, since the collection of more information, such as risk  factors or 
postcode of residence, may be seen as a th rea t to the  confidentiality of the 
participants.
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8.2.5 Evaluation of attributes of the CD4 Study
The objective of the  CD4 surveillance scheme is to m onitor the  clinical 
and immunological health  of those HIV-infected people, in Scotland, who 
are receiving CD4 monitoring.
Since there  are only five immunology laboratories participating  in 
th e  schem e, an d  th e ir  s ta f f  re p o rt a ll H IV -positive  im m uno log ica l 
requests prom ptly to SCIEH every month, th is  scheme ra te s  highly for 
sim p lic ity , se n s it iv ity  and tim e lin ess . H ow ever, since  m an y  of th e  
immunological m easurem ents m ust be perform ed w ith in  a few hours of 
the  p a tien t giving the  blood sample, these laboratories can only process 
b lood  sa m p le s  from  th e i r  own lo ca lity . T h e re fo re , a l th o u g h  th is  
surveillance scheme is representative of those requiring trea tm en t in the 
m ain cities, it does not represent those who live in the more rem ote p a rts  
of Scotland.
The quality of the data collected has been variable, w ith extrem ely 
good immunological information and extrem ely poor clinical d a ta  being 
re tu rn e d . A nalysis showed th a t approxim ately  one th ird  of all form s 
returned contained no clinical information. Hence, the scheme appears to 
be acceptable to the immunologists, but not acceptable to the  clinicians.
T h is  s tu d y  is ex trem ely  flexible; as im m uno log ica l ad v an ces  
continue and new m arkers of HIV progression are discovered, th is scheme 
will have the  flexibility to include any new immunological m easurem ents 
th a t are appropriate.
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8.3 Utilisation of HIV surveillance data
Surveillance has been defined as
"The ongo in g  s y s te m a t i c  co l lec t ion ,  a n a l y s i s  a n d  
interpretation of  health data essential to the p lanning,  
implementation and evaluation of public health practice, 
closely linked with the timely dissemination of  these data  
to those who need to know." [161].
Identification of the  information required by those in a position to use it, 
is fu n d am en ta l to good surveillance. In  th e  su rv e illan ce  of HIV, key 
areas where information is most useful include
(1) M onito ring  th e  h e te ro sex u a l sp re a d  of HIV  am ong  th e  
general population.
(2) Identification of the epidemiological characteristics of those 
infected recently.
(3) E stim a tio n  of the  cu rre n t and  fu tu re  p reva lence  of HIV 
infection.
8.3.1 Monitoring the heterosexual spread of HIV in the general population
From the beginning of the HIV epidemic, it has been apparen t th a t  most 
of the  reported  cases of HIV, in Scotland, have been confined to specific 
risk  categories, particularly IDUs and homosexual/bisexuals. Analysis of 
the HIV Register, to 30th June 1994, shows th a t of the 2,129 HIV positive 
reports, 50 per cent are attributed to injecting drug use, and a fu rther 29 
per cent to homosexual/bisexual risk [6].
T h e  h e te r o s e x u a l  s p re a d  of HIV, fro m  th e  ID U  a n d  
homosexual/bisexual risk  categories to the res t of the  general population, 
has stim ulated a great deal of interest [120-126]. Accordingly, a series of 
UAT schemes were established, between 1990 and 1993, to exam ine th is 
spread (see chapter 5).
In  1990, the  GUM Study was introduced to m onitor th e  sp read  of 
HIV am ong m en and  w om en p re se n tin g  w ith  a su sp e c te d  se x u a lly
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tran sm itted  disease a t GUM clinics. It was recognised th a t  if infection 
w ere to sp read  he terosexually  in to  th e  g en era l popu la tion , th e n  th is  
would firs t be apparen t among th is  group. This study  collects d a ta  on 
r isk  factors, therefore analysis can separa te  those whose risk  factor is 
so le ly  h e te ro s e x u a l  from  th o s e  w ho a re  e i t h e r  ID U  or 
homosexual/bisexual. It includes both males and females, covering GUM 
clinics in Glasgow, Edinburgh, Dundee, Aberdeen, Falk irk , S tirling  and 
Perth.
In addition to the GUM Study, other UAT studies were introduced 
to m easure the  spread of HIV in the general population. These included 
th e  A n te n a ta l Study, th e  G uthrie  Study, th e  H osp ita l S tudy  and  th e  
Fam ily P lanning Study. Of these studies, the  Hospital Study is the  only 
one in which the  spread of HIV among m ales is m easured. However, the  
study  design does not perm it HIV-risk factors to be collected, hence its  
da ta  is of lim ited value in assessing the heterosexual spread of HIV.
Sim ilarly, the  designs of both the  G uthrie  S tudy and  the  Fam ily  
P lann ing  Study do not perm it risk  factors to be collected. D espite th is  
drawback, the G uthrie Study is extremely useful because it covers every 
baby who has a G uthrie tes t in Scotland, providing valuable da ta  on the  
spread of HIV among childbearing women. Less useful are  the  H ospital 
Study, w hich is re s tr ic te d  to two Glasgow h o sp ita ls , an d  th e  F am ily  
P lanning Study which is restricted to one Glasgow clinic.
The A n te n a ta l S tudy  is th e  only one of th is  group of s tu d ie s  to 
collect risk  factors, thereby enabling m easurem ent of the  spread  of HIV 
a m o n g  w om en  w h o se  on ly  r i s k  fa c to r  fo r H IV  is  h e te r o s e x u a l .  
U nfortunately  th is  study is restric ted  to an ten a ta l clinics in  E dinburgh 
and Dundee.
8.3.2 Identification of new infection
T he  id e n t i f ic a t io n  of new  in fe c tio n  is a n  im p o r ta n t  p a r t  of H IV  
su rv e illan ce . If  in fection  is suspected  to be occu rring  in  id en tifia b le  
groups of people, education can be targeted a t those groups.
To d e te rm in e  w h e re  new  H IV  in fe c tio n  is  o c c u rr in g , is  a n  
e x trem e ly  d ifficu lt ta sk . The long and  v a r ia b le  in c u b a tio n  period , 
betw een infection w ith HIV and the  development of clinical sym ptoms, 
m eans th a t people who are infected with HIV may not know th a t they are 
infected. Even those who do know th a t they are infected, m ay not know
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when, or how, they became infected.
The HIV Register provides information on newly reported infection, 
b u t it canno t be used  to d iscrim inate  betw een new  and  old infection. 
C om parison w ith  the  Denom inator Study has provided inform ation  on 
p rev io u s  n e g a tiv e  te s ts  for abou t 4 pe r cen t of p e rso n s  on th e  H IV  
R egister, th u s  narrow ing  the  tim e of in fection  for th e se  p e rso n s to a 
specific interval.
The da ta  on the HIV Register may be fu rther enhanced by linkage 
w ith  the  CD4 Register. For some people on the  HIV Register, th e  CD4 
Study provides CD4 counts at the time of the ir HIV diagnosis. A lthough 
a high CD4 count does not prove th a t a person has been recently infected, 
it is generally an indication of recent infection.
In  th i s  w ay, th e s e  th r e e  s tu d ie s ,  th e  H IV  R e g is te r ,  th e  
D enom inator Study and the CD4 Study, together help to identify  recent 
infection.
8.3.3 Estimation of prevalence of HIV
E stim a te s  of th e  prevalence of HIV are  needed in  o rder to a ssess  th e  
dem and on resources. Some resources, such as provision of p a tien t care, 
need to be planned some years in advance, which necessitates furnishing 
inform ation not only on current num bers of HIV-infected people, b u t also 
on th e  num bers expected in the  years ahead. However, it  is extrem ely 
difficult to determine the prevalence of HIV.
The CD4 Study collects d a ta  on th e  im m unological and  clin ical 
s tag ing  of only those HIV-infected people who are receiving lym phocyte 
m onitoring a t the  participating immunology laboratories in  Edinburgh, 
Glasgow, Dundee and Aberdeen. Hence the CD4 Study plays a key role 
in assessing the num ber of people currently requiring resources in  these 
a re a s , b u t  needs to be su p p lem en ted  by in fo rm a tio n  from  th e  HIV 
Register about those thought to be living in other parts of Scotland.
E s t im a tio n  of th e  p re v a le n c e  of HIV, in  S c o tla n d , in v o lv e s  
combining the  num ber of persons known to be infected w ith  HIV (i.e. on 
the  HIV Register) w ith an estim ate of the  unknow n num ber of persons 
infected w ith  HIV (i.e. not on the HIV Register). This can be estim ated  
using the results of the GUM Study.
T he GUM S tudy  provides e s tim a te s  of th e  p ro p o rtio n  of HIV 
positive  people who a re  know n to be HIV positive , c la ss ified  by r isk
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category and  region. U sing da ta  from th is  study  it can be show n th a t  
approxim ately 66 per cent of all HIV positive people have had  a positive 
HIV te s t  and  are  know n a t SCIEH to be HIV positive, a lth o u g h  th is  
proportion varies between risk  categories and regions [8]. Therefore, in 
g e n e ra l, for every  two p e rso n s c u rre n tly  on th e  H IV R eg is te r, an d  
assum ed to be alive, there is another person w ith HIV infection who has 
not yet been reported.
Assessing future num bers of HIV-infected people, who will require 
substantial health  care owing to their HIV infection, is a complex exercise 
w h ich  h a s  b e en  c o n d u c ted  by v a r io u s  w o rk in g  g ro u p s  [8 ,1 6 -1 8 ]. 
M ethodology, to e s tim a te  fu tu re  n u m b e rs  of AID S cases , h a s  b een  
developed using  reports of AIDS cases, HIV infections, and  deaths, in 
addition to estim ates of HIV prevalence, and  ra te s  of progression from 
HIV infection to AIDS (see section 2.7). E stim ates of fu tu re  num bers of 
severe HIV infections have been based on previous, and  cu rren t, CD4 
counts.
Thus, for the  estim ation  of the  cu rren t and  fu tu re  prevalence of 
HIV infection, the  key surveillance schem es are  the  AIDS Register, the  
HIV Register, the CD4 Study and the GUM Study.
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8.4 Issues surrounding HIV surveillance in Scotland
If  su rveillance  schem es are to rem ain  effective, it  is im p o rta n t to re ­
exam ine them  regularly , and to look for possible im provem ents. T his 
helps to optim ise the  use of resources m ade availab le for surveillance. 
N um erous questions have been asked concerning the  perform ance and 
value of some of the HIV surveillance schemes. In particular, concern has 
been expressed as follows :-
(1) Is AIDS surveillance still relevant and useful?
(2) Should the Denominator Study be stream lined?
(3) Should the CD4 Study be modified?
(4) Are all the UAT schemes necessary?
8.4.1 Issues arising from AIDS surveillance
M any c lin icians a re  sceptical about th e  value  of th e  te rm  AIDS. The 
clinician, who may have been caring for the patien t from an early stage of 
HIV infection through to the later stages, often holds AIDS to be a ra th e r  
artificial milestone of little consequence. Indeed, the awareness th a t such 
a  m ilestone has been reached may create psychological problem s for the  
patien t [162].
The growth of immunological monitoring in Scotland (particularly  
CD4 monitoring) has played a large part in underm ining the  relevance of 
the  term  AIDS, since CD4 monitoring provides a m eans of m easuring  the 
d e te r io ra tio n  of th e  im m une sy s tem  th ro u g h o u t a ll s ta g e s  of H IV  
infection.
Is AIDS registration still relevant and useful? It is unquestionably 
tru e  th a t, in  the  early  1980’s, AIDS reg is tra tions w ere th e  only w ay of 
m easuring  the num ber of people affected by th is  newly discovered, and 
unexplained, imm une deficiency syndrome. However, fifteen years later, 
th is  is no longer tru e , w ith  the  te rm  ‘A ID S’ hav in g  becom e v ir tu a lly  
re d u n d a n t for m any  p ro fessionals w ork ing  in  H IV -re la ted  fie ld s  in  
Scotland. However, there  are many reasons why AIDS surveillance will 
continue for the foreseeable future :-
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(1) The AIDS Control Act (1987) m akes it a sta tu to ry  requirem ent 
to report the num ber of (and details concerning) AIDS cases in 
Scotland [163].
(2) Although immunological monitoring is w idespread in Scotland, 
th is is not the case in m any other countries. Therefore, for the  
p u rp o se s  of p ro d u cin g  fig u res  for c o m p ariso n  w ith  o th e r  
c o u n tr ie s ,  r e p o r t in g  of A ID S c a s e s  w ill  c o n tin u e  to  be  
important.
(3) W hile  th e  te rm  ‘A ID S’ m ay be an  a n a c h ro n ism  to  m an y  
professionals in Scotland, it is firmly established in the m ind of 
the public. The concern of the public, and the media, regarding 
the  num ber of people with AIDS, is unlikely to dim inish in the  
near future.
In  summary, the AIDS-registration scheme has m any inheren t problems, 
an d  is now p lay in g  a less im p o rtan t role in  th e  su rv e illan c e  of H IV  
infection in  Scotland th an  it previously did. However, it has become an  
estab lished  m eans of reporting, has in te rna tiona l im portance, and  will 
alm ost certainly rem ain an integral part of HIV surveillance in Scotland 
for the foreseeable future.
8.4.2 Issues arising from the Denominator Study
The long tim e delay between HIV tests being carried out and the  resu lts  
be ing  pub lished  needs addressed . T his is m ostly  a ttr ib u ta b le  to th e  
cumbersome task  of checking for persons who have been tes ted  on more 
th a n  one occasion w ith in  any one calendar year. T his ta s k  cannot be 
completed un til all the  tes ts  for th a t calendar year have been reported. 
As a consequence, results from the Denominator Study, for any one year, 
are not usually available until the middle of the  following year. The time- 
consuming nature  of duplicate-checking raises doubts about the  efficiency 
of th is task.
If full responsib ility  for the  iden tification  of dup licate  te s ts  w as 
tran sfe rred  to the  clerical officers employed by SCIEH a t th e  principal 
laboratories, th is would enable duplicates to be identified more accurately 
w ith in  each laboratory, at the expense of being unable to identify  in te r­
laboratory duplicates. This would only leave SCIEH to identify duplicate 
te s t s  w ith in  each  of th e  sm a lle r  la b o ra to r ie s . In  m y o p in io n , th e
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D enom inato r S tudy  should be s tream lin ed  by d e leg a tin g  th e  ta s k  of 
identifying duplicate tests to clerical officers at these laboratories.
A nother issue arising  from the  D enom inator S tudy involves the  
quality  of the  information collected. Many clinicians do not fill-in all the  
sections of the HIV test-request form, hence m uch of the  d a ta  collected is 
incomplete. The clinicians need to be questioned about the ir reasons for 
these  omissions: it m ay be necessary to modify or sim plify th e  req u est 
form.
8.4.3 Issues arising from the CD4 Study
The CD4 Study is currently  at the  end of its  pilot stage. Several issues 
have arisen  concerning the operation of the  study and the  quality  of the  
da ta  collected.
The quality of the clinical data  is poor. A new and sim pler request 
form  h a s  been  d ra fted , and will be u sed  a fte r  c o n su lta tio n  w ith  th e  
clinicians and immunologists.
Problem s were also identified w ith da ta -en try  a t the  imm unology 
la b o ra to rie s , lead in g  to the  in s ta lla tio n  of co m p u ters  a n d  s ta n d a rd  
DATAEASE software at the HIV immunology laboratories in  Edinburgh, 
Glasgow and Dundee.
Concern has also been expressed about the  use of CD4 counts as a 
m easure of immune deficiency. The CD4 count is simply a m easure of the 
quantity  of cells, disregarding quality. The fact th a t difficulties may arise 
from the  use of CD4 counts to m easure progression, was dem onstrated in 
th e  Concorde Study in which the  aim was to determ ine w he ther or not 
symptom-free HIV positive people would benefit from sta rtin g  trea tm en t 
w ith  zidovudine before they developed clinical d isease. The Concorde 
Study showed statistically  significant differences in  CD4 counts betw een 
the groups, but there were no corresponding differences in either disease- 
p rog ression  or su rv iva l [164]. However, as im m unological advances 
continue, and as new m arkers of HIV progression are  discovered, such 
aspects can easily be incorporated into th is flexible surveillance scheme.
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8.4.4 Issues arising from UAT
At the end of the pilot stage, each study was assessed, leading to changes 
being m ade in the  populations being studied in both the  H ospital Study 
and  th e  GUM Study. A fter i ts  p ilo t p h ase , th e  H o sp ita l S tu d y  w as 
re s tr ic te d  to m en, because sufficient in fo rm ation  on HIV p reva lence  
am ong wom en w as available from o ther UAT stud ies. A fter th e  p ilo t 
phase of the GUM Study, it was expanded (from Glasgow and Edinburgh) 
to encom pass GUM clinics in A berdeen, D undee, F a lk irk , P e r th  and  
Stirling.
Each of the UAT studies makes its own unique contribution to the  
understanding of HIV prevalence in Scotland, its value being reflected in 
the value of the data  collected
(1) The GUM Study m easures HIV prevalence among m en and women 
a tte n d in g  GUM clin ics th ro u g h o u t a w ide a re a  of S co tland . I t  
collects in fo rm ation  on HIV risk  as well as d a ta  on th e  p e rso n ’s 
cu rren t STDs. Hence, the data  it provides are extrem ely valuable. 
T a b le  8 .01 show s th a t  th e  p re v a le n c e  of H IV  a m o n g  p eo p le  
p resen ting  w ith a new risk  of a sexually tran sm itte d  disease, has 
rem ained relatively constant over the study period, a t approxim ately 
0.5 per cent in Glasgow and 1 per cent in  Edinburgh.
(2) The Hospital Study m easures HIV prevalence among m en attending 
tw o G lasgow  h o s p i ta ls .  T ab le  8 .01 sh o w s a r e la t iv e ly  h ig h  
prevalence of HIV among th is group a t approxim ately 0.8 per cent. 
Unfortunately, clinicians deemed it in trusive  to seek risk  category 
in fo rm a tio n  abou t th ese  m en, so th e  d a ta  co llected  a re  h a rd  to 
in te rp ret, and contribute little  to the  overall understand ing  of HIV 
prevalence in Scotland.
(3) The G uthrie Study m easures HIV prevalence among all women, in 
Scotland, whose baby is given a Guthrie test. Its m ain advantage is 
th a t  it  te s ts  th e  m others of over 99 per cen t of all b ab ies born  in  
Scotland every year [155]. Thus, th is study provides very valuable 
d a ta  on HIV prevalence. Table 8.01 show s th a t  HIV p revalence  
am ong these  women has rem ained re la tiv e ly  stab le , a t less th a n  
0.03 per cent, in all areas of Scotland except Edinburgh and Dundee,
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w here prevalence has fluctuated betw een 0.1 per cent and  0.3 per 
cent.
(4) T he F am ily  P lan n in g  S tudy m easu red  HIV p rev a len ce  am ong 
women attending a family-planning practice in Glasgow. Since th is  
study was restric ted  to one centre, and did not collect risk  factors, 
the  d a ta  gathered contributed little  to the  overall understand ing  of 
HIV prevalence in Scotland. Accordingly, th is study was term inated  
in 1995.
(5) The A n ten a ta l Study, s ta rted  in  Ju ly  1994, collects d a ta  on HIV 
prevalence among women attending an tenata l clinics in  E dinburgh 
an d  D undee. I t  collects r isk  ca teg o ry  in fo rm a tio n , a s  w ell as 
in fo rm a tio n  on th e  type  of c lin ic  a t te n d e d , a n d  th e  m o th e r ’s 
in tention to continue with her pregnancy. Hence, th is study  will be 
ex trem ely  valuab le  in m easuring  th e  p reva lence  of H IV  am ong 
women considered to be at low risk of acquiring HIV.
W hile some of the  UAT surveillance schem es a re  undoubted ly  of m ore 
v a lu e  th a n  o th e rs , th ey  all shed  lig h t on a d if fe re n t a sp e c t of H IV  
infection in Scotland, with none having a monopoly on the  tru th . Indeed, 
th e  inform al links betw een m any of the stud ies m akes th e  value of th e  
su rv e illan ce  program m e, as a whole, far g re a te r  th a n  th e  sum  of i ts  
component parts.
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Epilogue
The challenges posed by HIV to the scientific world have been immense. 
How ever, s u b s ta n tia l  p rogress h a s  been  m ade, and  m uch  h a s  been  
discovered about the  virus, its  s tru c tu re , and  its  effect on th e  im m une 
system. Likewise, considerable progress has been made in the  trea tm en t 
of the illnesses th a t are associated with the virus.
I t  is also tru e  th a t  HIV h as posed a g re a t cha llenge  to society, 
w here the  response has been handicapped by prejudice and fear, fuelled 
by m isunderstanding and ignorance [46]. While much has been achieved, 
th e re  is no room  for com placency. W ith  an  e s tim a te d  6,000 people  
becoming infected with HIV every day, equivalent to one every 14 seconds 
[165], much rem ains to be done.
As th e  re c e n t b ro ch u re  [166] p ro m o tin g  th e  XI In te rn a tio n a l  
Conference on AIDS in July 1996, in Vancouver, states
"The answers to our many questions about preventing,  
managing, and  curing HIV I AIDS lie in our ab i l i ty  to 
unite, in our willingness to accept difference, and in the 
unwavering commitment of  people  and  nations to one 
another."
I t is largely as a resu lt of the willingness of m any professionals, in  HIV- 
re la te d  d isc ip lin e s , to w ork to g e th e r  for th e  b e n e f it  of a ll, t h a t  th e  
surveillance schemes described in th is  thesis have been developed. I t is 
only w ith th e ir continuing support th a t  these  surveillance schem es will 
progress, leading to a better understanding of the spread of HIV infection 
in Scotland.
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Tables
AIDS Cases Reported to SCI EH bv 31/12/87
A I D S C A S E S
Number Percentage
TOTAL CASES 39 100.0%
GENDER
Male 34 87.2%
Female 5 12.8%
RISK CATEGORY
Homo/Bisex 26 66.7%
IDU 4 10.3%
Heterosex 1 2.6%
Haem/Blood 7 17.9%
Mother-to-Child 1 2.6%
YEAR OF AIDS DIAGNOSIS
1983 1 2.6%
1984 4 10.3%
1985 4 10.3%
1986 9 23.1%
1987 21 53.8%
AGE GROUP AT AIDS DIAGNOSIS
Male 0 - 9 (Years) 0 0.0%
10-19 2 5.1%
20-29 1 2.6%
30-39 17 43.6%
40-49 9 23.1%
50+ 5 12.8%
Male Total 34 87.2%
Female 0 - 9 (Years) 1 2.6%
10-19 0 0.0%
20-29 3 7.7%
30-39 1 2.6%
40 - 49 0 0.0%
50+ 0 0.0%
Female Total 5 12.8%
PRESENTATION AT AIDS DIAGNOSIS
OOI 15 38.5%
PCP 19 48.7%
KS 4 10.3%
KS+PCP 1 2.6%
Table 2.01
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AIDS Cases Reported to SCI EH bv 30/4/94
A I D S C A S E S
Number Percentage
TOTAL CASES 512 100.0%
RISK CATEGORY fbv Gendert
Male Homo/Bisex 224 43.8%
IDU 133 26.0%
Heterosex 35 6.8%
Haem/Blood 27 5.3%
Mother-to-Child 3 0.6%
Unknown 3 0.6%
Male Total 425 83.0%
Female Homo/Bisex 0 0.0%
IDU 52 10.2%
Heterosex 21 4.1%
Haem/Blood 5 1.0%
Mother-to-Child 8 1.6%
Unknown 1 0.2%
Female Total 87 17.0%
YEAR OF AIDS DIAGNOSIS
Pre 1990 162 31.6%
1990 73 14.3%
1991 99 0.0%
1992 73 14.3%
1993 91 17.8%
1994 14 0.0%
AGE GROUP AT AIDS DIAGNOSIS
Male 0 - 9 (Years) 4 0.8%
10-19 7 1.4%
20-29 124 24.2%
30-39 164 32.0%
40-49 91 17.8%
50+ 35 6.8%
Male Total 425 83.0%
Female 0 - 9 (Years) 8 1.6%
10-19 1 0.2%
20-29 34 6.6%
30-39 36 7.0%
40-49 6 1.2%
50+ 2 0.4%
Female Total 87 17.0%
PRESENTATION AT AIDS DIAGNOSIS
OOI 149 29.1%
PCP 256 50.0%
KS 29 5.7%
KS+PCP 4 0.8%
WASTING 17 3.3%
OTHER 57 11.1%
Table 2.05
136
Results of Univariate Survival Analysis 
from AIDS Diagnosis to Death
N DEATHS
MEDIAN
SURVIVAL AT
SURVIVAL 
X YEARS (%) P VALUE
* (Months) X=1 X=2 X=3
ALL CASES 394 304 17.04 59.64 36.68 21.59
GENDER
Male 341 267 16.18 57.86 35.3 21.02
P=0.08
Female 53 37 21.96 71.15 45.67 25.04
RISKCATEG9RY
Homo/Bisex 189 157 17.46 61.8 35.84 18.74
P=0.06
IDU 136 95 18.83 60.74 41.86 27.54
Heterosex 41 25 16.63 60 34.05 -
Haem/Blood 26 25 9.75 38.46 - -
Unknown 2 2 - - - -
PERIOD OF AIDS DIAGNOSIS 
Pre 1988 51 48 11.33 47.06 27.03 16.64
P=0.02
1988-1989 104 89 22.45 73.4 46.52 21.92
1990-1992 239 167 15.53 56.45 34.54 23.74
AGE GROUP AT AIDS DIAGNOSIS
15-24  (Years) 36 30 20.96 69.44 43.4 23.37
P<0.001
2 5 -2 9 98 59 25.58 72.77 51.65 39.13
3 0 -3 4 97 79 13.96 53.37 32.71 17.84
3 5 -4 4 103 79 18.18 61.58 39.09 18.24
45+ 60 57 9.92 39.5 12.02 -
PRESENTATION AT AIDS DIAGNOSIS 
OOI 106 76 14.99 53.62 39.1 21.9
P<0.001
Other 16 15 8 25 - -
HIV Enceph. 20 18 8.57 30 - -
KS 30 24 16.14 62.71 25.82 -
POP 211 162 20.34 68.97 41.69 24.04
HIV Wasting 11 9 9 33.33 - -
HEALTH BOARD OF FIRST REPORT
Greater Glasgow 121 93 16.04 57.63 34.95 19.97
P=0.01
Lothian 183 139 20.43 65.84 43.3 25.14
Tayside 49 39 10.5 42.86 19.69 -
Other 41 33 15.73 58.02 32.24 20.51
* DEATHS refer to uncensored deaths only.
Table 2.06
137
Results of Multivariate Survival Analysis 
from AIDS Diagnosis to Death
C O EFFIC IE N T R E LA TIV E R ISK  
(R.R.)
S T A N D A R D  ER R O R  
of R.R.
95%  C .l. fo r R.R.
G E N D E R
Male 0.000 1.000 - -
Female -0.214 0.807 0.198 (0.548, 1.190)
R ISK C A T E G O R Y
Heterosex 0.000 1.000 - -
Homo/Bisex -0.138 0.871 0.220 ( 0.566 , 1.342 )
IDU -0.108 0.898 0.224 (0.579 , 1.392)
Haem/Blood 0.333 1.395 0.291 ( 0.789 , 2.466 )
Unknown 0.472 1.603 0.748 ( 0.370 , 6.937 )
PE R IO D  O F A ID S  D IA G N O S IS
Pre 1988 0.000 1.000 - -
1988- 1989 -0.168 0.846 0.192 (0.581 , 1.231 )
1990- 1992 -0.145 0.865 0.186 (0.600, 1.247)
A G E G R O U P  A T  A ID S  D IA G N O SIS
15-24 (Years) 0.000 1.000 - -
25 -29 -0.149 0.862 0.243 (0.535 , 1.388)
30 -34 0.370 1.448 0.237 (0.910, 2.305)
35 -44 0,233 1.262 0.242 ( 0.785 , 2.029 )
45+ 0.852 2.344 0.260 (1.410,3 .898)
P R E S E N T A TIO N  A T  A ID S D IA G N O SIS
PCP absent 0.000 1.000 - -
PCP present 1.163 3.201 0.628 (0.935 , 10.962)
KS absent 0.000 1.000 - -
KS present 1.113 3.044 0.598 ( 0.944 , 9.820 )
OOI absent 0.000 1.000 - -
OOI present 1.248 3.483 0.645 (0.984, 12.326)
HIV Enceph. absent 0.000 1.000 - .
HIV Enceph. present 1.665 5.283 0.677 (1.402, 19.914)
HIV Wasting absent 0.000 1.000 _ .
HIV Wasting present 1.905 6.719 0.729 (1.610 , 28.038)
OTHER absent 0.000 1.000 - -
OTHER present 2.190 8.937 0.696 ( 2.286 , 34.945)
HE A LTH  B O A R D  O F F IR S T R E PO R T
Lothian 0.000 1.000 - -
Greater Glasgow 0.118 1.125 0.147 (0.843 , 1.502)
Tayside 0.578 1.782
.
0.200 ( 1.204 . 2.637)
Other 0.109 1.115 0.205 ( 0.746 , 1.668 )
Significant at 5% level.
Table 2.07
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HIV+ Tests Reported to SCIEH
from 1/1/89 to 30/6/94
H I V  + T E S T S
Number Percentage
SOURCE OF HIV TEST REQUEST
Hospital 261 37.1%
Gum Clinic 142 20.2%
Counselling Clinic 74 10.5%
GP 112 15.9%
Other 115 16.3%
TOTAL 704 100.0%
REASON FOR HIV TEST REQUEST
Doctor Concerned 244 34.7%
Patient Concerned 297 42.2%
Other 67 9.5%
Unknown 96 13.6%
TOTAL 704 100.0%
Table 3.01
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Average Number of HIV Tests per Year 
by HIV Testing Laboratories
LABORATORY LOCATION HIV TESTS
Principal Laboratories
Average No. 
per Year
Aberdeen University Aberdeen 1,738
Ninewells Hospital Dundee 1,668
City Hospital Edinburgh 2,661
East of Scotland HIV Ref. Lab. Edinburgh 2,227
Ruchill Hospital Glasgow 3,880
Western Infirmary Glasgow 713
Small Laboratories
Dumfries & Galloway Royal Infirmary Dumfries 183
Victoria Infirmary Kirkaldy 261
Inverclyde Royal Infirmary Greenock 132
Crosshouse Hospital Kilmarnock 376
Law Hospital Carluke 90
Monklands District General Hospital Airdrie 266
Stirling Royal Infirmary Stirling 561
Royal Alexandra Hospital Paisley 131
Raigmore Hospital Inverness 421
Table 4.01
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Persons Tested and Rate of Testing HIV+ 
by Gender, Age Group, and Year of HIV Test
YEAR OF HIV TEST
1989 1990 1991 1992
NUMBER OF PERSONS TESTED 
Gender
Male 6,228 6,678 8,076 8,100
Female 3,423 4,041 5,178 4,949
Total 9,651 10,719 13,254 13,049
Age Group
15-19 (Years) 748 750 1,094 1,116
2 0 -2 9 4,013 4,502 6,113 6,076
3 0 -3 9 2,409 2,862 3,429 3,332
40 + 2,481 2,605 2,618 2,525
Total 9,651 10,719 13,254 13,049
PERSONS TESTING HIV+ 
(PER 1000 TESTED)
Overall 13.0 11.5 10.8 9.8
Gender
Male 16.1 14.2 13.7 10.8
Female 7.3 7.2 6.4 8.1
Age Group
1 5 -1 9  (Years) 4.0 4.0 1.8 1.8
2 0 -2 9 18.4 13.8 11.6 9.9
3 0 -3 9 12.9 15.4 12.0 13.5
40 + 6.9 5.4 11.5 7.9
Table 4.02
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Persons Testing HIV+ and Test Rates 
by Gender, Age Group, and Health Board
TOTAL
TESTS
POPULATION
(T h o u s a n d s )
TEST*
RATE
NUMBER
HIV+
HIV+ ** 
RATE
MALE
Age Group
15-19 (Years) 1,887 172.8 2.7 2 1.1
20-24 6,351 207.1 7.7 60 9.4
25-29 6,286 208.5 7.5 118 18.8
30-34 4,586 194.0 5.9 82 17.9
35-39 3,225 171.6 4.7 57 17.7
40-44 2,118 178.9 3.0 33 15.6
45+ 4,629 837.7 1.4 39 8.4
FEMALE
Age Group
15-19 (Years) 1,821 166.0 2.7 8 4.4
20-24 4,188 203.3 5.2 44 10.5
25-29 3,879 207.5 4.7 45 11.6
30-34 2,586 193.9 3.3 12 4.6
35-39 1,635 171.2 2.4 10 6.1
40-44 888 179.4 1.2 1 1.1
45+ 2,594 1048.2 0.6 8 3.1
HEALTH BOARD OF RESIDENCE
Greater Glasgow 11,114 751.3 3.7 93 8.4
Lothian 13,669 619.5 5.5 239 17.5
Grampian 4,887 416.4 2.9 23 4.7
Tayside 4,409 320.9 3.4 84 19.1
Other 12,157 2032.5 1.5 75 6.2
Test rate per 1000 population (per year).
Number of persons testing HIV positive per 1000 tested.
Table 4.03
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Results of Logistic Regression Analysis
TO TA L
TE STS
N U M B ER
HIV+
HIV+ * 
RATE
O DDS RA TIO
( O R )
( U n a d j u s t e d )
O D D S  RA TIO
(OR)
( A d j u s t e d )
95%  C.l. fo r  
O .R . (A d ju sted )
A L L  C A SE S 46,673 519 11.1 " - -
R IS K  C A T E G O R Y
Heterosex: Low Risk 21,015 80 3.8 1 .0 0 1 .0 0 -
Heterosex: High Risk 4,070 61 15.0 3.98 3.13 (2.22 , 4.41)
Injecting Drug User 5,570 161 28.9 7.78 3.94 (2.92 , 5.32)
Homo/Bi sex 3,681 158 42.9 12.16 7.48 (5.56, 10.05
Other 1,966 7 3.6 0.93 0.59 (0.27 , 1.29)
Unknown 10,371 52 5.0 1.28 1.40 (0.70, 1.53)
H E A LT H  B O A R D  O F J E S T  R E Q U E S T
Lothian 14,269 241 16.9 1.00 1.00 -
Greater Glasgow n 't i 11 7.9 0 4 1 0 40 (0.32 . 0.51)
Tayside 4,677 90 19.2 1.14 1.21 (0.92 , 1.57)
Grampian 5,081 23 4.5 0.27 0.28 (0.18,0.44)
Other 8,436 54 6.4 0.37 0.41 (0.30 , 0.56)
Unknown 201 0 0.0 - - -
R E A S O N  FO R  T E S T
Patient Concerned 26,643 246 9.2 1.00 1.00 -
Doctor Concerned 4,717 227 48.1 5.43 3.11 (2.42 , 4.00)
Screening 10,633 3 0.3 0.03 0.06 (0.02 ,0.19)
Confirmatory Test 185 17 91.9 10.86 4.99 (2.81 , 8.89)
Other 3,995 20 5.0 0.51 0.69 (0.52 , 1.46)
Unknown r 12.0 4 (3.17 , 3.77)
SOURCE OF. REQUEST
GP 15,606 99 6.3 1.00 1.00 -
Hospital 10,221 204 20.0 3.19 1.86 (1.41 , 2.44)
GUM Clinic 10,376 117 11.3 1.79 1.85 (1.36,2.50)
Counselling Clinic 4,246 59 13.9 2.21 2.54 (1.79,3.67)
Other 6,013 40 6.7 1.02 1.65 (1.11 , 2.45)
Unknown 211 0 0.0 - - -
G E N D E R
Male 29,082 391 13.4 1.00 1.00 -
Female 17,591 128 7.3 0.53 0.99 (0.78 , 1.24)
A G E  G R O U P
15-19 (Years) 3,708 10 2.7 1.00 1 .0 0 -
20-29 20,704 267 12.9 4.82 4.23 (2.24 , 8.00)
30-39 12,032 161 13.4 5.02 5.22 (2.74 , 9.97)
40-49 4,911 47 9.6 3.58 4.02 (2.01 , 8.06)
50+ 5,318 34 6.4 2.40 3.61 (1.74, 7.48)
C L IN IC A L  S Y M P TO M S
Absent 28,532 197 6.9 1.00 1.00 -
Present 3,585 183 51.0 7.74 3.83 (3.02 ,4.86)
Unknown 14,556 139 9.5 1.39 1.58 (1.21 , 2.05)
Y E A R  O F TE S T
1989 9,651 125 13.0 1.00 1.00 -
1990 10,719 123 11.5 0.89 0.96 (0.74 , 1.25)
1991 13,254 144 10.9 0.83 1.01 (0.79 , 1.30)
1992 13,049 127 9.7 0.75 0.89 (0.69 ,1.16)
Significant at 5% level.
* Number of persons testing HIV positive per 1000 tested.
Table 4.04
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Estimated Probability of Testing HIV+
PARAMETER
ESTIMATE
EXAMPLE 1 EXAMPLE 2 EXAMPLE 3
CONSTANT -7.263 -7.263 -7.263 -7.263
RISK CATEGORY
Heterosex: Low Risk 0.000 - - -
Heterosex: High Risk 1.141 - - -
Injecting Drug User 1.372 - - -
Homo/Bisex 2.012 2.012 2.012 2.012
Other -0.531 - - -
Unknown 0.338 - - -
HEALTH BOARD OF TEST REQUEST
Lothian 0.000 - - -
Greater Glasgow -0.908 -0.908 -0.908 -0.908
Tayside 0.187 - - -
Grampian -1.261 - - -
Other -0.892 - - -
REASON FQR JE?T
Patient Concerned 0.000 - - 0.000
Doctor Concerned 1.135 1.135 1.135 -
Screening -2.828 - - -
Confirmatory Test 1.608 - - -
Other -0.142 - - -
Unknown 1.241 - - -
SOURCE OF REQUEST
GP 0.000 - - -
Hospital 0.018 - - -
GUM Clinic 0.013 0.613 0.613 0.613
Counselling Clinic 0.941 - - -
Other 0.500 - - -
GENDER
Male 0.000 0.000 0.000 0.000
Female -0.013 - - -
AGE GROUP
15-19 (Years) 0.000 - - -
20-29 1.443 - - -
30-39 1.653 1.653 1.653 1.653
40-49 1.392 - - -
50+ 1.283 - - -
CLINICAL SYMPTOMS
Absent 0.000 - 0.000 0.000
Present 1.342 1.342 - -
Unknown 0.456 - - -
YEAR OF TE$T
1989 0.000 - - -
1990 -0.036 -0.036 -0.036 -0.036
1991 0.012 - - -
1992 -0.115 - - -
a -1.452 -2.795 -3.930
PROBABILITY (HIV+) * 0 . 1 9 0 . 0 6 0 . 0 2
* Probability (HIV+) = exp(a)/[1+exp(a)]
Table 4.05
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Persons Testing HIV+ and Test Rate
by Date of Test and Test Centre
TOTAL
TESTS
NUMBER
HIV+
HIV+ * 
RATE
EDINBURGH 
CALENDAR QUARTER :
Oct - Dec 1990 957 10 10.4
Jan - Mar 1991 1,199 9 7.5
Apr - Jun 1991 1,149 18 15.7
Jul - Sep 1991 1,153 11 9.5
Oct - Dec 1991 1,207 10 8.3
Jan - Mar 1992 1,172 15 12.8
Apr - Jun 1992 1,073 12 11.2
Jul - Sep 1992 1,038 8 7.7
Oct - Dec 1992 1,022 11 10.8
Jan - Mar 1993 1,082 5 4.6
Apr - Jun 1993 976 5 5.1
Jul - Sep 1993 953 10 10.5
Oct - Dec 1993 990 9 9.1
Jan - Mar 1994 1,107 6 5.4
Apr - Jun 1994 1,025 7 6.8
EDINBURGH TOTAL 16,103 146 9.1
GLASGOW
CALENDAR QUARTER :
Oct - Dec 1990 1,072 6 5.6
Jan - Mar 1991 1,500 13 8.7
Apr - Jun 1991 1,395 7 5.0
Ju l-Sep 1991 1,417 5 3.5
Oct - Dec 1991 1,197 5 4.2
Jan - Mar 1992 1,311 6 4.6
Apr - Jun 1992 1,213 6 4.9
Jul - Sep 1992 1,292 4 3.1
Oct - Dec 1992 1,174 10 8.5
Jan - Mar 1993 1,257 8 6.4
Apr - Jun 1993 1,054 4 3.8
Jul - Sep 1993 1,343 6 4.5
Oct - Dec 1993 1,010 6 5.9
Jan - Mar 1994 1,045 3 2.9
Apr - Jun 1994 1,009 7 6.9
GLASGOW TOTAL 18,289 96 5.2
Number of persons testing HIV positive per 1000 tested.
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Persons Testing HIV+ and Test Rate
by Date of Test and Hospital
TOTAL
TESTS
NUMBER
HIV+
HIV+ * 
RATE
GLASGOW ROYAL INFIRMARY
CALENDAR QUARTER :
Oct - Dec 1991 1,050 17 16.2
Jan - Mar 1992 1,767 25 14.1
Apr - Jun 1992 1,478 22 14.9
Jul - Sep 1992 1,448 19 13.1
Oct - Dec 1992 1,611 21 13.0
Jan - Mar 1993 1,723 17 9.9
Apr - Jun 1993 1,625 20 12.3
Jul - Sep 1993 1,357 15 11.1
Oct - Dec 1993 1,625 11 6.8
Jan - Mar 1994 1,745 19 10.9
Apr - Jun 1994 1,701 15 8.8
GRI TOTAL 17,130 201 11.7
STOBHILL GENERAL HOSPITAL
CALENDAR QUARTER :
Oct - Dec 1991 772 1 1.3
Jan - Mar 1992 1,185 3 2.5
Apr - Jun 1992 1,171 2 1.7
Jul - Sep 1992 1,093 0 0.0
Oct - Dec 1992 907 1 1.1
Jan - Mar 1993 844 0 0.0
Apr - Jun 1993 741 1 1.3
Jul - Sep 1993 693 0 0.0
Oct - Dec 1993 805 1 1.2
Jan - Mar 1994 899 1 1.1
Apr - Jun 1994 832 0 0.0
SGH TOTAL 9,942 10 1.0
Number of persons testing HIV positive per 1000 tested.
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Persons Testing HIV+ and Test Rate
by Date of Test
CALENDAR
QUARTER
TOTAL
TESTS
NUMBER
HIV+
HIV+ * 
RATE
Jan - Mar 1990 15,673 6 0.38
Apr - Jun 1990 16,486 2 0.12
Jul - Sep 1990 17,242 6 0.35
Oct - Dec 1990 16,372 5 0.31
Jan - Mar 1991 16,419 4 0.24
Apr - Jun 1991 16,858 5 0.30
Ju l-Sep 1991 17,531 6 0.34
Oct - Dec 1991 16,251 4 0.25
Jan - Mar 1992 16,310 9 0.55
Apr - Jun 1992 16,499 6 0.36
Jul - Sep 1992 17,062 3 0.18
Oct - Dec 1992 15,816 3 0.19
Jan - Mar 1993 15,709 5 0.32
Apr - Jun 1993 15,876 3 0.19
Jul - Sep 1993 16,975 7 0.41
Oct - Dec 1993 15,429 3 0.19
TOTAL 262,508 77 0.29
*  Number of HIV positive tests per 1000 tests.
Table 5.05
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HIV+ Tests and Test Rate
by Year of Test and Location
YEAR OF TEST
TOTAL
1990 1991 1992 1993
GLASGOW
Total Tests 
Total HIV+ Tests 
HIV+ Rate *
16,308
0
0.00
16,781
5
0.30
16,237
1
0.06
15,887
2
0.13
65,213
8
0.12
EDINBURGH
Total Tests 
Total HIV+ Tests 
HIV+ Rate *
5,276
13
2.46
5,471
9
1.65
5,237
6
1.15
5,093
8
1.57
21,077
36
1.71
DUNDEE
Total Tests 
Total HIV+ Tests 
HIV+ Rate *
2,130
3
1.41
2,210
0
0.00
2,118
6
2.83
2,117
2
0.94
8,575
11
1.28
OTHER
Total Tests 
Total HIV+ Tests 
HIV+ Rate *
42,059
3
0.07
42,597
5
0.12
42,095
8
0.19
40,892
6
0.15
167,643
22
0.13
* Number of HIV positive tests per 1000 tests.
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Number of Tests and Persons Testing HIV4 
by Date of Test
CALENDAR
QUARTER
TOTAL
TESTS
NUMBER
HIV+
Jan - Mar 1992 846 0
Apr - Jun 1992 989 1
Jul - Sep 1992 1,051 0
Oct - Dec 1992 942 0
Jan - Mar 1993 1,111 0
Apr - Jun 1993 861 1
Jul - Sep 1993 1,051 0
Oct - Dec 1993 989 0
Jan - Mar 1994 1,014 0
Apr - Jun 1994 1,075 0
TOTAL 9,929 2
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Results of Loa-Linear Modelling Analysis
95 % CONFIDENCE INTERVAL
MAIN EFFECTS
0.73 , 1.04
Glasgow -0.26 , 0.09
Dundee f l H H  -1.04 -0.55 i H H
Homosexual/Bisexual
Heterosexual
-0.68 , -0.20 
0.62 , 0.93
*U.O£ , “U. I o
Moderate HIV Infection 
Severe HIV Infection
mmk o .15 , 0.29 mum
-0.29 , -0.01
INTERACTIONS
Edinburgh X Homo/Bisex 
Edinburgh X IDU 
Edinburgh X Heterosex
-0.12 , 0.39 
-0.11 , 0.24 
-0.41 , 0.01
Glasgow X Homo/bisex 
Glasgow X IDU 
Glasgow X Heterosex 
Dundee X Homo/bisex 
Dundee X IDU
0.74 , 1.28 
-0.81 , -0.38 
-0.67 , -0.15 
-1.58 , -0.70 
0.26 , 0.80
Dundee X Heterosex 0.31 , 0.91
Edinburgh X Moderate HIV 
Edinburgh X Severe HIV 
Glasgow X Moderate HIV 
Glasgow X Severe HIV 
Dundee X Moderate HIV 
Dundee X Severe HIV
-0.24 , 0.07 
-0.07 , 0.24 
-0.01 , 0.34 
-0.34 , 0.01 
-0.16 , 0.32 
-0.32 , 0.16
IDU X Severe HIV
■ ■ H - 59 >n 11 n rqU. 1 I , U.09
0 02 0 34 
-0.34 , -0.02
H eterosex X Moderate HIV 
Heterosex X Severe HIV
-0.01 , 0.35 
-0.35 , 0.01
lilBMMMBMMM Significant at 5% level.
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HIV+ Adults. Alive and Under Monitoring fat 31/12/94) 
by Health Board, Date, and Value of most recent CD4 Count
HEALTH BOARD 
OF REQUEST
TIME PERIOD
CD4 COUNT
TOTAL
0-199 200 - 500 >500
LOTHIAN Jan - Jun 1992 7 15 7 29
Jul - Dec 1992 6 6 2 14
Jan - Jun 1993 5 16 3 24
Jul - Dec 1993 14 15 6 35
Jan - Jun 1994 31 31 20 82
Jul - Dec 1994 94 113 64 271
Jan - Jun 1995 * 70 49 14 133
LOTHIAN TOTAL 227 245 116 588
GREATER GLASGOW Jan - Jun 1992 0 5 4 9
Jul - Dec 1992 4 2 4 10
Jan - Jun 1993 5 2 3 10
Jul - Dec 1993 10 4 3 17
Jan - Jun 1994 19 15 8 42
Jul - Dec 1994 38 33 16 87
Jan - Jun 1995* 33 24 9 66
GREATER GLASGOW TOTAL 109 85 47 241
TAYSIDE Jan - Jun 1992 1 1 3 5
Jul - Dec 1992 1 3 3 7
Jan-Jun 1993 6 3 5 14
Jul - Dec 1993 6 8 9 23
Jan - Jun 1994 11 24 15 50
Jul - Dec 1994 42 24 22 88
Jan - Jun 1995* 2 3 0 5
TAYSIDE TOTAL 69 66 57 192
GRAMPIAN Jan - Jun 1992 0 0 0 0
Jul - Dec 1992 0 0 0 0
Jan - Jun 1993 0 0 1 1
Jul - Dec 1993 2 1 1 4
Jan - Jun 1994 8 7 0 15
Jul - Dec 1994 5 4 1 10
Jan - Jun 1995* 0 0 0 0
GRAMPIAN TOTAL 15 12 3 30
’OTHER' Jan - Jun 1992 2 1 1 4
Jul - Dec 1992 0 1 1 2
Jan - Jun 1993 0 3 0 3
Jul - Dec 1993 4 0 3 7
Jan - Jun 1994 6 2 1 9
Jul - Dec 1994 4 9 5 18
Jan - Jun 1995* 3 1 0 4
'OTHER' TOTAL 19 17 11 47
* Incomplete Data.
Table 6.07
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HIV+ Adults. Alive and Under Monitoring fat 31/12/94) 
by Risk Category, Date, and Value of most recent CD4 Count
RISK CATEGORY TIME PERIOD
CD4 COUNT
TOTAL
0 -1 9 9 200 - 500 >500
HOMO/BISEX Jan - Jun 1992 3 3 0 6
Jul - Dec 1992 1 4 2 7
Jan - Jun 1993 1 7 0 8
Jul - Dec 1993 9 2 3 14
Jan - Jun 1994 24 25 9 58
Jul - Dec 1994 51 46 24 121
Jan - Jun 1995* 42 24 6 72
HOMO/BISEX TOTAL 131 111 44 286
IDU Jan - Jun 1992 1 8 7 16
Jul - Dec 1992 5 4 3 12
Jan - Jun 1993 10 8 11 29
Jul - Dec 1993 16 15 14 45
Jan - Jun 1994 31 37 26 94
Jul - Dec 1994 84 91 59 234
Jan - Jun 1995* 48 44 10 102
IDU TOTAL 195 207 130 532
HETEROSEX Jan - Jun 1992 2 5 2 9
Jul-Dec 1992 2 2 1 5
Jan - Jun 1993 2 7 1 10
Jul - Dec 1993 5 9 5 19
Jan - Jun 1994 14 13 8 35
Jul - Dec 1994 35 29 17 81
Jan - Jun 1995 * 9 10 5 24
HETEROSEX TOTAL 69 75 39 183
HAEM/BLOOD Jan - Jun 1992 2 0 1 3
Jul - Dec 1992 0 0 1 1
Jan - Jun 1993 2 0 0 2
Jul - Dec 1993 0 0 0 0
Jan - Jun 1994 3 1 0 4
Jul - Dec 1994 6 3 1 10
Jan - Jun 1995 * 4 2 0 6
HAEM/BLOOD TOTAL 17 6 3 26
UNKNOWN/OTHER Jan - Jun 1992 2 6 5 13
Jul - Dec 1992 3 2 3 8
Jan - Jun 1993 1 2 0 3
Jul - Dec 1993 6 2 0 8
Jan - Jun 1994 6 7 4 17
Jul - Dec 1994 13 19 10 42
Jan - Jun 1995 * 7 3 2 12
UNKNOWN/OTHER TOTAL 38 41 24 103
* Incomplete Data.
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HIV Prevalence 
by Year, Location and UAT Study
Y E A R
1990 1991 1992 1993
EDINBURGH
GUM Study 
Guthrie Study
n/a
0.25%
1.02%
0.17%
1.07%
0.12%
0.73%
0.16%
GLASGOW
GUM Study 
Guthrie Study 
Hospital Study 
Family Planning Study
n/a
0.00%
n/a
n/a
0.55%
0.03%
n/a
n/a
0.52%
0.01%
0.87%
0.03%
0.51%
0.01%
0.69%
0.03%
DUNDEE
GUM Study 
Guthrie Study
n/a
0.14%
n/a
0.00%
n/a
0.28%
n/a
0.09%
REST OF SCOTLAND
GUM Study 
Guthrie Study
n/a
0.01%
n/a
0.01%
n/a
0.01%
n/a
0.02%
Table 8.01
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02
Sample Report Form : AIDS (Control! Act
Greater Glasgow Health Board (To 31/3/94)
A(C)A1
AIDS (CONTROL) ACT 1987 : STATISTICS ON REPORTED AIDS CASES AND DEATHS
Health Board: G r e a t e r  G l a s g o w
Year ending 31 March 1994
Signed:
Name:
Tel. N o.:
Period People With AIDS
First Reported 
From This 
Health Board
Known to be 
Resident of this 
Health Board
1 April 1993 
to 31 March 1994
- reported to, and 
accepted by SCIEH 
in period 42 34
- numbers of above 
known by 31 March 
1994 to have died 10 8
Cumulative to 
31 March 1994
- cumulative number 
reported to, and 
accepted by SCIEH 
by end of period
151 118
- numbers of above 
known by 31 March 
to have died 98 75
Notes:
1. This form should be completed as part of the reports made by Health Boards under the AIDS (Control) Act 1987.
2. The form should be completed from information supplied by SCIEH
Figure 2.01
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2.
09
AIDS Cases Reported to SCIEH bv 30/4/94 
by Health Board of Residence
ARGYLL & CLYDE 
AYRSHIRE & ARRAN 
BORDERS 
DUMFRIES & GALLOWAY 
FIFE
FORTH VALLEY 
GRAMPIAN 
GREATER GLASGOW 
HIGHLAND 
LANARKSHIRE 
LOTHIAN 
TAYSIDE 
UNKNOWN/OTHER
0 5 0  1 0 0  1 5 0  2 0 0  2 5 0
N U M B E R  O F  C A S E S
Figure 2.10
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Location of HIV Testing Laboratories
Dundee.
' / / / / / / /  / / flrtTTITT / / / / / / / / /
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Glossary
AIDS acquired immune deficiency syndrome
ANSWER AIDS news supplement to the weekly report
APPGA All-Party Parliam entary Group on AIDS
BMDP a computer package for statistical analysis
BPASU British Paediatric Associated Surveillance Unit
BTS Blood Transfusion Service
CD4 count the num ber of CD4 T-lymphocyte cells per cubic
millimetre of blood 
CDC Centers for Disease Control
CDEH(S)U Communicable Diseases and Environm ental H ealth
(Scotland) Unit 
CDSC Communicable Disease Surveillance Centre
CD(S)U Communicable Diseases (Scotland) Unit
Cl confidence interval (statistical term)
DATAEASE a computer package for da ta  processing
DNA deoxyribonucleic acid
EH(S)U Environmental H ealth (Scotland) Unit
ELISA enzyme linked immunosorbent assay
FOP form of particulars
FORTRAN a computer language compiler
GP general practitioner
GUM genito-urinary medicine
HBV hepatitis B virus
HEBS Health Education Board for Scotland
HEALS HIV Epidemiology and Laboratory Sub-committee
HIV hum an immunodeficiency virus
HTLV-I hum an T-cell leukaem ia virus - type one
HTLV-III hum an T-cell leukaem ia virus - type three
ICH Institu te  of Child Health
IDU injecting drug user
KS Kaposi’s sarcoma
LAV lymphadenopathy associated virus
MMWR Morbidity and M ortality Weekly Report
MRC Medical Research Council
NHS National Health Service
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Glossary (contiO
OOI other opportunistic infection
OR odds ratio (statistical term)
POP pneumocvstis carinii pneumonia
PCR polymerase chain reaction
PHLS Public Health Laboratory Service
PML progressive multifocal leukoencephalopathy
RGS Registrar General for Scotland
RNA ribonucleic acid
RR relative risk (statistical term)
SAM Scottish AIDS Monitor
SAS a computer package for statistical analysis
SCIEH Scottish Centre for Infection and Environm ental
Health
SMR Scottish morbidity record
SPSSPC+ a computer package for statistical analysis
STD sexually transm itted  disease
UAT unlinked anonymous testing
UK United Kingdom
USA United States of America
w c c white cell count
WHO World Health Organization
